Discovery and development of anti-infectives with novel modes of action for the treatment of respiratory tract infections by Thomann, Andreas
  
 
DISCOVERY AND DEVELOPMENT OF ANTI-INFECTIVES 
WITH NOVEL MODES OF ACTION FOR THE TREATMENT 
OF RESPIRATORY TRACT INFECTIONS  
 
 
DISSERTATION 
zur Erlangung des Grades  
des Doktors der Naturwissenschaften  
der Naturwissenschaftlich-Technischen Fakultät  
der Universität des Saarlandes  
 
 
von  
Apotheker & Dipl.-Pharm. Andreas Thomann  
 
 
Saarbrücken  
2016
 II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag des Kolloquiums:  17.02.2017  
Dekan:    Prof. Dr. Guido Kickelbick 
Berichterstatter:   Prof. Dr. Rolf W. Hartmann  
Prof. Dr. Dr. h. c. Hans H. Maurer 
Vorsitz:    Prof. Dr. Alexandra K. Kiemer 
Akad. Mitarbeiter:   Dr. Josef Zapp 
 
 III 
Die vorliegende Arbeit wurde von Januar 2012 bis Dezember 2015 unter Anleitung 
von Herrn Univ.-Prof. Dr. Rolf W. Hartmann in der Fachrichtung 8.2 Pharmazeutische 
und Medizinische Chemie der Naturwissenschaftlich-Technischen Fakultät III der 
Universität des Saarlandes sowie am Helmholtz-Institut für Pharmazeutische 
Forschung Saarland (HIPS) in der Abteilung Drug Design and Optimization (DDOP) 
angefertigt. 
  
 IV 
“Je suis de ceux qui pensent que la science est d’une grande beauté. Un scientifique 
dans son laboratoire est non seulement un technicien: il est aussi un enfant placé 
devant des phénomènes naturels qui l’impressionnent comme des contes de fées.” 
        Marie Curie (1867 - 1934) 
Abstract 
V 
Abstract 
Function of the lung is a prerequisite for human survival. Infection of the lung is 
therefore a life-threatening illness. Treatment is constantly losing its effectivity due to 
resistance development. Moreover, pathogens developed mechanisms to evade the 
immune response, e.g. biofilms. Hence, developing new antibiotic drugs with novel 
targets, restoring activity of old drugs or blocking pathogenicity is highly necessary. 
These concepts are the basis of this work focused on Pseudomonas aeruginosa (PA) 
and Mycobacterium tuberculosis (Mtb) both causing severe pulmonary infections. 
The quorum sensing system of PA is a highly sophisticated network using small 
molecules for group coordinated release of virulence factors, biofilm formation and 
persistence. A key sensor is the Pseudomonas Quinolone Signal (PQS). Blocking the 
downstream effects of PQS can be achieved by interference with its receptor (PqsR) 
or synthases (e.g. PqsD). Targeting PqsR and PqsD is a promising goal to lower 
pathogenicity, restore antibiotic activity and - immune response while reducing risks 
for resistance. 
Infections by extreme drug resistant Mtb are on the rise making discovery of novel 
anti-mycobacterial agents inevitable. Novel potential targets are cytochrome-P-450 
enzymes. CYP125 & CYP121 are two representatives of which the first is essential 
during host infection and the latter for bacterial survival. Hence development of 
inhibitors for these enzymes is a promising strategy to fill the antibiotic gap. 
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Zusammenfassung 
Die Funktion der Lunge ist essentiell für unser Überleben. Daher sind Infektionen 
lebensbedrohlich. Zusätzlich verlieren Antibiotika aufgrund steigender 
Resistenzentwicklungen ihre Wirkung. Weiterhin haben Pathogene 
Schutzmechanismen z.B. Biofilme entwickelt um dem Immunsystem zu entkommen. 
Daher ist die Entwicklung neuer-/ Reaktivierung alter Antibiotika oder Blockade der 
Pathogenität äußerst wichtig. Dies ist die Basis dieser Arbeit, welche sich auf die 
Bekämpfung der Keime Pseudomonas aeruginosa (PA) und Mycobacterium 
tuberculosis (Mtb) fokussiert. 
Das Quorum Sensing System von PA nutzt kleine Moleküle als Regulatoren von 
Virulenz Faktoren, Biofilmen und der Persistenz. Ein Molekül ist das Pseudomonas 
Quinolone Signal (PQS). Die Blockierung der Effekte von PQS kann einerseits durch 
Blockade des Rezeptor PqsR oder durch Hemmung der Synthasen (z.B. PqsD) 
erfolgen. Interferenz mit PqsR und PqsD ist ein vielversprechender Ansatz die 
Pathogenität von PA zu verringern & die Wirksamkeit von Antibiotika und 
Immunzellen wiederherzustellen, bei verringertem Resistenzrisiko. 
Infektionen mit resistenten Mtb steigen stetig, was eine Entwicklung neuer Antibiotika 
unumgänglich macht. Die Inhibierung der essentiellen Cytochrom-P450 Enzyme 125 
& 121 ist ein neues Konzept um Mtb zu bekämpfen. Daher ist die Entwicklung von 
Hemmstoffen dieser CYP Enzyme eine vielversprechende Strategie die Antibiotika-
Lücke zu füllen.  
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1 Introduction 
1.1 Bacterial infections and resistance development 
Bacteria are the oldest life-form on earth and without them no higher organisms could 
have been evolved. Prime examples of this dependency are humans. Health of e.g. 
the skin, the gut as well as the immune system highly depends on a balanced 
multispecies flora of bacteria living in total symbiosis with us. However, besides the 
positive effects of these microorganisms, there are also other strains that can either 
cause minor infections or deadly diseases. Till the discovery of these bacteria in 1673 
by Leewenhoeck et al.[1] and the concept by Koch[2] that these microorganisms are 
the origin of the symptoms of infection, a rational search for medicines to fight these 
diseases was not possible. Fortunately, in the 1930s the first antibacterial 
compounds, the sulfonamides, were introduced into the clinic ultimately leading to the 
cure of the bacterial infection which is, till today, an outstanding characteristic of 
successful antibiotic treatment. This was the beginning of an era which is today often 
referred to as “the golden age of antibiotic drug discovery” as many of these 
compounds with different modes of action were found in between 1940 and 1960 
(Figure 1). As a result, these agents were rapidly used throughout the globe to fight 
bacterial infections. Unfortunately, mankind was not aware of the evolutionary power 
of bacteria. Only a few years after the approval and clinical usage, resistance began 
to spread making treatment more and more ineffective (Figure 1, red marks). This is 
a general trend also observed for antibiotics that were introduced later. 
 
Figure 1. Approval of a collection of antibiotics for human use (black, depicted above the timeline) and 
first appearance of resistance in the clinic against the respective class (red, below the timeline).[3] 
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Hence, we have to identify novel drug targets and, discover new sites of action to 
develop new drugs against these pathogens. 
 
1.2 Rational strategies in drug discovery 
To understand the meaning of the wording “rational drug design” itself, a look into the 
dictionary aids to decipher this phrase (from Oxford English Dictionary, Copyright © 
2015 Oxford University Press). Rational: Based on or derived from reason or 
reasoning, esp. as opposed to emotion, intuition, instinct, etc. Drug: a natural or 
synthetic substance used in the prevention or treatment of disease, a medicine; 
(also) a substance that has a physiological effect on a living organism. Design: a plan 
or scheme conceived in the mind and intended for subsequent execution; the 
preliminary conception of an idea that is to be carried into effect by action; a project. 
To sum up and combine these definitions, rational drug design is the reasonable 
approach for the structured development of a medicine. Alternatively, one can also 
define the process as the development of a small molecule compound interfering with 
a critical step in a disease-related pathophysiological process represented by a 
molecular target. In terms of function, this could imply intervening at essential 
metabolic steps or perturbing of a specific receptor system by stimulation or 
inhibition. Furthermore, this molecule should be ideally non-toxic and specific for one 
(or more) target(s) to reduce side-effects. 
To rationalize the development of a compound towards a drug, there are basically 
two major approaches in medicinal chemistry: ligand-based and structure-based 
design. These two strategies are outlined in the following chapters.  
 
1.2.1 Ligand-based design 
This approach is usually applied when there is no structural information about the 
target available or when the target is unknown. The starting point of the drug 
optimization process is a compound that can either be a known substrate of the 
target or a described ligand.[4] The shape and structure of the target’s pocket defines 
the position and character of the functional groups of the ligand. The three-
dimensional (3D) arrangement of these hot-spots for ligand-target interaction is 
defined as “pharmacophore”.[5] An example of a pharmacophore of FDA-approved 
1 Introduction 
3 
fluoroquinolones is given in Figure 2A. The colored spheres represent a common 
functional group feature shared by the compounds (e.g. red sphere as an anionic 
feature (F4) placed on the carboxylic acid moiety, Figure 2A). This three-dimensional 
model can then be used to search for molecules that fit into the latter blueprint. This 
can be achieved by screening an in silico library of millions of compounds leading to 
the discovery of novel scaffolds for the inhibition of the fluoroquinolone target. By 
derivatization of a compound class and subsequent study of its in vitro and/or in vivo 
effects it is possible to directly connect the observed results to the structure of the 
molecule. Such a qualitative relationship is referred to as “structure activity 
relationship”, in short SAR. An example is given in Figure 2B where distinct structural 
prerequisites for e.g. activity or pharmacokinetic properties are directly related to the 
residues of the fluoroquinolone core. With such a pattern in hand, medicinal chemists 
are able to rationally design inhibitors based on experimental knowledge. For 
quantifying these 
 
Figure 2. Assembly of different methods for ligand-based design: pharmacophore modelling based on 
a flexible alignment search of fluoroquinolone derivatives (A),[6] structure activity relationship (SAR) of 
in vivo properties (B),[7] quantitative structure activity relationship (QSAR, here Hansch analysis) of a 
subset of fluoroquinolone derivatives correlating in vitro activity with two physicochemical properties: 
Hammet constant δ and STERIMOL parameter B1 (C). The correlation of calculated and empiric IC50 is 
striking providing evidence for a quantitative relationship of molecular properties and activity (D).[8] 
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effects and making predictions for novel compounds in terms of biological activity, a 
“quantitative structure activity relationship” (QSAR) can be set up as mathematical 
expression. Figure 2C shows such a 2D QSAR model, a so-called Hansch analysis,[9] 
where steric as well as electronic properties at the phenyl ring of a substituted 
fluoroquinolone are correlated with the biological activity expressed as 1/MIC.[8] 
Moreover, the calculated IC50 values correlate with the experimentally determined 
ones very well, underlining the good predictivity of the model (Figure 2D). With the 
resulting equation, medicinal chemists can estimate, which group is the most 
reasonable choice to be introduced in order to obtain higher activity. However, 
besides those classical approaches, more sophisticated 3D QSAR methods have 
been developed as well, including 3D properties (e.g. conformation) of the 
compounds. In such a model, every grid point in the 3D matrix around the molecule is 
represented by physicochemical properties. This approach is referred to as CoMFA 
and relies on extensive in silico calculation times limited by current computer power 
and consumption for the respective calculations.[10] 
 
1.2.2 Structure-based design 
Making use of 3D protein structures for drug development is, compared to ligand-
based approaches, a relatively novel field introduced in the mid 1980s. Already in the 
beginning of the 1990s, first success stories have been published making use of 
structural information for drug design.[11] The first and, today still, the method of 
choice to is protein crystallography with subsequent X-ray structure elucidation. 
However in the last decade, novel approaches like NMR and Cryo-EM have evolved 
accelerating research and elucidation of the new structures. CryoEM has been 
proven to be exceptionally useful for poorly crystallizable membrane proteins.[12] 
Even in case of unknown protein structures, computational methods became 
available allowing creation of a model of the drug target based on a highly identical or 
homologous protein with known structure. This method is referred to as homology 
modelling and was applied to identify and optimize hits into lead structures.[13] 
Applying in silico methodology for effective drug optimization is not limited to protein 
homology modeling. It can also be used for binding pose prediction, giving the 
medicinal chemist the opportunity to examine his ideas for drug development at the 
site of action. This process is generally described by the term “docking”.[14] However, 
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structural information gathered today by X-ray crystallography is, in most cases, still 
lacking the understanding of movement and conformational changes in protein 
structures, which can be of crucial interest for protein function and by this means for 
drug development.[15] Nevertheless, computational efforts in the field of molecular 
dynamics simulations have been undertaken to close this gap.[16] Based on the 
growing information regarding protein structure and co-crystallized ligands, a novel 
field has been developed in the past decade to accelerate drug discovery with more 
efficient molecules by using smaller libraries: the fragment-based design approach. 
The idea is to use compounds small in size (< 300 Da) to cover a wide range of 
chemical space with a minimum of compounds (normally between 100-1000 
fragments) compared to high-throughput screening methods employing millions of 
lead-like molecules.[17] The combination of this approach with X-ray crystallography 
had a tremendous impact on the field of medicinal chemistry. Having access to the 
co-crystal structure of ligand and target protein, one can basically follow two different 
strategies: fragment linking (Figure 3, orange boxes) or fragment growing (Figure 3, 
grey boxes). For fragment-linking, at least the structures of two fragments in close 
proximity in the binding pocket have to be elucidated to successfully link them to one 
structure. This ideally results in a compound that is much more affine because the 
entropy terms for translational and rotational energy costs for binding to a protein are  
 
Figure 3. Examples for two strategies in structure-based design for the discovery and optimization of 
CYP121 inhibitors: fragment linking (upper scheme, orange, PDB-IDs: 4G45 (green structure), 4G44 
(red structure), 4G1X (cyan structure)) and fragment growing (lower scheme, gray, PDB-IDs: 4G47 
(green structure), 4KTL (cyan structure)). Activity was subsequently increased by rational enlargement 
of the molecule based on overlapping fragments (upper left structures, green and red molecule) or 
careful study of the binding-site’s properties and spacing for fragment growing (lower left structure, 
green).[18,19]  
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then only accounted once.[20] If only one fragment is solved or others are not 
accessible via linking, the fragment-growing approach can be applied. Therefore, the 
surrounding pocket has to be carefully studied to generate ideas - usually supported 
by docking - on how to enlarge the fragment into neighboring cavities to pick up 
additional interactions with the target. These strategies were successfully applied in 
generation of more hydrophilic and efficient drugs and have become one standard 
approach in the past decade.[21] 
 
1.3 Pseudomonas aeruginosa  
Pseudomonas aeruginosa (PA) is a rod-shaped, ubiquitous, gram-negative, 
opportunistic bacterial pathogen that causes severe nosocomial pulmonary 
infections, especially in immunocompromised patients.[22] Treatment of diseasges in 
such patients is heavily complicated by PA’s ability to shield itself against the human 
immune system, to inactivate antibiotics, and to remain as a dormant, persisting 
bacterium with down-regulated metabolism in the lung.[22,23] In chronic PA infections, 
lungs drastically lose their functionality, and, finally leading to death of e.g. cystic 
fibrosis, COPD or AIDS patients.[24,25] The loss of lung function is connected to PA’s 
ability to form biofilms, a heterogeneous hydrogel which is a barrier for the immune 
system but also a resistance mechanism against different antibiotics.[26,27] Besides 
biofilm-production, PA has an arsenal of numerous virulence factors to harm the 
epithelium of the lung and, as a result, manifest at the site of infection.[28–30] Thus, 
novel therapies to reduce the pathogenicity of PA and to restore the efficiency of 
antibiotics as well as host defensive mechanisms is of great importance to maintain 
plumonary function and by this means, to increase survival of patients.  
1.4 Quorum sensing in Pseudomonas aeruginosa – A novel drug-target  
Quorum sensing (QS) is a cell-density-dependent communication system of bacteria 
employing small molecule sensors to alter gene expression, coordinate group 
behavior and regulate phenotypes in the bacterial community.[31] In PA, four 
hierarchically organized systems (las, rhl, iqs and pqs) which are interconnected and 
dependent on each other, are the key players of the QS network (Figure 4).[31] 
Regarding druggability of QS per se, it was shown that QS gene mutations or 
treatment with QS inhibitors, resulted in strains being heavily impaired in their 
virulence and pathogenicity in vitro and in vivo.[32] As antibiotic resistance is on the 
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rise (see chapter 1.1) QS inhibition is a promising new concept compared to classic 
antibiotic treatment because of its non-essentiality for bacterial survival. 
Consequently, selection pressure should be low.[33]  
The class of N-acyl-L-homoserine lactones (BHL and OdDHL) are the chemical 
signals of the las and rhl systems which are widespread in Gram-negative bacteria 
and also found in PA.[34] However, the Pseudomonas Quinolone Signal (PQS) 
system and the Integrated Quorum Sensing System (IQS) Signal  is to present date, 
exclusively found in Pseudomonas and, in case of the PQS system, also in 
Burkholderia species.[35] Mutational studies designed to diminish the QS activity in PA 
confirmed reduction of virulence and pathogenicity in vivo together with lower risk to 
resistance development.[36],Targeting the pqs-systems has several advantages, as 
the human beneficial microbiome will be not impaired by a selective approach and if 
resistance arises it will not be useful for bacteria other than PA via horizontal gene 
transfer 
 
 
Figure 4. Schematic presentation of the interplay of the four quorum sensing networks in PA, namely 
las (orange), rhl (grey), iqs (blue) and pqs (green), their biosynthetic enzyme(s), signaling molecule 
structures and corresponding receptors. Arrows indicate activation, blunt-end lines inhibition of the 
respective system. The iqs receptor still remains elusive.[31] 
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1.5 Targeting PqsD and PqsR to block pathogenicity of Pseudomonas 
aeruginosa 
Synthesis of the signaling molecules (HHQ and PQS) of the pqs system starts with 
anthranilic acid which is subsequently modified by the synthases of the pqs operon, 
namely pqsABCDE (Figure 5).The last oxidation step from HHQ to PQS is catalyzed 
by PqsH, the only required enzyme outside the PQS operon. In addition to their 
signaling character, HHQ and PQS have also virulence factor characteristics which 
is, for example, interfering with NF-κB function, inhibiting T-cell proliferation, inducing 
biofilm formation, and increasing HIF-1a degradation.[39] Additionally, during 
synthesis of HHQ and PQS two products of the biosynthetic intermediates 2-ABACoA 
and 2-ABA are spontaneously formed: DHQ and 2-AA. DHQ is known to impair 
viability of lung epithelial cells and 2-AA for its ability to induce persister cell formation 
and antibiotic tolerance.[30,40] Therefore, blocking the production of the signaling 
molecules HHQ and PQS as well as the two degradation products DHQ and 2-AA is 
of high interest in order to reduce pathogenicity and virulence of PA. Interfering with 
the key synthase PqsD being responsible for the synthesis of the intermediate 2-
ABACoA, one could accomplish the aforementioned goal.[37] 
 
Figure 5. Representation of PQS biosynthesis and the auto-inductive positive feedback loop 
employing PqsR as the transcriptional regulator of the pqsABCDE operon. Activation of PqsR by HHQ 
and PQS leads to biofilm formation, virulence factor production and PQS biosynthesis. 2-AA = 2-
aminoacetophenone, 2-ABA = 2-aminobenzoylacetate, 2-ABACoA = 2-aminobenzoylacetyl-
CoenzymeA, AA = anthranilic acid, ACoA = anthraniloyl-CoenzymeA, DHQ = 2,4-dihydroxyquinoline, 
HHQ = 2-heptyl-4(1H)-quinolone, MCoA = malonyl-CoenzymeA, OCoA = octanoyl-CoenzymeA, PQS 
= Pseudomonas Quinolone Signal.[37,38]  
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By blocking PqsD’s function none of the latter mentioned signaling and virulence 
determining molecules should be produced. Thus, a promising strategy is to develop 
PqsD inhibitors. It has been shown previously that inhibitors designed for this 
purpose are able to strongly impair signal molecule production and interfere with 
biofilm formation.[41–43] Examples for such PqsD inhibitors are depicted in Figure 6 (5 
– 8). However, most of them lack favorable physicochemical properties either for oral 
bioavailability or activity in Gram-negative bacteria.[44] Thus, compounds addressing 
PqsD in cellulo are of high demand. Besides inhibition of biosynthesis, another 
strategy to reduce PQS-associated virulence is to antagonize its receptor PqsR, also 
known as multiple virulence factor regeulator (MvfR).[45] PqsR was validated in vivo 
by a HHQ related small molecule antagonist 1 as well as in vitro by several other 
compound classes (2 – 4, Figure 6). By antagonizing PqsR, it is possibile to reduce 
the production of one of the major virulence factors of PA: pyocyanin (Figure 5, light 
green structure in upper left corner).[46,49,51] This redox-active molecule has been 
shown to be essential for full virulence of PA. In detail, administration of pyocyanin 
causes a cystic fibrosis-like lung, induces mucin production as well as inflammation, 
and harms epthilial cells by an increase of reactive oxygen species.[28,29,54] 
Additionally, PqsR mutant strains of PA showed impaired production of several other 
virulence factors and toxins, e.g., hydrogen cyanide, lecA, lecB, and rhamnolipids.[45] 
As for the PqsD inhibitors, an antagonism of PqsR also leads to significant reduction 
of biofilm volume.[47] Hence, the development of PqsR antagonists is a worthwhile 
endeavor to reduce pathogenicity of PA. Ideally, a dual inhibition of both PqsR and 
PqsD might lead to a superior compound acting additively or synergistically on 
virulence reduction. 
 
Figure 6. Examples for classes of reported PqsR antagonists (compounds 1-4, green background) 
and PqsD inhibitors (compounds 5-8, blue background).[41,42,46,47,48,49–53]  
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Regarding drug design, both aforementioned drug discovery strategies can be 
applied to these targets, as the crystalstructure of the proteins has been determined 
and their natural substrates/ligands have been identified (Figure 7). 
 
 
Figure 7. X-ray cocrystalstructures of PqsR’s ligand-binding domain with ligand NHQ (green, PDB-ID: 
4JVD) and PqsD with its substrate anthraniloyl-CoenzymeA (blue, PDB-ID: 3H77). Binding-site 
architectures of both proteins are displayed in the colored boxes each. The surfaces of the binding 
sites were colored with regard to the lipophilicity (red = lipophilic, blue = hydrophilic) of the 
corresponding amino acids. 
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1.6 Chemical synthesis of substituted pyrimidines 
Substituted pyrimidines are important scaffolds in many bioactive small molecules 
and, moreover, are present in numerous FDA-approved drugs, e.g., aronixil, 
buspirone, enazadrem, minoxidil, sulfametoxydiazine (Figure 8). Additionally, 
pyrimidine-based compounds have been identified by us to inhibit PqsD (Figure 6, 
Cmpd 8).[53] Thus, a chemical synthesis to gain access to this desirable motif is highly 
interesting for researchers in general and for those working in the field of medicinal 
chemistry in particular. In small molecule drug discovery, usually, synthetic routes are 
employed which grant fast access to the structure, are cost efficient, highly robust 
and ideally allow introduction of a broad range of functional groups or fragments. 
These requirements are key criteria for in-time library generation in a combinatorial 
chemistry fashion in order to rapidly acquire SAR information. Hence, the 
development of methods to accomplish the latter mentioned requirements is an 
ambitious aim. A general route for the synthesis of substituted pyrimidines often 
starts from the (poly-)chlorinated pyrimidine as precursor. However, these traditional 
approaches have several drawbacks, as they can take between several hours and 
days of reaction time per step and are restricted to sophisticated laboratory 
equipment and cost-intensive chemicals.  
 
 
Figure 8. Five examples of pyrimidine-containing FDA-approved drugs for various kinds of diseases.  
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Figure 9. Examples for reaction types routinely used by medicinal chemists to decorate the 2-
thiomethylpyrimidine core with different substituents starting from chlorinated precursor 1. Most of the 
reactions rely on metal catalysis (e.g., Buchwald-Hartwig) or harsh reaction conditions (e.g., sodium 
hydride and/or high temperature).  
These include for example, Schlenk lines, dry solvents and expensive and/or toxic 
catalysts (Figure 9). These prerequisites make them less attractive for medicinal 
chemists. Thus, novel methods are needed that meet the criteria of medicinal 
chemistry driven drug discovery and circumvent the limitations of traditional 
approaches. 
 
1.7 Mycobacterium tuberculosis  
Mycobacterium tuberculosis (Mtb) is a rod-shaped, Gram-positive, obligate human 
pathogen and causes one of the most deadly diseases worldwide claiming about 1.5 
million lives per year in 2014.[55] Mtb primarily infects the lungs through transmission 
by aerosol.[56] After arrival in the lung, Mtb is incorporated by phagolytic cells, i.e., 
macrophages or neutrophils.[57] Although many drugs against tuberculosis have been 
approved or are at a late stage clinical development, the need for novel strategies is 
undisputed.[58] A problematic issue of treating Mtb infections arises from the 
pathogen’s ability to change from an actively replicating bacillus to a dormant, non-
replicating persister inside the phagosome of human macrophages.[59] In the latter life 
cycle, Mtb’s metabolic activity is strongly reduced resulting in increased tolerance to 
antibiotics targeting active metabolism (e.g., cell wall synthesis or protein 
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biosynthesis).[56] Thus, novel antibiotics are of high demand, which ideally address 
targets required for Mtb’s survival in the dormant state. Such a strategy would 
presumably reduce treatment time, which is one of the major cost factors, and failure. 
Besides the naturally occurring behavior of Mtb to form persister cells, there is a 
raising number of extremely drug resistant tuberculosis strains (XDR TB) which does 
not respond to any available antibiotic treatment.[60] For these reasons, developing 
new treatment options with alternate mode of action against tuberculosis is of urgent 
need to counter resistance development and prolonged treatment. 
 
1.8 The cytochrome P450 family – enzymatic reaction and types of inhibition 
Since their first discovery by Omura in 1962 in liver microsomes, cytochrome P450 
(CYP, CY = cytochrome and P = pigment) enzymes have been found in all classes of 
living organisms.[61] The name corresponds to the characteristic spectral absorbance 
peak at 450 nm when carbon monoxide binds to the reduced ferric-heme in the active 
site of the enzyme.[62] The substrate scope of these oxidoreductases can either be 
narrow for specific conversions (e.g., CYP11B1) or broad for modification of e.g. 
xenobiotics (e.g., CYP3A4).[63] The oxidative cycle of CYP enzymes requires electron 
transfer involving reductases and ferrodoxins to generate superoxide anions, which 
are inserted into a C-H bond of a substrate in a second step (Figure 10).[64,65]  
 
 
Figure 10. Catalytic cycle and mechanism of the oxidation of a generic substrate by P450 enzyme at 
the heme iron via the intermediate formation of an O22- anion at the iron(III) center.[64,65]  
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Targeting CYP enzymes in drug discovery was proven to be a success story for 
various kinds of diseases (e.g., CYP17 in prostate cancer or CYP19 in breast cancer) 
and led to the approval of several drugs such as Abiraterone and Letrozol. Besides 
human targets, CYP enzymes also represent interesting structures to be addressed 
in bacteria for the discovery of novel antibiotics.[66] Based on the unique spectral 
characteristics of CYP enzymes, different binding modes can be observed for ligands 
interacting with the ferric-heme. A compound that directly coordinates to the iron(II) 
center shifts the so-called Soret-band at 420 nm to higher wavelengths, whereas a 
ligand interacting through coordinated water molecule(s), a so-called water-bridge, 
induces a shift to lower wavelengths.[67] These two types of ligation are referred to as 
type II (direct interaction) and type I (water-bridged interaction) and can be 
distinguished by difference spectroscopy versus non-bound protein (Figure 11). This 
information can then be used to determine the KD of the ligand via titration 
experiments while the binding type itself can be exploited for structure-based design 
strategies. 
 
Figure 11. Schematic representations of UV-VIS difference spectra of a type I (A, substrate cYY , 
PDB-ID: 3G5H) and a type II ligand binding to CYP121 (B, inhibitor of CYP121, PDB-ID: 4G1X).[18,68]  
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1.9 CYP121 and CYP125 as anti-mycobacterial drug targets 
The discovery of CYP enzymes for anti-mycobacterial drug discovery started with the 
study on azole antifungals for antibacterial properties against Mtb.[69] First, CYP51, a 
mycobacterial CYP enzyme closely related to the fungal CYP target of the azoles, 
was suspected to be the primary target of these compounds and a X-ray co-crystal 
structure with fluconazole was derived.[70] However, recent results suggested that 
CYP121 might be the more relevant target, as it has been shown to be essential for 
growth of Mtb, and in addition, the latter mentioned azoles bind also more strongly to 
CYP121 than to CYP51.[69,71] Moreover, CYP51 is not essential for mycobacterial 
growth in vitro.[72] CYP121 catalyzes an unusual C-C bond formation of the C-2 
positions of the tyrosine residues of the cyclic-dipeptide cyclo-di-L-tyrosine (cYY) with 
high substrate specificity (Figure 12).[68] Also the exact function of the reaction 
product, mycocyclosine or its predecessor for mycobacterial survival is unknown. 
However, the vital necessity of the enzyme itself is undisputed.[71] Thus, essentiality 
and novelty of the target renders CYP121 an excellent starting point for anti-
tuberculosis drug discovery.  
Another essential mycobacterial CYP enzyme is CYP125, which is involved in the 
sidechain oxidation of cholest-3-en-4-one at C-26 (Figure 12) in order to detoxify this 
cholesterol-derived metabolite for Mtb.[73]  
 
 
Figure 12. Schematics of the first steps of cholesterol/cholest-3-en-4-one metabolism by 3β-
HSD/CYP125 (grey pathway) and the synthesis of mycocyclosine by CYP121 (orange pathway). The 
role of mycocyclosine or its precursor is still not elucidated to present date . In contrast , the products 
of CYP125 reaction are known to serve as carbon source during adaptation to the site of 
infection.[68,73,74]  
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Cholest-3-en-4-one is primarily generated upon infection of the host, when Mtb faces 
a cholesterol-rich environment, e.g., in the phagosome of macrophages.[74] 
Consequently, the expression of CYP125 is induced and enables survival of Mtb 
upon infection of the host. Essentiality of CYP125 could be shown in vitro using a 
CYP125 defective strain which was unable to grow on cholesterol or cholest-3-en-4-
one enriched media.[75] But, more importantly, this was also confirmed in vivo by the 
use of defective mutants in mouse infection models.[76] The biological role of CYP125 
makes it an ideal target candidate for the development of anti-infective agents 
against Mtb exploiting a novel mode of action. More importantly, regarding selectivity 
towards human CYP enzymes, especially hepatic CYPs, none of the two targets has 
a high degree of homology. In addition to that, this strategy should not induce cross 
resistance with existing, approved Mtb drugs which opens up the possibility of a 
combination to increase treatment efficiency against resistant strains of Mtb. 
Besides the azole-antifungals (e.g., compounds 14, 16, 19) which, by chance, inhibit 
both targets, CYP121 and CYP125 have already attracted the attention of medicinal 
chemists and drug developers in order to develop specific inhibitors (Figure 13). 
These discovery campaigns were driven by either random screening (compound 13), 
ligand-based (compound 20), or structure-guided fragment-based approaches 
(compounds 17, 18).[18,19,77,78]  
 
 
Figure 13. Examples of CYP125 (compounds 13-16, gray) and CYP121 inhibitors (compounds 17-20, 
orange).[18,19,71,77–79] 
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Nevertheless, none of the developed compounds was shown to have cellular activity 
on Mtb. Additionally, the reported compounds lack convincing on-target activity, as 
they have affinities in the triple to double digit micromolar range. Thus, for target 
validation and proof of drugability, further studies showing effects on the bacterium 
and in in vivo models are of high demand to rationalize further drug discovery 
attempts. As mentioned before, first drug discovery campaigns were based on the 
crystal structure of CYP121 (Figure 14, orange). From this approach, several 
structures with co-crystallized ligands were derived, making structure-based drug 
design even more applicable. Besides those studies, the natural substrate of CYP121 
is also known and several different synthetic analogues of cYY were tested for their 
ability to serve as substrates and inhibitors.[68]  
 
 
Figure 14. X-ray co-crystal structures of CYP121 with natural substrate cYY bound to heme (orange, 
PDB-ID: 3G5H) and CYP125 with its substrate cholst-4-en-3-one coordinating the iron (II) centre of the 
heme (gray, PDB-ID: 2X5W). The binding-site architectures of both proteins are displayed in the 
colored boxes each. The surfaces of the binding sites were colored with regard to the lipophilicity of 
the substrate surrounding amino acids in 6 Å proximity. 
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Thus, a ligand-based approach in drug discovery using cYY as a template seems 
also plausible. With regard to CYP125, almost the same starting conditions for 
rational drug discovery hold true. The substrate and the protein X-ray crystal 
structure (Figure 14, grey) is known and fist inhibitors have been published. Thus, 
both ligand- and structure-based design are possible which provides, for both targets, 
an excellent starting point for medicinal chemists to rationally develop potent but 
selective compounds for both enzymes. 
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2 Aims of the thesis 
Upcoming resistance is a major problem for the treatment of respiratory tract 
infections by PA and Mtb. Therefore, in this thesis, two different approaches were 
followed to maximize the success of anti-infective drug development. For PA a novel, 
innovative concept was chosen: combating pathogenicity without effecting growth to 
circumvent resistance development by selection pressure. Regarding Mtb, a classic 
antibiotic strategy was followed by targeting an essential process to eradicate the 
pathogens at the site of infection. The discovered inhibitors should not show any 
cross resistance to existing anti-mycobacterial drugs and hence may counter the 
resistance problem in tuberculosis treatment. 
 
Development of PQS quorum sensing inhibitors against PA infections 
I. Identification, biological evaluation and optimization of novel drug-like 
inhibitors targeting the PQS cell-to-cell communication system. To accomplish 
this goal, previous work by Storz and Lu served as the basis for the 
development of inhibitors of PqsD and antagonists of PqsR.[41,51] The herein 
developed compounds should have improved physicochemical properties and 
biological activities to overcome the limitations of the previously developed 
inhibitors and provide more drug-like compounds and further proof for the 
drugability of the two targets.  
 
II. Development of a robust, fast, and economic synthetic route allowing the 
introduction of a broad scope of substituents into the identified compound is 
essential for library generation and to subsequently derive structure activity 
relationship information. Therefore, it was a key objective to develop a robust 
and rapid synthetic route for the in-time generation of drug-like compounds to 
address the latter requirements in a medicinal chemistry environment.  
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Discovery of Cytochrom-P450 inhibitors against Mtb infections 
III. Identification and biological evaluation of first anti-mycobacterial hits against 
CYP121 and CYP125 from Mtb was the major goal of this part of the thesis. 
To achieve this aim a focused CYP-inhibitor library composed of in-house 
available compounds from human CYP projects should be compiled. This 
library would then be the basis for a subsequent biophysical screening 
procedure for the discovery of first binders to the mycobacterial CYP enzymes. 
The most promising inhibitors from this in vitro screening are then prime 
candidates for further evaluation in several cellular models (e.g., M. bovis 
BCG, Mtb, HEK Cells, HEP Cells) to identify frontrunner compounds with a 
promising biological and physicochemical profile. As crystallographic data is 
available on both targets, a goal is to predict the binding modes of the front 
runner compounds for a structure-guided design approach towards novel anti-
tuberculosis drug candidates. 
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3.1 Microwave-Assisted Synthesis of 4-Substituted 2-Methylthiopyrimidines 
Andreas Thomann, Carsten Börger, Martin Empting, and Rolf W. Hartmann 
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Figure 15. Graphical abstract of publication I. 
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Figure 16. Graphical abstract of publication II. 
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Figure 17. Graphical abstract of publication III. 
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3.5 Optimization of 2-sufonylpyrimidines to tackle biofilm formation and 
eDNA release of Pseudomonas aeruginosa 
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Reproduced with permission from ChemMedChem; Published online: 12.10.2016, 
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Figure 19. Graphical abstract of publication V. 
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3.6 Biophysical Screening of a Focused Library for the Discovery of Novel 
Anti-mycobacterials Targeting CYP121 
 
 
Chapter VI 
 
 
 
 
Figure 20. Graphical abstract of chapter VI. 
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Abstract: The appearance of multi-drug resistance (MDR) combined with a generally 
complicated long-term treatment hamper the therapy of Mycobacterium tuberculosis 
(Mtb) infections. Therefore, the development of novel antimycobacterial agents with 
new modes of action is urgently required. CYP121 was shown to be a promising 
novel target for inhibition of mycobacterial growth. However, besides the identification 
of azole antifungals as molecules that interfere with this system, not many efforts 
have been made to develop new inhibitors. In this study, we describe the rational 
discovery of new CYP121 inhibitors by a systematic screening based on biophysical 
and microbiological methods. Best hits originating from only one structural class gave 
first information about molecular motifs required for binding and activity. The initial 
screening procedure was followed by mode of action studies and further biological 
characterizations. The results demonstrate a superior antimycobacterial efficacy and 
a reduced toxicity profile of our frontrunner compound compared to the reference 
econazole. Due to its low molecular weight, promising biological profile and 
advantageous physicochemical properties this compound displays an excellent 
starting point for further rational optimization. 
 
INTRODUCTION 
Tuberculosis belongs to the most lethal infectious diseases caused by bacteria. 
According to the WHO Global Tuberculosis Report,[1] 1.5 million people died in 2013 
due to infections caused by Mtb. This goes along with an estimated amount of 9 
million new cases of Mtb infections arising each year. Despite a broad spectrum of 
first and second line antimycobacterial drugs, there is an antibiotic gap for the 
treatment of infections with multi-drug-resistant (MDR) and extensively-drug-resistant 
(XDR) Mtb.[1] Additionally, alarming reports have been published describing totally-
drug-resistant Mtb (TDR-TB).[2] Moreover, tuberculosis still requires long-term 
treatment leading to an increased probability for non-compliance which impairs the 
therapeutic outcome.[3] Hence, there is an urgent need for new antimycobacterial 
agents with novel modes of action which in best case could also lead to shorter 
treatment periods. 
Driven by the elucidation of the Mtb genome in 1998[4], new potential drug targets 
were identified.[5] Interestingly, Mtb exhibits an unusual high number of twenty P450 
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enzymes in contrast to other bacteria. Further studies have revealed some of them to 
be essential for viability, survival and/or pathogenicity.[6] Out of these, CYP121 was 
shown to be essential for bacterial growth by an in vitro knock out study.[7] Moreover, 
the deficient strain could be revived by a complementary plasmid.[7,8] The first 
evidence of CYP121 function in Mtb was derived from its gene position which is 
located in an operon harboring two enzymes involved in the formation of cyclo-di-l-
tyrosine (cYY).[9] In vitro studies provided proof, that CYP121 catalyzes the reaction 
of cYY to mycocyclosin with high substrate specificity.[9,10] The role of its substrate 
and product in the cellular setting remains to be elucidated. However, the variety of 
biological functions of diketopiperazines is well described e.g. as quorum sensing 
signals.[11] Thus, besides development of antimycobacterials targeting CYP121, a 
small selective molecule with in cellulo efficiency may help to understand the precise 
function of CYP121.  
Despite the fact that CYP121 is a potential target for Mtb treatment only little efforts 
have been undertaken to identify potent inhibitors. Hudson et al. published several 
compounds designed for selective CYP121 binding and inhibition. However, none of 
them were shown to be effective against Mtb.[12] Fonveille et al. described a CYP121 
inhibitory effect of cYY derivatives without data on bacterial growth.[10,13] Regarding 
compounds with cellular activity, it was shown that azole antifungals bind tightly to 
CYP121 and exhibit an in vitro and in vivo activity against Mtb.[14–19] Furthermore, the 
binding to the enzyme was in good correlation with the antimycobacterial effect.[7,19] 
As the azole antifungals are active on Mtb cells and effective in mice infection models  
they display a valuable reference for antimycobacterial CYP inhibitors.[14–19] 
The essential role of CYP121 for Mtb survival and our expertise in developing potent 
and selective human steroidogenic CYP enzyme inhibitors, motivated us to identify 
novel CYP121 inhibitors with increased efficiency and improved properties compared 
to the azole antifungals.[20] Potential antimycobacterial activity could provide further 
evidence of target validity, drugability and stimulate development of respective 
inhibitors towards new therapeutic agents bearing the potential to treat MDR and 
XDR Mtb infections. For these reasons, we established a screening strategy based 
on in vitro and cell-based assays (Scheme VI 1). By the use of a small highly diverse 
library composed of our CYP-inhibitors, we could identify a CYP121 inhibitor with 
increased antimycobacterial potency compared to positive control econazole. This  
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Scheme VI 1. Hit finding progress. The initial library (139 compounds) was built of inhibitors designed 
for inhibition of human CYP11B1/2, CYP17 and CYP19 with regard to structural diversity. A positive 
SPR screening hit was defined by the coefficient of its response divided by the response of the 
positive control (econazole) which had to be above 0.5 (R/Rpos > 0.5). This resulted in 44 positives. 
From this preselection, eight compounds coordinated iron-heme with a KD < 15 µM. These compounds 
were tested against BCGT and three showed a MICBCGT < 10 mg/L. Finally, one compound was highly 
active on Mtb with a MICMtb < 1 mg/L. 
compound possesses desirable physicochemical properties, low toxicity towards 
human cells and high antibacterial selectivity against Mtb, rendering it an appropriate 
candidate for further optimization. 
 
RESULTS AND DISCUSSION 
Library generation. For hit discovery we selected 139 compounds from our in-house 
CYP-inhibitor library designed for inhibition of CYP17, CYP19, CYP11B1 and B2 
(Supporting Information). The screening library is composed of six different scaffolds 
to ensure a broad structural diversity (Figure VI 1). Additionally, known 
pharmacological profiles,  
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Figure VI 1. Classes of the library used for screening against CYP121 with their respective number of 
representatives stated in brackets. The structures represent the core scaffold of the compound where 
R is a substituent, X represent the position of either nitrogen or CH, and []n the alkyl chain length of n 
methylene units. 
drug-likeness, and established synthetic routes of the compounds provide an ideal 
starting point for future optimization. As a reference compound we chose econazole 
which was shown to have the highest reported affinity to CYP121 (UV/Vis heme 
P450 binding assay) and the strongest inhibition of mycobacterial growth in the class 
of azole antifungals.[16,19] 
Enzyme expression, characterization and initial SPR Screening. As starting point 
for SPR screening we expressed CYP121 in a heterologous host (E. coli K12 BL21) 
and purified the protein by ion affinity chromatography (IMAC). Notably, addition of 
1% Triton-X-100 into the lysis buffer during purification increased the protein yield by 
about 10-fold.[21] The purity of the enzyme was determined by SDS-PAGE (Supp. 
Data, section 2, Figure S1). To ensure active protein conformation we conducted 
enzymatic in vitro activity tests. A first experiment to gain information about activity of 
P450 enzymes is the determination of CO-binding spectra.[22] 50% of the expressed 
enzyme showed the typical P450 band of CO- bound heme after dithionate reduction 
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Figure VI 2. SPR screening results: compounds plotted versus their R/Rpos values. Econazole (100 
µM) was used as a positive control and its SPR response was set to 1 (Rpos). The compounds were 
tested at a concentration of 100 µM and their response (R) was divided through the response of 
positive control (R/Rpos). Hit compounds possess R/Rpos values > 0.5 (horizontal solid grey line). 
Vertical dashed lines separate the six classes. 
 (Supp. Data, section 3, Figure S2 and S3). Using the same experimental conditions 
but replacing sodium dithionate, we were able to identify Etp1fd (516-618) as 
ferredoxin and Arh1_A18G as ferredoxin reductase, two proteins of the fungus/fission 
yeast Schizosaccharomyces pombe,[23,24] as suitable heterologous electron transfer 
system for CYP121. Additionally, utilizing the latter system, we could show 
conversion of cYY to mycocyclosin proving enzymatic activity of CYP121 (Supp. 
Data, section 4, Figure S4 and S5).  
For SPR immobilization of the protein we used the biotin-streptavidin interaction.[25] 
Prior to immobilization we conjugated a biotin tag to CYP121. To confirm applicability 
of the SPR method, we determined a response curve of econazole to the target 
protein (Supp. Data, section 5, Figure S6).[7] The SPR signal of econazole, measured 
in response units (RU), was set to one (Rpos). The binding event of library compounds 
(R) was referenced to the positive control and declared as R/Rpos. We defined R/Rpos 
> 0.5 as the threshold for hits from SPR screening procedure. Using this approach, 
we identified 44 binders out of 139 compounds with representatives from all of the six 
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classes (Figure VI 2). Notably, we found 17 compounds with higher responses than 
econazole (Supp. Data, section 6, Table S1). 
Binding mode and affinity characterization via UV/Vis heme binding assay. The 
44 SPR binders were investigated for their ability to interact with the iron(II)-heme by 
monitoring the shift of the characteristic absorbance band at 416 nm of CYP121 
(Figure VI 3).[7,12] In addition to the 44 SPR hits, we also took two weak SPR binders 
into consideration (I:1 and I:33, R/Rpos < 0.5) to conduct a retrospective evaluation of 
the reliability of our SPR screening. McLean et al. reported that econazole has a 
tight-binding profile to CYP121 with a KD = 0.02 µM.[7] However, we observed a KD of 
3 µM. This discrepancy could be due to a difference in UV/Vis spectrometric devices 
used and, thus, limited sensitivity. To provide a higher throughput employing 96-well 
plates, we were limited to a higher enzyme concentration which impairs 
measurement in lower nanomolar ranges. Compounds were initially tested at a 
concentration of 100 µM to identify iron-heme interactions and distinguish between 
type I (water bridged iron-interaction) and type II (direct iron-interaction) binding. 30 
compounds showed a type II shift while none showed type I binding behavior. The 
latter compounds appear in class I, II, III and IV indicating that the catalytic center 
accepts imidazolyl- and pyridinyl-moieties for iron-heme coordination. 
 
 
Figure 3. Binding of I:47 to CYP121 as determined from heme coordination assay. (a): UV/Vis 
spectrum (left inset) and difference spectra (upper right inset) were recorded of the enzyme in the 
presence of I:47 (100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20, 0,10 µM; dotted lines) and in the 
absence of I:47 (solid line). (b): The KD value of I:47 was derived by non-linear fitting of the data using 
Equations 1 and the difference in absorption at 430 and 410 nm. 
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I:1 and I:33 (weak SPR binders) did not coordinate the heme-iron which emphasizes 
the suitability of our SPR screening procedure. The identified type II binders were 
further investigated regarding their KD. For eight binders an affinity better than 15 µM 
was observed (Supp. Data, section 6, Table S1). Interestingly, this subset of 
compounds only arose from classes I and II. Pyridinyl (class II) as well as imidazolyl 
(class I) motifs were tolerated as heme coordinators while the imidazolyl ligands 
showed higher affinities (Supp. Data, section 6, Table S1). With regard to class I the 
highest affinity could be found for compounds decorated with hydrophobic and 
space-demanding moieties connected to the benzylimidazole substructure. This is 
also a structural trend in the class of antimycobacterial azoles (e.g. econazole, 
clotrimazole).[7] The most affine binder I:16 showed three-fold improved KD compared 
to econazole (KD = 3 µM) (Supp. Data, section 6, Table S1). Furthermore, two 
linearized, para-substituted biphenyl compounds of this class (I:47 and I:48) 
possessed a CYP121 affinity comparable to econazole. As mentioned before, 
molecules with linear biphenyl units bearing an N-methylenbenzimidazoyl moiety 
instead of an unsubstituted benzylimidazolyl scaffold did not bind to the heme (I:33). 
Additionally, replacement of the interconnecting phenyl group within this class by 
pyridinyl resulted in inactive compounds (I:1). Moreover, the analysis of all 
regioisomers of benzylimidazol scaffolds substituted with phenyl revealed that the 
para- (I:32) and meta- (I:30) position lead to comparable affinities. A phenyl group at 
the ortho-position (I:15) impairs binding. The para-benzodioxine substituent of I:48 
and the para-benzodioxole substituent of I:47 increase the affinity by about two-to 
threefold (Supp. Data, section 6 Table S1). However, compared to econazole our 
most active compounds showed similar (e.g.: I:47; 5 µM and I:48; 5 µM) or slightly 
better KD (I:16; 1 µM) (Supp. Data, section 7, Figure S7). MIC determination in BCGT 
and Mtb. For investigating cellular activity we focused on those compounds with a KD 
lower than 15 µM, but also added selected compounds showing low affinity to 
CYP121 as negative controls (Supp. Data, section 6, Table S1). In this setting, 
econazole was used as described antimycobacterial reference compound.[26] For 
initial screening on mycobacterial growth inhibition we used the bovine strain BCGT. 
The strain serves as a suitable substitute for Mtb as it carries a copy of CYP121 in its 
genome with an overall amino acid identity of 100% in comparison to its Mtb 
congener (Supp. Data, section 8, Figure S8).[27] Regarding the more complex 
situation in the cellular context, the six identified classes have to be discussed 
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separately. In case of subset III to VI, we could only detect weak growth inhibition 
(MICBCGT > 10 mg/L; Supp. Data, section 6, Table S1). In class II three compounds 
were found to have a KD value below 15 µM but none of them had MICBCGT below 
10 mg/L (II:20, see Supp. Data, section 6, Table S1). For econazole, we observed a 
MICBCGT= 5.4 mg/L which is in good correlation to previous findings.[26] Most active 
compounds were observed in class I (Supp. Data, section 9, Figure S9 and S10). 
The best heme-binder to CYP121 (I:16) with a three-fold increased affinity compared 
to econazole showed a MICBCGT of 1.6 mg/L. For I:47 and I:48 we could determine 
MICBCGTs = 0.3 mg/L and 2 mg/L which renders I:47 to be the most potent 
antimycobacterial compound in this subset. The MIC tests of negative controls out of 
class I (I:1 and I:33) showed no significant growth inhibition. Within class I results of 
the MIC assay are in good correlation to the KD values on the target enzyme CYP121 
(Table VI 1). To test the potency of the most effective antimycobacterial compounds 
against the human pathogen Mtb, we used the MABA assay system.  
 
Table VI 1. Structures, relative SPR responses (R/Rpos), binding affinities (KD) and antimycobacterial 
activities of econazole, most active hits (I:16, I:47, I:48), examples for negatives (I:1, I:33) and for 
moderately active hits (I:15, I:30, I:32).  
Cmpd. SPR [R/Rpos] 
Haem KD 
[µM] 
MICBCGT  
[mg/L] 
MICBCGT  
[µM] 
MICMtb  
[mg/L] 
MICMtb  
[µM] 
Ecoa 1 3 5.4 14 4.2b 11b 
I:1 0.4 >100 >25 >100 - - 
I:15 0.3 34 9.6 41 - - 
I:16 1.2 1 1.6 5 1.9 6 
I:30 1.4 11 2.6 11 11.2 48 
I:32 1.1 14 7.0 30 9.6 41 
I:33 0.1 >100 >25 >100 - - 
I:47 0.6 5 0.3 1 0.3 1 
I:48 0.6 5 2.0 7 3.5 12 
a Eco = econazole, b MICMtb determined previously.[26] 
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For MICMtb determination we chose the common laboratory strain H37Rv. In several 
studies the MICMtb value of econazole was determined ranging from 0.12 mg/L to 8 
mg/L.[7,17] To facilitate comparability of the MICMtb values, we referenced them to 
results made in our assay system where a MICMtb for econazole of 4.2 mg/L was 
determined previously.[26] The most effective compounds were I:47 with MICMtb = 
0.3 mg/L followed by I:16 (MICMtb = 1.9 mg/L) and I:48 (MICMtb = 3.5 mg/L, see Table 
VI 1). Notably, in terms of cellular efficiency metrics, I:47 has an AE = 0.39 and 
hence, a higher AE than econazole (0.24) and rifampicin (0.16) (Supp. Data, section 
10, Table S2). 
Toxicity on human cell lines. The azole antifungals are known to attenuate growth 
of several human cell lines.[28,29] To compare cellular toxicity of econazole with our 
three most promising hits we used HEK293 cells in a MTT-based assay.[30] 6.0 mg/L 
of econazole killed 50% of HEK 293 cell population after 48 h. Notably, the toxicity of 
our most active antimycobacterial compounds was lower compared to the azole 
antifungal drug (I:16 LD50 = 6.1 mg/L; I:47 LD50 = 18.6 mg/L; I:48 22.3 mg/L). For 
comparability reasons, we calculated the toxicity factor for I:47 (MICMtb/LD50), which 
revealed a 44-fold improvement compared to econazole (Table VI 2). One of the 
most prominent undesirable effects of azole antifungals is their hepatotoxicity 
observed in mice.[29,31] For this reason, we also conducted toxicity experiments 
employing HepG2 cells. We could observe an approximately 2-fold increased toxicity 
for econazole (3.1 mg/L) and I:16 (3.9 mg/L) compared to HEK293 cells. The LD50 of 
I:47 was 17.1 mg/L which is close to the toxicity seen in HEK cells. (vide supra, 
Supp. Data, section 11, Table S3). 
 
Table VI 2. Comparison of human cellular toxicity and anti-Mtb effect.  
Compound MICMtb  [mg/L] 
LD50 HEK 293 cells 
[mg/L] 
Toxicity factor 
MICMtb/LD50a 
Eco 4.2 6.0 1.4 
I:16 1.9 6.1 3.2 
I:47 0.3 18.6 62.0 
I:48 3.5 22.3 6.4 
a Toxicity factor (MICMtb (Mtb) divided by LD50 (HEK293)) was used to enhance comparability of 
compounds with regard to their antimycobacterial effect. 
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In vitro and in cellulo mode of action studies. In addition to the binding constant, 
we determined inhibition of CYP121 enzymatic reaction by I:47. The enzyme 
catalyzes the formation of an intramolecular C-C bond between the carbon atoms in 
ortho-position to the hydroxyl-group of the phenol-moiety of cYY resulting in the 
production of mycocyclosin.[9] For assessing CYP121 activity we used an artificial 
redox-system from Schizosaccharomyces pombe (ferredoxin Etp1fd (516-618) and 
ferredoxin reductase Arh1_A18G).[24] This redox-system is known for its broad 
applicability as electron-donor for CYP enzymatic reactions but firstly described for 
CYP121 herein. Indeed, we could observe an inhibition of product formation 
confirming I:47 to be a potent inhibitor of mycocyclosin production by interference 
with CYP121 in vitro (Supp. Data, SI section 1). 
To gather further evidence for target-based mycobacterial selectivity towards other 
bacteria, we assessed the activity of our compounds on growth of E. coli TolC as a 
representative for Gram-negative bacteria and S. aureus Newmann strain for Gram-
positive. The results show no significant growth inhibition of I:47 and I:48 against the 
latter bacteria (MICMtb > 100µM or > 25 mg/L). In contrast to econazole and I:16 that 
showed certain inhibitory effects for E. coli and S. aureus in higher concentrations 
(Supp. Data, section 12, Figure S11). 
Physicochemical and selectivity profile of I:47. The aforementioned compounds 
were originally designed as inhibitors of human CYP17, CYP19 and CYP11B1/2 
known to be involved in steroid biosynthesis. I:47 was initially synthesized as an 
inhibitor of CYP17. The compound showed only a low activity on CYP17 compared to 
other inhibitors with an IC50 = 3.1 µM. Additionally, only a 48 % inhibition of 
aromatase at a concentration of 25 µM was observed.[32]  
Regarding physicochemical properties suitable for permeation through the cellular 
membranes, one has to differentiate between biological barriers of human and 
mycobacterial origin. For humans, a guidepost for appropriate physicochemical 
properties is the Lipinski’s rule of five for oral bioavailability of drugs (< 5 hydrogen 
bond donors, ≤ 10 hydrogen bond acceptors, MW < 500 Da, logP ≤ 5).[33] Our 
frontrunner compound I:47 fulfils all four criteria (0 hydrogen bond donors, 3 
hydrogen bond acceptors, MW = 278 Da, log P = 3.1) (Supp. Data, section 13). To 
the best of our knowledge, akin correlations for physicochemical properties with  
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Figure VI 4. Molecular docking of I:47 against the prepared co-crystal structure of CYP121. Heme 
coordination was a prerequisite for the docking process which was achieve by placing a 
pharmacophore feature on the interacting metal and ligand position. Resulting docking poses were 
sorted by score (E_refine) and the highest scored pose is depicted as 3D model (a) and 2D-interaction 
chart (b). I:47 shows close van der Waals contacts to surrounding amino acids but also possibilities for 
compound enlargement (b). The grey surface in panel (a) represents the van der Waals surface of the 
protein, which is also shown as dotted lines in panel (b). 
mycobacterial membrane passage were not set up, yet. Thus, a respective guide for 
compound development is still missing.[34] 
Molecular modelling studies on the binding mode of I:47. As a type II binding 
profile was observed for I:47, we set up a constrained docking protocol to predict its 
binding mode to the heme center of CYP121. Docking to the active site of CYP121 
was restricted by two essential pharmacophore features reflecting the direct 
interaction between the coordinated iron and I:47 (type II binding). The resulting 
docking poses were sorted by their predicted binding energies and the best scored 
docking pose was chosen for further studies (Figure VI 4). This modelling approach 
revealed new possibilities for further derivatization or rigidification. For instance, 
intramolecular linking of the methylene bridge at the imidazolyl unit with the ortho-
position of phenyl using e.g. a five-membered ring should be tolerated by CYP121 
and increase affinity through reduction of entropic penalties upon binding. 
Furthermore, the central hydrophobic aromatic moiety shows Van-der-Waals 
contacts to flanking hydrophobic amino acids Phe-168 and Met-62. Regarding steric 
factors, the ring could easily rotate in this position. This degree of rotatable freedom 
might be necessary to place the aforementioned phenyl in a suitable position to grant 
access to a large flat subpocket (composed of Met-61, Asn-84 and the backbone of 
Asn-83) which could then be reached by substituents at its 2-postion. The 1,3-
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benzodioxole moiety was placed in a hydrophilic subpocket, formed by Arg-72, Asn-
74 and Thr-65, which is in good accordance with the low lipophilicity of this motif 
(cLogP = 0.27). Moreover, the 5-position of 1,3-benzodioxole holds great potential for 
further enlargement of the molecule, as it directly points to another subpocket which 
is decorated with several hydrophobic amino acids, namely Leu-73, Phe-280, Leu-
284 and the sidechain of Gln-385. 
 
CONCLUSION 
Despite the fact that CYP121 had been reported to be a potential target for the 
treatment of Mtb infections, not many inhibitors with cellular activity had been 
discovered. Herein we have presented a rational screening approach to address 
CYP121 by a small library focused on privileged scaffolds for CYP enzyme inhibition. 
The identified compounds could help to clarify the hitherto unknown role of CYP121 
in Mtb metabolism and provide a good starting point for a drug optimization program. 
Our search for new inhibitors of CYP121 started with an initial SPR screen of the 
aforementioned focused library. As the compounds were designed for P450 inhibition 
we observed a high number of binders (32%). The identified compound classes 
differed highly with regard to their structures. Obviously, the large pocket of CYP121 
(1350 Å3) which is necessary for the sterically demanding enzyme reaction can 
accept a large variety of differently shaped molecules.[7,9,35,36] However, it has to be 
noted that the SPR method does not exclude compound attachment outside the 
enzymes active site. 
For rational design approaches it is of high interest to clarify the binding mode and 
affinity of our hit compounds. A common method for P450 enzymes to address this 
issue is the heme coordination assay.[7] All SPR-binders from classes III, IV, V and VI 
had only weak affinity to the heme-iron (KD > 100µM). IV:13 is the only compound 
from this subset that could be titrated and gave a KD of 62 µM (Supp. Data, section 6, 
Table S1). Therefore, we conclude that most of the compounds from these classes 
do not bind directly to heme but address another unknown site. This information 
could, however, be valuable for fragment-linking approaches at a later stage of drug 
development. For classes I and II we identified eight compounds with KD values 
below 15 µM. Notably, the best compounds of class II (II:20 and II:34) contained a 
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space-demanding trityl-moiety. It was discussed for a crystal structure of CYP121 
(PDB-ID: 1N40) that Arg-386 may restrict access of voluminous moieties to the iron-
heme.[35] Nevertheless, we observed that the enzyme can accommodate space-
demanding molecules at the heme-site as shown by our UV/Vis experiments. Binders 
with the best affinity were found in class I. A comparison of compound structures and 
binding efficiencies within this class gave first evidence for properties needed to gain 
affinity towards CYP121. Imidazolyl head group linked by an methylene bridge to a 
hydrophobic core can be considered as an important basic structure for a good 
binding efficiency (I:16, I:47 and I:48). In case of the linearized compounds, an N- 
methylenbenzimidazoyl head group (I:33), ortho-substituted biphenyl system (I:15), 
and an interconnecting pyridinyl (I:1) ring had unfavorable binding properties. In a hit 
optimization process these structural characteristics should be avoided. In contrast to 
this observation, a para-benzodioxine substituent (I:48) and a para-benzodioxole 
substituent (I:47) linked to the biphenyl system increases affinity. This might provide 
a possible position for further derivatization. Our docking study supports this result as 
this motif was predicted to be placed in a subpocket having a great potential for new 
interactions. 
A straightforward approach for target validation is to correlate on-target potency and 
cellular activity. Although it has to be noted, that such a correlation can be flawed by 
the fact that compounds might also be inefficient due to e.g. poor membrane 
penetration.  We hypothesized that class II might be a prime example for compounds 
that poorly permeate the membrane of mycobacteria and, thus, cannot reach their 
intracellular target. This could be an explanation for the lack of in cellulo activity 
although a moderate affinity to the target was measured. 
Class I is the most remarkable of the six classes showing reasonable affinity towards 
CYP121 and, more importantly, also high activity in cellulo against Mtb and BCGT. 
Furthermore, the on-target affinity of class I compounds directly correlates with their 
activity on mycobacteria which provides further evidence of a CYP121-dependent 
effect. In detail, on-target inactive compounds like I:1 and I:33 had no activity against 
BCGT, while moderate binders e.g. I:15, I:30 and I:32 had low antimycobacterial 
effects. Finally, compounds with highest affinity (I:16, I:47, I:48) were the most potent 
in the cellular setting. Especially, compounds I:16, I:47, and I:48 are even more 
effective on mycobacteria than the positive control, econazole, although no 
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optimization has been undertaken, yet (Table VI 1). In terms of antibacterial efficiency 
(AE), I:47 is superior to econazole and the first-line drug rifampicin indicating an 
excellent optimization potential of this novel inhibitor class. Moreover, we could 
provide data that I:47 does not only bind to CYP121 but does also inhibit the enzyme 
reaction (Supp. Data, section 4). The correlation between MIC and KD bares minor 
inconsistences, which might be due to poor penetration through the mycobacterial 
cell wall of some compounds (see e.g. I:47 and econazole). A highly lipophilic 
molecule (e.g. econazole cLogP = 5.3 vs. I:47 cLogP = 3.1) might be trapped in this 
lipophilic barrier containing mycolic acids and slowly or only partially released into the 
mycobacterial cytoplasm. This results in lower cellular activity than expected from on-
target affinities. A second explanation for the differences in MIC and KD, at least for 
econazole, is its promiscuous behavior in different growth inhibition assays. This 
suggests that there are additional targets for econazole. An explanation for the 
antibacterial activity of econazole against E. coli and S. aureus was already provided 
before. In these studies econazole was described as an inhibitor of 
Flavohemoglobin.[37] Further possible target systems of azole antifungals within Mtb 
metabolism have also been described.[38]  However, evaluation of I:47 and I:48 leads 
to the conclusion that these novel structures are of improved selectivity towards Mtb 
with a good correlation of CYP121 affinity and antimycobacterial activity. 
Furthermore, the two compounds possess lower toxicity against human cells than 
determined for econazole. Although toxicity to hepatocyctes was low, it is of high 
interest to clarify potential inhibition of metabolizing CYP enzymes (e.g. CYP3A4). 
These results further underline the target-based mycobacterial specificity of our 
compounds, at least in the subset of bacterial and human cells tested. Taken 
together the in vitro and cell-based studies conducted herein, CYP121 is most 
certainly the major target of I:47 and I:48.  
In summary, we have reported a biophysical screening procedure employing a 
focused library of privileged scaffolds, which ultimately lead to the discovery of novel 
CYP121 inhibitors. From this process, I:47 turned out to be the most promising hit 
compound pairing convincing antimycobacterial activity and bacterial selectivity with 
a good toxicity profile. Furthermore, this compound exhibits a fragment-like molecular 
weight and preferable physiochemical properties that fulfil the Lipinski rules for oral 
bioavailability (Supp. Data, section 13). Thus, I:47 is an excellent starting point for 
rational structure-based drug discovery. Our in silico studies revealed several 
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possible modifications to be investigated in future optimization steps. Additionally, the 
inhibitor might be a suitable candidate for an in vivo proof-of-concept study towards 
validation of CYP121 as a drug target. 
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EXPERIMENTAL SECTION 
SPR-Screening: SPR binding studies were performed using a Reichert SR7500DC 
instrument optical biosensor (Reichert Technologies, Munich, DE) and SAD500m 
sensor chips obtained from XanTec Bioanalytics.CYP121 was immobilized on a 
SAD500m sensor chip at 12 °C using standard biotin-streptavidin complexation. The 
surface of both channels was quenched by a 3 min injection of 0.003 mg/mL biotin. 
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CYP121 was immobilized at densities between 5000 and 6000 RU for binding 
studies.  
UV/Vis heme P450 binding assay. Optical titration experiments were performed in 
96 well plates (Greiner, Kremsmünster, AT; transparent round bottom). The data 
were recorded using Tecan infinite M200Pro Nano Quant (Tecan Groupe Ltd., 
Männedorf, DE). Absorbance of enzyme and enzyme-inhibitor complex was 
measured between 350 and 500 nm in 1 nm steps with 10 flashes. Compounds were 
titrated from DMSO stock solutions maintaining a final DMSO concentration of 1%. 
CYP121 was used in a concentration of 0.25 µM. Data were plotted as optical shift 
versus ligand concentration. Equation VI 1 (Eq. VI 1) was used for non-linear 
regression of the resulting dose–response curves employing the Levenberg–
Marquardt algorithm of Sigma Plot 12 (Systat Software GmbH, Erkrath, DE). 
 = 	 + 	
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Equation VI 1. f is the observed difference in absorbance at wavelengths 410 nm and 430 nm within 
the difference spectrum (see Figure VI 3) at ligand concentration x. This difference spectrum is 
obtained by subtracting the pure heme absorption spectrum from those with ligand present. ymax refers 
to the absorbance change at ligand saturation, ymin is the extrapolated minimal difference in 
absorbance; KD refers to the dissociation constant of the CYP121 ligand complex.[19] 
Determination of BCGT MICBCGT by OD600 assay. A pre-culture of BCGT was 
grown in 7H9 medium supplemented with ADC Enrichment for 10 days. The assay 
was performed in 48 well plates (Greiner, Kremsmünster, AT). Prior to culture 
addition, compounds were serially diluted in DMSO to fit a final DMSO concentration 
of 1%. For compound susceptibility the pre-culture was diluted 1:100 with fresh 
medium (7H9 + ADC enrichment). After 168 h of incubation at 37 °C and 80% air 
moisture, bacterial growth was measured by determination of OD600. Absorption data 
was recorded on a Polarstar Omega Multidetection Plate Reader (BMG LABTECH, 
Ortenberg, DE). Graphs were plotted with GraphPad Prism using OneSite Log IC50 
model provided by the software. MICBCGT was defined as the concentration at which 
50 percent of growth was detected in accordance with previous methods used.[26] In 
analogy to ligand efficiency, which relates activity of compounds to their number of 
heavy atoms, a new metric has been introduced: antibacterial efficiency (AE).[39] This 
coefficient was developed for better comparability of antimicrobial compounds 
differing in molecular weight (Eq. VI 2). 
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Equation VI 2. AE refers to the antibacterial efficiency, MIC is the minimal inhibitory concentration, 
and NHA equals the number of heavy atoms in a given compound. 
Human cytotoxicity assay. HEK 293 cells (2×105 cells per well) were seeded in 24-
well, flat-bottomed plates (Greiner Bioscience, Kremsmünster, AT). Culturing of cells, 
incubations and OD measurements were performed as described previously[30] with 
minor modifications. 24 h after seeding of the cells the incubation was started by the 
addition of the compounds from DMSO stock solutions to a final DMSO concentration 
of 1%. The living cell mass was determined 48 h after addition of the compounds and 
was followed by the calculation of LD50 values. The calculation of the LC50 values was 
performed by plotting the percent inhibition vs. the concentration of inhibitor on a 
semi-logarithmic plot. From this, the molar concentration causing 50% reduction of 
the living cell mass was calculated. At least three independent experiments were 
performed for each compound. 
Supporting Information. Chemical synthesis of cYY and Mycocyclosin, SDS-PAGE 
of His-tagged CYP121, Activity of CYP121/ CO Spectra, LC-MS analysis of in vitro 
CYP121 enzyme reaction and effect of I:47, Surface Plasmon Resonance 
Sensorgramm of econazole, Screening overview, KD determination by UV-VIS Heme 
coordination assay, Protein Blast of Mtb H37RV CYP121 (Rv2276) and M. bovis BCG 
Pasteur CYP121 (BCG_2293), MICBCGT determination against Mycobacterium bovis, 
Calculation of antimicrobial efficiency, Toxicity assessment against human cancer 
cell lines HEK293 and HepG2, MIC against Escherichia coli and Staphylococcus 
aureus in comparison to growth inhibition against Mycobacterium bovis BCG, 
Physicochemical data. 
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4 Concluding discussion and perspectives 
4.1 Novel synthetic methods to access substituted pyrimidines  
Pyrimidines are highly valuable heterocycles in medicinal chemistry as they 
frequently appear in FDA-approved drugs. Pyrimidines are hydrophilic but not 
protonated under physiological conditions, which makes them an ideal choice as a 
core scaffold for orally bioavailable drugs. Synthetic chemists in general, but 
medicinal chemists in particular, are usually interested to simplify synthetic methods, 
increase yield, and safe time and money on the route to the final compound. 
However, in the field of pyrimidine chemistry, to the best of our knowledge, only 
traditional approaches towards introduction of substituents have been reported. 
These require disadvantageous prerequisites as discussed in chapter 1.6. Thus, one 
aim of the thesis was to develop a novel strategy to gain fast access towards 
substituted pyrimidines while circumventing the flaws of traditional pyrimidine 
chemistry. Inspired by the work on pyridine chemistry by Vera-Luc et al.,[80] we tested 
whether a similar procedure (neat conditions, microwave) might be suitable for our 
pyrimidine scaffold (see Paper I and VIII). Indeed, as for pyridine, 1H-benzotriazole 
could be attached within minutes in quantitative yield without the need of solvent, 
catalyst, inert atmosphere conditions or strong bases. Motivated by these results, we 
tested the scope of these reaction conditions and, interestingly, substituted 
benzimidazoles and benzotriazoles could also be successfully linked to the 
pyrimidine core. By broadening the scope towards five-membered heterocycles we 
saw that almost all unsubstituted N-pentacycles could be attached by this 
methodology to pyrimidine as well. Regarding limitations, only pyrrol and indole fall 
out of the scope, as they do not react. To the best of our knowledge this is the only 
method to synthesize 4-tetrazolyl-2-(methylthio)pyrimidines directly (I/20*), since 
several trials using the traditional approach which employs sodium azide, trimethyl 
orthoformate and an amino-substituted pyrimidine in acetic acid failed in our hands. 
This pentacycle is of high interest in medicinal chemistry, due to its metabolic 
stablility, suitability as bioisoster for carboxylic acid, amides or esters (when 
substituted at N1 or N2) and of high hydrophilicity making compounds more soluble. 
In addition, as we were the first to synthesized 4-tetrazolyl-2-(thiomethyl)pyrimidines 
as precursor for dual inhibitor compounds, we were also interested in the chemistry 
                                            
*In the following chapters the compounds are numbered with two identifiers, separated by a slash: a roman number referring to 
the publication or chapter they were described in, followed by their identifier within the respective publication or chapter. 
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of tetrazoles to generate a compound library. Gaining synthetic access to the 6-
position of pyrimidine, while keeping the tetrazole in 4-position was the major goal to 
be accomplished for rapid library generation. As we were the first to discover this 
particular scaffold as a bioactive entity, the challenge was to develop a new 
chemistry with the requirements of a medicinal chemistry environment (see chapter 
2, paragraph II). Inspired by an unexpected quantitative conversion that occurred 
during the deprotection of a TMS-protected triazole (Figure 22), we hypothesized that 
we could use this information to generate a novel reactive intermediate granting 
access to the aforementioned class. This intermediate should be substituted with the 
azole of choice at the 4- and 6-poisition of 2-thiomethylpyrimidine and one of the 
pentacycle is then to be the leaving group for a nucleophile of interest. 2-(methylthio)-
4,6-di(1H-tetrazol-1-yl)pyrimidine (III/1) is the mentioned intermediate which can be 
achieved in high yields in minutes under microwave irradiation (Paper III). To clarify 
the regiochemistry of the attached tetrazole moieties, which cannot be univocally 
elucidated by NMR, we crystallized the compound and derived an X-ray crystal 
structure. As for the unexpected conversion mentioned above, the tetrazole 
substituent can be replaced in a microwave reaction by a broad scope of substrates 
covering thio-, amino- and hydroxyl nucleophiles as well as N-pentacycles. To 
investigate the robustness of the approach and with regard to the fact that III/1 can 
be obtained in high yield, we investigated if the reaction is applicable for a one-pot 
setup as well. Indeed, all tested substrates reacted smoothly in a one-pot reaction via 
in situ generated III/1 within 20 minutes.  
N
N SN
NN
TMS K2CO3
MeOH,
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N
N SO
N
N SN
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Figure 22. Deprotection of the TMS-protected triazole moiety in 4-position of 2-thiomethylpyrimidine 
did not yield the unprotected compound but yielded 4-methoxy-2-thiomethylpyrimidine in quantitative 
yield.  
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In summary, two novel approaches were developed enabling fast and efficient 
synthesis of substituted pyrimidines. Furthermore, the methodology seems to be 
suitable for combinatorial chemistry approaches. In the future, this novel synthetic 
route might speed up drug discovery efforts focused on pyrimidine scaffolds but could 
also inspire synthetic chemists to transfer these findings to other heterocycles. 
 
4.2 Two approaches - one goal: fighting treatment-resistant bacterial 
infections of the respiratory tract 
The respiratory tract diseases cystic fibrosis and tuberculosis have many things in 
common: both illnesses are caused by bacteria, long term hospitalization is often 
required, resistance development hinders or makes treatment ineffective and 
dormant or persisting pathogens are hard to eradicate with common antibiotics. Thus, 
in this thesis two different approaches were pursued to address the latter mentioned 
problems. For PA, the pathogen involved in cystic fibrosis-associated pulmonary 
infection, a novel strategy was investigated trying to circumvent resistance 
development by interference with the non-vital QS machinery to lower pathogenicity 
(see chapter 4.21). Such agents may help to establish a new paradigm in anti-
infective treatment of cystic fibrosis patiens and could lead to first “pathogenicity-
blockers” with lowered resistance development. In case of Mtb, the major pathogen 
causing tuberculosis, a classical antibiotic drug discovery campaign was initiated by 
addressing two novel potential drug targets. Ideally, the developed compounds 
should not show any cross resistance to any other anti-mycobacterial drug. Thus, the 
identified compounds could serve as starting point for the development of new anti-
mycobacterial drug candidates to broaden the portfolio of anti-tuberculosis treatment 
options (see chapter 4.2.2). 
 
4.2.1 Addressing PqsD and PqsR to reduce pathogenicity of Pseudomonas 
aeruginosa 
Disruption of virulence-associated targets has proven to be a valuable approach 
towards the reduction of pathogenicity of PA. Pioneering work in this field which was 
conducted in previous studies on PqsD and PqsR, dealt with compounds that were 
either of limited drug-likeness due to high lipophilicity resulting in low solubility or of 
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limited cellular efficiency.[46,50,52] Thus, the development of hydrophilic, drug-like 
compounds with the capability to pass the Gram-negative cell envelope to effect 
virulence factors without impairing growth is a formidable challenge. Nevertheless, 
the use of aforementioned inhibitors of PqsD and antagonists of PqsR led us to a 
novel polypharmacological concept. By a combination of both compounds we could 
increase the beneficial outcome regarding virulence factor production with respect to 
the effect of the single agent alone. These conceptual studies on dual inhibition of 
auto-loop regulated systems paved the way for the development of dual active 
inhibitors. In the compound class of 2-sulfonylpyrimidines, we identified a common 
scaffold for the inhibition of PqsD and antagonism on PqsR. Reduction to the 
essential common structural features necessary for activity, lead to the discovery of 
the first reported dual PqsD/PqsR inhibitor IV/5. The discovered hit compound was 
then further modified with a strong focus on hydrophilicity. The latter was exclusively 
addressed by the use of a Ligand Lipophilicity Efficiency score as a guidepost for 
drug design. This led us to the design of IV/6 (Figure 23) which was also active on 
both targets but of higher lipophilic efficiency and solubility than its parent compound 
IV/5. As it is of tremendous importance in drug discovery to validate a compound as 
early as possible in the optimization process, we challenged the inhibitor against 
cultures of PA in planktonic and biofilm state. As the compound showed promising 
activity against two major virulence factors, pyocyanin and pyoverdine, without 
impairing PA growth, we extended our studies on biofilm formation. The positive 
outcome on biofilm formation aroused our interest to investigate in depth how IV/6 
interferes with the biofilm architecture. In these studies, besides reduction of 
polysaccharide and protein content of the biofilm, we observed a prominent decrease 
of extracellular DNA (eDNA) release. The eDNA of PA is one of the major 
determinants for antibiotic tolerance as well as resistance to host defensive peptides 
like LL-37 in the biofilm.[27] Thus, we were motivated to see if the reduction of eDNA 
might partly or fully restore the efficacy of an antibiotic against biofilm-encapsulated  
 
Figure 23. Physicochemically improved hit IV/6 with dual activity on PqsD and PqsR 
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PA. Indeed, compound IV/6 reduced PA’s ability to tolerate Ciprofloxacin treatment 
and could restore its antibacterial activity in a combination experiment. As in vitro 
results were promising we wanted to validate the compound in an in vivo model to 
have the most promising starting point for drug optimization. Thus, we decided to 
challenge the compound in our established infection model employing Galleria 
mellonella larvae. In these trials, administration of 1.25 nmol (= 0.63 mg/kg) of IV/6 
granted the survival of larvae and protected about 60% of the population against PA 
infection. In summary, the in vivo validation, the compounds low molecular weight 
and convincing physicochemical properties rendered this inhibitor an ideal hit for 
optimization. To improve target affinities, we identified three positions for possible 
prolongation of the molecule, which were easily accessible via our novel synthetic 
methodology (see Paper I and III, Figure 24). Exchanging the tetrazole substituent at 
position R2 by different six-membered, five-membered or bicyclic aromatic systems 
led to an impairment of activity on both targets, rendering 1N-tetrazole and 1N-1,2,3-
triazole the group of choice from the investigated subset. Next, we explored whether 
we could gain higher activity by growing from the 4-position of the 1,2,3-triazolyl 
moiety at R2. The enlargement of the western part (R2) of the molecule resulted in 
higher activity on PqsD and elevated antagonism on PqsR. However, a major 
drawback was the strongly reduced solubility of such compounds and the strong drop 
of the LLE score. As physicochemical properties and a rational metrical guidance is 
of great importance to keep focus on developing drug-like molecules, we defined this 
particular position as unsuitable for further optimizations. Introduction of different 
substituents at R3 (e.g., N-aminomethyl, N-acetamide, phenoxy) yielded only 
compounds of either reduced activity or undesirable ligand efficiency. Thus, by 
probing R3, we recognized that the common pharmacophore for dual inhibition is 
much narrower than we initially thought. Hence, we used computational methods in a 
 
Figure 24. The development of novel synthetic methods enabled the generation of substituted 
pyrimidines at R1, R2 and R3 by a robust route to generate a library of dual active inhibitors for deriving 
SAR information. 
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ligand-based approach and conducted a flexible alignment of our initial hit IV/5 and 
the natural ligand of PqsR (HHQ) as well as a described substrate of PqsD (β-
decanoic acid, see Paper V). These studies drew our attention to R1 which might be 
suitable for the introduction of alkyl chains. The alkyl substituted compounds were of 
increased activity on PqsD which could be correlated with the chain length introduced 
using a Hansch approach. However, the most effective compound V/34 (hexyl chain) 
was of slightly reduced activity on PqsR (IC50 ~ 50µM). In light of these new results, 
we tested whether PqsR and PqsD could accommodate other substituents at R1. A 
phenyl substituent increased activity on PqsD and was tolerated by PqsR. Hence, we 
conducted a Topliss derivatization of the phenyl ring.[81] It turned out, that the 
Hammett constant of introduced groups at the phenyl ring strongly correlated with the 
biological activity on PqsD. A Hansch analysis, suggesting the introduction of 
stronger electron-withdrawing groups, led to the discovery of an improved hit with 
higher potency on PqsD (V/44). This compound possesses very good ligand 
efficiency indices and, additionally, its activity on PqsR was not impaired compared to 
the initial hit IV/6 (see chapter V and Figure 25). As one of the desired features of the 
inhibitor class within this work was increased susceptibility against Ciprofloxacin and 
reduced biofilm volume we tested if dual active compounds V/44 and V/34 were able 
to interfere with these resistance determinants. Indeed, both compounds reduced 
biofilm formation and, in good accordance with the initial hit IV/6, also inhibited eDNA 
release into the biofilm matrix.  
As PqsD is a validated anti-biofilm target, we were interested if we could generate 
new starting points for fragment-based inhibitor design with desirable properties (low 
molecular weight, high solubility, high Ligand Efficiencies). From our studies on the 
tetrazole-azido equilibrium at 4-azidopyrimidines (Paper II), we gained access to 
stabilized tetrazolo[1,5-c]pyrimidines that share a high degree of similarity towards 
adenine (Figure 26). This moiety is a reappearing motif in many natural compounds 
N
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IC50 PqsR = 24 µM (LLE = 0.30)
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Solubility = 100-200 µM
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Figure 25. Ligand-based design guided by LLE & QSAR led to the discovery of a dual inhibitor 
compound (V/44) with increased activity on PqsD. 
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Figure 26. Comparison of stabilized tetrazolo[1,5-c]pyrimidines with the naturally occurring adenosyl 
motif.  
also being part of PqsD’s substrates (malonyl and anthraniloyl-coenzyme A). Thus, 
by simple comparison of adenine with tetrazolo[1,5-c]pyrimidines, we hypothesized 
that these compounds might inhibit the enzyme reaction. Interestingly, thionyl 
derivative II/9 and carbonyl derivative II/5 showed prominent inhibition of PqsD in the 
low micromolar range. In terms of efficiency these compounds represent excellent 
starting points for future fragment-linking or -growing approaches. These improved 
hits could then pave the way towards our long term goal: developing novel drug-like 
anti-virulence agents with the perspective to improve treatment of PA infections.  
In summary, we could successfully apply a concept study towards the design of dual 
target inhibitors, which were further improved regarding activity on PqsD leading to 
biofilm-active agents with preferable physicochemical properties. In depth analysis of 
the azido-tetrazole equilibrium was used to identify fragments suitable for FBDD in 
the future. 
 
4.2.2 The cytochrome P450 enzymes 121 and 125 as novel drug targets for the 
treatment of mycobacterial infections 
Identification of a suitable and validated drug target is the primary goal before any 
drug discovery can be conducted. For an antibiotic drug target a few hallmarks need 
to be fulfilled. For example, the function needs to be essential for bacterial growth 
and the target must not have an identical copy in mammals. For CYP121 and 
CYP125 the first aspect was shown in in vitro and in vivo experiments.[71,76] The 
second requirement can be checked by a protein blast search of the mycobacterial 
protein sequences versus the human proteome. For CYP121, the most homologous 
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protein was CYP17 with an overall amino acid identity of 29% and a homology of 
44%. Regarding CYP125, the blast search delivered CYP2R1 to be the most 
identical protein found in humans with an amino acid identity of 24% and an overall 
homology of 41%. These pre-conditions render CYP121 and CYP125 ideal target 
candidates for anti-mycobacterial drug discovery regarding selectivity towards human 
CYP enzymes, which is important for circumventing potential toxic side effects. 
Finding a hit structure for a drug target can be achieved by different approaches: 
randomly, by screening a library of millions of lead-like compounds, hundreds of 
fragments or by more rational approaches. As shown by our group for PqsD, a 
general trend regarding the screening method used is: the more information about a 
target is available (e.g., X-ray structures, substrates, known inhibitors) the higher the 
chances are to increase hit rates.[53] Driven by this rational, we made use of inhibitors 
especially designed to interfere with the function of CYP P450 enzymes to build a 
privileged library for the discovery of drug-like compounds targeting CYP121 and 
CYP125. This library was of small size (< 150 compounds) but covered a chemical 
space of six different scaffolds. In detail, these compounds were developed to target 
human CYP enzymes from the human steroidogenic pathway, namely CYP11B1/B2 
(11β-hydroxylases),[82] CYP17 (steroid-17α-hydroxylase) and CYP19 (aromatase).[83] 
As the primary screening technology we used surface plasmon resonance 
spectroscopy (SPR) which allowed us to identify first binders in an automated 
medium throughput fashion. Fortunately, a common binder, the antifungal drug 
Econazole, was already known to bind to the hemes of CYP121 and CYP125 and 
was able to inhibit growth of mycobacteria.[69,79] Thus, the compound served as 
positive control in all subsequent assays. In the SPR screening, Econazole’s 
response (Rpos) was chosen as reference to evaluate the hits. Therefore, we 
introduced a metric which is the quotient of the response of the hit (R) divided by the 
response of Econazole (Rpos). Every compound which had at least a R/Rpos ≥ 0.5 was 
regarded as a hit and hence subject to further investigation in the UV-VIS heme 
binding assay. For CYP121 we had a hit rate of 33% while for CYP125 17% of the 
library compounds were binders regarding the aforementioned score. The 
compounds were further evaluated by their ability to bind to the iron(II) center of the 
heme of respective enzymes. For this reason, we chose photometric UV-VIS analysis 
as an assay to address this question. The basis for this experiment is the fact that 
upon binding to the heme – either by direct coordination to iron center or indirectly by  
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Figure 27. Chemical structure of CYP125/142 dual inhibitor VII/128 which was the most promising hit 
derived from the screening campaign against CYP125 as potential anti-mycobacterial agent. 
forming an H-bond to the labile aqua-ligand, a test compound changes the UV-VIS 
spectrum of the CYP enzyme (Chapter 1.8). This phenomenon was used to derive 
dissociation constant of binders (KD) and to differ between the two possible heme 
binding types (Chapter 1.8). For CYP121 we found eleven compounds with a KD 
below 10 µM all of which showed a type II binding profile. 14 compounds had an 
affinity to CYP125 below 30 µM including six type I and eight type II binders. The 
most potent compound, VII/128, had already an affinity in the low nanomolar range 
(KD = 0.085 µM, Figure 27).Notably, this compound was also active on CYP142, a 
bypass enzyme for the CYP125 reaction reported in the laboratory strain Mtb 
H37Rv,[84] with a KD of 0.008 µM. Although this enzyme was only found in the 
laboratory strain Mtb H37Rv to date, this finding might give a hint how future 
resistance could develop. In this respect, a dual inhibitor of CYP125 and CYP142 
might be superior over single target compounds. These compounds are somehow 
also related to quorum sensing inhibitors, as they are not lethal for the bacterium per 
se, but become active as soon as the bacterium enters the host.  
Regarding CYP121, the best binders were further evaluated for their potential to 
inhibit mycobacterial cell growth. Three of the eleven compounds showed an anti-
mycobacterial activity against a bovine strain which was below 10 µg/mL. To validate 
the compound for the human pathogen Mtb, we conducted an additional growth 
inhibition assay employing this pathogen. From the three compounds, one compound 
(VI/I:47, Figure 28) inhibited bacterial growth with a MIC90 of 0.3 µg/mL which is in  
 
Figure 28. Chemical structure of CYP121 inhibitor VI/I:47 which was the most promising hit regarding 
its anti-mycobacterial effect (MIC90 = 0.3 µg/mL) against the human pathogen Mtb. 
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the same range as the first line drug ethambutol (0.4 µg/mL).[85] Interestingly, VI/I:47 
was almost inactive on CYP17, the human enzyme for which is was originally 
synthesized.[86] However, for further biological profiling, we tested the compound in a 
HEK cell assay to evaluate its toxicity on human cells. VI/I:47 was almost 20 times 
less toxic to human than to mycobacterial cells underlining the great potential for drug 
development. Thus, we conducted docking experiments to the crystal structure of 
CYP121 and retrieved a binding pose suggesting hot spots for further structure 
modifications (Paper VI). In the future, for the identified CYP121 inhibitor VI/I:47, 
evaluation of the compound in macrophage infection models and in vivo profiling in a 
mouse model are planned. Furthermore, as the crystallization conditions for CYP121 
are reported, a prospective co-crystal structure of the enzyme and VI/I:47 is plausible 
which could serve as the basis for the structure-guided design towards a more potent 
anti-mycobacterial compound. Regarding the potential of the identified CYP125 
inhibitors, a cellular proof of their efficacy has to be provided. Therefore, regarding 
the mode of action and the mechanism of CYP125, a macrophage infection model 
needs to be established to reliably simulate the in vivo scenario. However, although 
the identified compounds show already lead-like activities on the target, further 
structure modifications need to be carried out to circumvent selectivity issues with 
their originally intended human targets but which is highly probable based on our 
initial in silico selectivity screen using a protein blast search (vide supra). 
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Analytical Data 
Compound 1: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.68 (s, 1 H), 8.63 (d, J=5.6 Hz, 1 H), 
8.21 (d, J=7.6 Hz, 1 H), 7.88 (d, J=7.3 Hz, 1 H), 7.35 - 7.50 (m, 2 H), 7.22 (d, J=5.6 
Hz, 1 H), 2.68 ppm (s, 3 H); 13C NMR (75MHz, CHLOROFORM-d): δ = 174.1, 159.0, 
155.8, 145.0, 140.6, 131.7, 125.0, 124.3, 121.1, 114.0, 104.1, 14.4 ppmppm; ESI-
MS: 243.1 [M+H]+. 
 
Compound 2+3: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.53 - 8.67 (m, 4 H), 8.05 (d, J=8.4 Hz, 1 
H), 7.98 (s, 1 H), 7.73 (d, J=8.2 Hz, 1 H), 7.65 (s, 1 H), 7.10 - 7.34 (m, 4 H), 2.68 (s, 3 
H), 2.67 (s, 3 H), 2.54 (s, 3 H), 2.51 ppm (s, 3 H); 13C NMR (75MHz, 
CHLOROFORM-d): δ =159.0, 158.9, 155.8, 155.8, 145.3, 143.1, 140.5, 140.1, 135.1, 
134.2, 131.7, 129.5, 126.4, 125.7, 120.9, 120.5, 113.9, 113.5, 104.1, 103.9, 22.1, 
21.5, 14.3 ppm; ESI-MS: 257.1 [M+H]+.  
 
Compound 4: 
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1H NMR (300MHz, CHLOROFORM-d): δ = 8.55 - 8.61 (m, 2 H), 7.93 (s, 1 H), 7.59 
(s, 1 H), 7.17 (d, J = 5.6 Hz, 1 H), 2.67 (s, 3 H), 2.42 (s, 3 H), 2.39 ppm; 13C NMR 
(75MHz, CHLOROFORM-d): δ = 174.0, 158.9, 155.8, 143.5, 139.8, 134.2, 133.3, 
129.8, 121.0, 114.2, 103.9, 20.8, 20.2, 14.3 ppm (s, 3 H); ESI-MS: 271.1 [M+H]+. 
 
Compound 5+6: 
 
1H NMR (300 MHz, CHLOROFORM-d) δ = 8.57 - 8.68 (m, 4H), 8.30 (s, 1H), 8.19 (d, 
J = 8.75 Hz, 1H), 7.85 (s, 1H), 7.77 (d, J = 8.57 Hz, 1H), 7.32 - 7.45 (m, 2H), 7.17 (d, 
J = 5.77 Hz, 2H), 2.69 (s, 3H), 2.67 (s, 3H); 13C NMR (75MHz, CHLOROFORM-d): δ 
= 159.1, 155.6, 141.5, 140.9, 125.5, 124.9, 121.7, 120.8, 115.1, 114.7, 104.0, 14.4 
ppm; ESI-MS: 277.1 [M+H]+. 
 
Compound 7: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.58 (d, J=5.7 Hz, 1 H), 8.43 (s, 1 H), 
7.90 (s, 1 H), 7.29 (s, 1 H), 7.13 (d, J=5.7 Hz, 1 H), 3.98 (s, 3 H), 3.96 (s, 3 H), 2.67 
ppm (s, 3 H); 13C NMR (75MHz, CHLOROFORM-d): δ = 174.0, 158.7, 156.0, 148.2, 
147.7, 138.6, 138.3, 125.2, 103.6, 102.3, 97.9, 56.4, 56.2, 14.3 ppm; ESI-MS: 303.1 
[M+H]+.  
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Compound 8: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.66 (d, J=5.7 Hz, 1 H), 7.42 - 7.57 (m, 2 
H), 7.37 (d, J=5.6 Hz, 1 H), 7.23 (d, J=7.6 Hz, 1 H), 7.11 (t, J=8.2 Hz, 1 H), 6.56 (br. 
s., 2 H), 2.63 ppm (s, 3 H); 13C NMR (75MHz, CHLOROFORM-d): δ = 173.2, 159.1, 
156.8, 153.4, 143.2, 131.0, 124.1, 120.6, 117.2, 110.6, 106.4, 14.2 ppm; ESI-MS: 
258.1 [M+H]+. 
 
Compound 9:  
 
mp: 178 °C; UV-VIS (MeOH) (nm): 203, 242, 263, 311(sh), 320; FT-IR (cm-1): 3097, 
2156, 2017, 1893, 1596, 1564, 1552, 1506, 1486, 1463, 1428, 1347, 1324, 1306, 
1288, 1242, 1205, 1144, 1121, 1090, 1065, 1039, 1009, 976, 917, 864, 841, 826, 
801;  1H NMR (300 MHz, CHLOROFORM-d) δ = 2.82 (s, 3 H), 7.55 (t, J = 8.3 Hz, 1 
H), 7.70 (t, J = 8.9 Hz, 1 H), 8.06 (d, J = 5.9 Hz, 1 H), 8.18 (d, J = 8.3 Hz, 1 H), 8.57 
(d, J = 8.3 Hz, 1 H), 8.72 (d, J = 5.9 Hz, 1 H), 9.19 ppm (br. s, 1 H); 13C NMR (75 
MHz, CHLOROFORM-d) δ = 14.3, 103.2, 115.6, 116.4, 122.0, 131.6, 135.1, 157.9, 
159.3, 161.0, 174.1 ppm; ESI-MS: 244.1 [M+H]+; HRMS: [M+H]+ calc 244.06514, 
found 244.06501. 
 
Compound 10+11: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.66 (d, J=5.5 Hz, 2 H), 8.46 (d, J=8.5 
Hz, 1 H), 8.39 (s, 1 H), 8.00 (d, J=8.5 Hz, 1 H), 7.91 (s, 1 H), 7.90 (s, 2 H), 7.47 (d, 
J=8.6 Hz, 1 H), 7.32 (d, J=8.5 Hz, 1 H), 2.72 (s, 3 H), 2.71 (s, 3 H), 2.60 (s, 3 H), 2.56 
ppm (s, 3 H) 13C NMR (75MHz, CHLOROFORM-d): δ = 173.4, 158.8, 157.5, 157.3, 
147.5, 145.5, 140.6, 135.8, 131.6, 131.6, 129.5, 127.6, 119.6, 119.3, 114.4, 105.1, 
105.0, 22.3, 21.5, 14.5, 14.4 ppm; ESI-MS: 258.1 [M+H]+. 
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Compound 12: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.64 (dd, J=5.5, 1.1 Hz, 1 H), 8.34 (s, 1 
H), 7.89 (dd, J=5.6, 1.0 Hz, 1 H), 7.85 (s, 1 H), 2.72 (s, 3 H), 2.48 (s, 3 H), 2.44 ppm 
(s, 3 H); 13C NMR (75MHz, CHLOROFORM-d): δ = 173.3, 158.7, 157.4, 146.0, 
140.1, 135.4, 130.0, 119.4, 114.5, 105.0, 21.2, 20.4, 14.4 ppm; ESI-MS: 272.1 
[M+H]+. 
 
Compound 13+14: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.70 (d, J=5.5 Hz, 2 H), 8.66 (s, 1 H), 
8.57 (d, J=8.8 Hz, 1 H), 8.14 (s, 1 H), 8.07 (d, J=8.8 Hz, 1 H), 7.87 - 7.95 (m, 2 H), 
7.63 (d, J=8.8 Hz, 1 H), 7.49 (d, J=8.8 Hz, 1 H), 2.73 (s, 3 H), 2.71 ppm (s, 3 H); 13C 
NMR (75MHz, CHLOROFORM-d): δ = 159.1, 147.5, 145.4, 136.2, 130.5, 126.7, 
121.1, 119.7, 115.8, 115.0, 105.0, 105.0, 14.5 ppm; ESI-MS: 278.1 [M+H]+. 
Compound 15: 
 
1H NMR (300MHz, CHLOROFORM-d): δ =  8.58 (d, J=5.5 Hz, 1 H), 8.44 (s, 1 H), 
7.66 (s, 1 H), 7.23 (s, 1 H), 6.96 (d, J=5.5 Hz, 1 H), 2.62 ppm (s, 3 H); 13C NMR 
(126MHz,  CHLOROFORM-d): δ = 174.0, 159.3, 154.5, 135.1, 131.5, 115.6, 103.2, 
14.2 ppm; ESI-MS: 193.1 [M+H]+. 
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Compound 16: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.51 (dd, J=2.7, 0.6 Hz, 1 H), 8.48 (d, 
J=5.5 Hz, 1 H), 7.71 (d, J=1.0 Hz, 1 H), 7.50 (d, J=5.5 Hz, 1 H), 6.43 (dd, J=2.7, 1.6 
Hz, 1 H), 2.54 ppm (s, 3 H) 13C NMR (75MHz, CHLOROFORM-d): δ = 172.6, 158.9, 
143.8, 127.6, 109.0, 103.8, 14.2 ppm; ESI-MS: 193.1 [M+H]+. 
 
Compound 17: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 9.22 (s, 1 H), 8.66 (d, J=5.4 Hz, 1 H), 
8.14 (s, 1 H), 7.51 (d, J=5.4 Hz, 1 H), 2.63 ppm (s, 3 H); 13C NMR (75MHz, 
CHLOROFORM-d): δ = 173.4, 159.9, 155.0, 153.7, 142.2, 104.1, 14.2 ppm; ESI-MS: 
194.1 [M+H]+. 
 
Compound 18+19: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 8.70 (d, J=5.4 Hz, 1 H), 8.66 (d, J=5.5 
Hz, 0.3 H), 8.61 (d, J=0.8 Hz, 1 H), 7.96 (s, 0.6 H), 7.86 (d, J=0.8 Hz, 1 H), 7.83 (d, 
J=5.4 Hz, 1 H), 7.67 (d, J=5.5 Hz, 0.3 H), 2.66 (s, 1 H), 2.63 ppm (s, 3 H); 13C NMR 
(75MHz, CHLOROFORM-d):  = 173.7, 159.8, 159.2, 154.9, 138.0, 134.5, 121.1, 
104.9, 14.3, 14.2 ppm; ESI-MS: 194.1 [M+H]+. 
No change in the ratio of regioisomers was observed when applying different 
temperatures (60°C, 20 min, 50 Watt, yield 22%; 100°C, 10 min, 50 Watt, yield: 
73%).  
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Compound 20: 
 
1H NMR (300MHz, CHLOROFORM-d): δ = 9.56 (s, 1 H), 8.79 (d, J=5.2 Hz, 1 H), 
7.71 (d, J=5.3 Hz, 1 H), 2.65 ppm (s, 3 H); 13C NMR (126MHz , CHLOROFORM-d): δ 
= 174.5, 160.6, 152.8, 140.1, 105.2, 14.3 ppm; ESI-MS: 195.1 [M+H]+. 
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6.2 Supporting information for Publication II 
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I. Experimental 
All reagents used were of reagent grade or higher. 1H and 13C-NMR spectra were 
recorded on Bruker Fourier spectrometers (500/300 or 176/126/75 MHz) at ambient 
temperature with the chemical shifts recorded as δ values in ppm units by reference 
to the hydrogenated residues of deuteriated solvent as internal standard. Coupling 
constants (J) are given in Hz, and signal patterns are indicated as follows: s, singlet; 
d, doublet; dd, doublet of doublets; t, triplet; m, multiplet, br, broad signal. The 
Surveyor LC system consisted of a pump, an autosampler, and a PDA detector. 
Mass spectrometry was performed on a MSQ electrospray mass spectrometer 
(ThermoFisher, Dreieich, Germany).The system was operated by the standard 
software Xcalibur. A RP C18 NUCLEODUR 100-5 (125 mm × 3 mm) column 
(Macherey-Nagel GmbH, Dühren, Germany) was used as the stationary phase. All 
solvents were HPLC grade. In a gradient run, the percentage of acetonitrile 
(containing 0.1% trifluoroacetic acid) was increased from an initial concentration of 
0% at 0 min to 100% at 15 min and kept at 100% for 5 min. The injection volume was 
10 µl, and flow rate was set to 800 µL/min. MS analysis was carried out at a spray 
voltage of 3800 V and a capillary temperature of 350 °C and a source CID of 10 V. 
Spectra were acquired in positive mode from 100 to 1000 m/z at 254 nm for the UV 
trace. IR Spectra were recorded on a Perkin Elmer FT-IR Spectrum 100 
spectrometer equipped with an UATR accessory. High Resolution mass 
Spectrometry for compounds 5 and 9 were performed on a Dionex Ultimate 3000 
RSLC system using a Waters BEH C18, 50 x 2.1 mm, 1.7 µm dp column by injection 
of two µl methanolic sample. Separation was achieved by a linear gradient with (A) 
H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl/min and 45 °C. The 
gradient was initiated by a 0.33 min isocratic step at 5 % B, followed by an increase 
to 95 % B in 9 min to end up with a 1 min flush step at 95 % B before reequilibration 
under the initial conditions. UV and MS detection were performed simultaneously. 
Coupling the HPLC to the MS was supported by an Advion Triversa Nanomate nano-
ESI system attached to a Thermo Scientific Orbitrap. Mass spectra were acquired in 
centroid mode ranging from 200 – 2000 m/z at a resolution of R = 30000. High 
Resolution Mass Spectrometry for compounds 1-4, 6-8 and 10-12 was performed on 
a Dionex Ultimate 3000 RSLC system using a Waters BEH C18, 50 x 2.1 mm, 1.7 
µm dp column. Separation of 1 µL sample was achieved by a linear gradient with (A) 
H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl/min and 45 °C. The 
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gradient was initiated by a 1 min isocratic step at 5 % B, followed by an increase to 
95 % B in 6 min to end up with a 1.5 min step at 95 % B before reequilibration under 
the initial conditions. UV spectra were recorded by a DAD in the range from 200 to 
600 nm. The LC flow was split to 75 µl/min before entering the maXis 4G hr-ToF 
mass spectrometer (Bruker Daltonics, Bremen, Germany) using the standard ESI 
source.  Mass spectra were acquired in centroid negative mode ranging from 150 – 
2000 m/z at a 2 Hz scan speed. 
 
Caution: High nitrogen-content compounds are known to be instable. 
Although we experienced no difficulties in handling these compounds, all 
experiments were performed in small scale and with best safety 
precautions (e.g. gloves, protective eyewear, labcoat, shield)! 
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a) Chemical synthesis 
 
1: 4-azido-2-(methylsulfonyl)pyrimidine 
 
2.0 g (12 mmol) of 3 was dissolved in EtOAc (30 ml) and 22.2g Oxone (36 mmol) 
dissolved in 50 ml water was added. The mixture was stirred for 3 hrs at ambient 
temperature. The aqueous layer was extracted 3 times with 60 ml EtOAc. The 
combined organic layers were dried over Na2SO4 and the solvent was removed in 
vacuo to yield 1 as a pale yellow solid (2.2 g, 92%). 
1H-NMR (300 MHz, DMSO-d6): δ = 8.90 (d, J=5.5 Hz, 1 H), 7.40 (d, J=5.5 Hz, 1 H), 
3.41 ppm (s, 3 H) ppm 
13C-NMR (75 MHz, DMSO-d6): δ = 165.2, 163.4, 160.0, 113.8 ppm 
ESI-MS(+): m/z 200.0 [M+H]+ 
HRMS: m/z calcd. for C5H6N5O2S+: 200.02367 found: 200.02353 [M+H]+ 
 
2: 4-azido-2-(methylsulfinyl)pyrimidine 
 
70mg (0.4 mmol) of 3 was dissolved in EtOAc (5 ml) and 60mg oxone (0.2 mmol) 
dissolved in 5 ml water was added. The mixture was stirred for 3 hours at ambient 
temperature. The aqueous layer was extracted 3 times with 30 ml EtOAc. The 
combined organic layers were dried over NaSO4 and the solvent was removed in 
vacuo. The residue was purified by flashchromatography (ethylacetate:methanol, 
97.5:2.5) to yield 2 as a white solid (15 mg, 17%). 
6 Supporting information 
125 
Tetrazole: 1H-NMR (300 MHz, DMSO-d6) δ =  8.82 (d, J = 5.49 Hz, 1H), 7.22 (d, J = 
5.49 Hz, 1H), 2.90 (s, 3H) ppm 
Azide: 1H-NMR (300 MHz, DMSO-d6) δ =  8.58 - 8.68 (m, 1H), 8.37 - 8.49 (m, 1H), 
3.16 (s, 3H) ppm 
13C-NMR (75 MHz, DMSO-d6): δ = 174.1, 163.4, 160.3, 112.1, 40.1 ppm 
ESI-MS(+): m/z 184.1 [M+H]+ 
HRMS: m/z calcd. for C5H6N5OS+:184.02876 found: 184.02844 [M+H]+ 
 
3: 4-azido-2-(methylthio)pyrimidine 
 
3.2 g of 4-chloro-2-(methylthio)pyrimidine (20 mmol) was dissolved in DMF (60 ml) 
and 4.0 g NaN3 (60 mmol) was added. The suspension was stirred at ambient 
temperature for 72 hours. To the mixture was added 200 ml water and the aqueous 
layer was extracted 3 times with 300ml EtOAc. The combined organic layers were 
dried over NaSO4, filtered and the solvent was removed in vacuo to obtain a 
brownish oil. Residual DMF was removed by azeotropic destillation with heptane to 
yield 3 as a pale yellow solid (3.3 g, 98%). 
Tetratole: 1H-NMR (300 MHz, DMSO-d6) δ =, 8.37 (d, J = 6.33 Hz, 1H), 7.99 (d, J = 
6.33 Hz, 1H),, 2.80 (s, 3H) ppm 
Azide: 1H-NMR (300 MHz, DMSO-d6) δ = 8.49 (d, J = 5.40 Hz, 1H), 6.78 (d, J = 5.59 
Hz, 1H), 2.52 (s, 3H) ppm 
13C-NMR (75 MHz, CDCl3) δ = 173.0, 161.9, 158.1, 152.9, 149.1, 145.5, 105.8, 
105.0, 14.0, 13.5 ppm 
ESI-MS(+): m/z 168.1 [M+H]+ 
HRMS: m/z calcd. for C5H6N5S+: 169.03384 found: 168.03362 [M+H]+ 
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4: 4-azido-N-methylpyrimidin-2-amine 
 
100 mg of 1 (0.5 mmol) was dissolved in EtOH, 203 µl TEA (1.5 mmol) and 130 µl 
40% aminomethyl in water (3 mmol) was added in a krimp vial. The mixture was 
heated to 60°C for 3 hrs. Solvent was removed in vacuo and the residue was purified 
by flashchromatography (Ethylacetate:Hexane, 1:1) to yield 4 as white needles (60 
mg, 80%). 
1H-NMR (300 MHz, DMSO-d6) δ = 8.90 (br. s., 1H), 8.01 (d, J = 6.24 Hz, 1H), 7.23 (d, 
J = 6.24 Hz, 1H), 3.06 (d, J = 3.26 Hz, 3H) ppm 
13C-NMR (75 MHz, DMSO-d6) δ = 150.3, 148.0, 145.2, 96.3, 27.8 ppm 
ESI-MS(+): m/z 151.0 [M+H]+ 
HRMS: m/z calcd. for C5H7N6+: 151.07267 found: 151.07249 [M+H]+ 
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5: 4-azidopyrimidin-2(1H)-one 
 
100 mg (0.5 mmol) of 1 was dissolved in Dioxane (2 ml) and 20 mg NaOH (0.5 mmol) 
in 3 ml Water was added. The mixture was heated to 100°C in a krimp vial for 3 
hours. Solvent was removed in vacuo and the residue was purified by 
flashchromatography (ethylacetate:hexane, 7:3) yielding 5 as a white solid (30 mg, 
43%). 
1H-NMR (300 MHz, DMSO-d6) δ = 12.44 (br. s., 1H), 7.68 (d, J = 7.36 Hz, 1H), 6.99 
(d, J = 7.36 Hz, 1H) ppm 
13C-NMR (75 MHz, DMSO-d6) δ = 152.0, 143.3, 136.9, 92.7 ppm 
ESI-MS(+): m/z 138.0 [M+H]+ 
HRMS: m/z calcd for C4H2N5O-:136.0265 found: 136.0266 [M-H]- 
 
6: 4-azido-N,N-dimethylpyrimidin-2-amine 
 
100 mg (0.5 mmol) of 1 was dissolved in THF, 203µl TEA (1.5 mmol) and 750 µl of 
dimethylamine in THF (1.5mmol) was added. The mixture was heated to 60°C in a 
krimp vial. Solvent was removed in vacuo and the residue was purified by 
flashchromatography (ethylacetate:hexane, 2:8) to yield 6 as a colorless oil (50mg, 
61%).   
Tetrazole: 7.97 (d, J = 6.15 Hz, 1H), 7.29 (d, J = 6.05 Hz, 1H),  3.50 (s, 6H) ppm 
Azide: 1H-NMR (300 MHz, DMSO-d6) δ = 8.23 (d, J = 5.22 Hz, 1H),  6.15 (d, J = 5.22 
Hz, 1H),  3.11 (s, 6H) ppm 
13C-NMR (75 MHz, DMSO-d6) δ = 161.5, 161.3, 159.7, 98.2, 36.3 ppm 
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ESI-MS(+): m/z 165.0 [M+H]+ 
HRMS: m/z calcd. for C6H9N6+: 165.08832 found: 165.08836 [M+H]+ 
 
7: 4-azido-2-methoxypyrimidine 
 
100 mg (0.5 mmol) of 1 was dissolved in dry MeOH and 105 mg sodium methanolate 
40% in methanol (0.75 mmol) was added. The mixture was stirred at room 
temperature in a krimp vial. Solvent was removed in vacuo and the residue was 
purified by flashchromatography (ethylacetate:hexane, 1:9) to yield 7 as a white solid 
(15 mg, 20%). 
Tetrazole: 1H-NMR (300 MHz, DMSO-d6) δ = 8.48 (d, J = 5.40 Hz, 1H), 6.72 (d, J = 
5.40 Hz, 1H), 3.92 (s, 3H) ppm 
Azide: 1H-NMR (300 MHz, DMSO-d6) δ = 8.16 (d, J = 6.43 Hz, 1H), 7.80 (d, J = 6.43 
Hz, 1H), 4.29 (s, 3H) ppm 
13C-NMR (126 MHz, DMSO-d6): δ = 164.9, 163.3, 161.0, 151.7, 148.0, 146.2, 104.7, 
103.4, 57.0, 54.7 ppm 
ESI-MS(+): m/z 152.0 [M+H]+ 
HRMS: m/z calcd. for C5H6N5O+:152.05669 found: 152.05643 [M+H] + 
 
8: 4-azidopyrimidin-2-amine 
 
100 mg (0.5 mmol) of 1 was dissolved in 2 ml MeOH, 1.3 ml of 7 N Ammonia in 
MeOH (1.7 mmol) and 203 µl TEA (1.5 mmol) was added. The mixture was heated to 
60°C in a Krimp vial. Solvent was removed in vacuo and the residue was purified by 
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flashchromatography (Ethylacetate:Hexane, 6:4) to yield 8 as a brownish solid (30 
mg, 44%). 
1H-NMR (300 MHz, DMSO-d6) δ = 8.54 (br. s., 2H), 7.95 (d, J = 6.24 Hz, 1H), 7.23 (d, 
J = 6.33 Hz, 1H) ppm 
13C-NMR (75 MHz, DMSO-d6) δ = 150.6, 148.3, 146.2, 96.6 ppm 
ESI-MS(+): m/z 137.0 [M+H]+ 
HRMS: m/z calcd. for C4H5N6+: 137.05702 found: 137.05644 [M+H]+ 
 
9: 4-azidopyrimidine-2(1H)-thione 
 
100 mg (0.5 mmol) of 1 was given to a mixture of EtOH (2.5 ml) and 0.025M HClaq 
(2.5 ml). 158 mg of NaS2O3 (1 mmol) was added and the suspension was refluxed for 
16 hours. A white precipitate formed which was filtered, washed 3 times with water 
and dried in vacuo to give 9 as a white solid (35 mg, 45%). 
1H-NMR (300 MHz, DMSO-d6) δ = 14.15 (br. s., 1H), 7.77 (d, J = 7.26 Hz, 1H), 7.43 
(d, J = 7.26 Hz, 1H) ppm 
13C-NMR (75 MHz, DMSO-d6) δ = 165.8, 148.1, 136.7, 97.9 ppm 
ESI-MS(+): m/z 154.0 [M+H]+ 
HRMS: m/z calcd. for C4H2N5S-: 152.0036 found: 152.0009 [M-H]- 
 
10: 2-(methylsulfonyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrimidine 
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100 mg of 1 (0.5 mmol) and 51 mg phenylacetylene (0.5 mmol) was dissolved in 5ml 
tertBuOH:H2O (1:1), 10 mg sodium ascorbate (0.1 mmol) and 2.5 mg CuSO4x5H2O 
(0.02 mmol) was added argon atmosphere. The mixture was stirred at ambient 
temperature for 24 hours. The reaction mixture was extracted 3 times with EtOAc and 
the solvent was removed in vacuo. The residue was purified by flash chromatography 
(Ethylacetate:Hexane, 1:1)  to yield 10 as a white solid (82 mg, 55%). 
1H-NMR (300 MHz, DMSO-d6) δ = 9.60 (s, 1H), 9.29 (d, J = 5.59 Hz, 1H), 8.47 (d, J = 
5.59 Hz, 1H), 7.99 - 8.19 (m, 2H), 7.48 - 7.58 (m, 2H), 7.24 - 7.48 (m, 1H), 3.60 (s, 
3H) ppm 
13C-NMR (75 MHz, DMSO-d6) δ = 165.9, 162.6, 155.8, 148.4, 129.7, 129.5, 129.4, 
126.3, 119.3, 113.4, 39.5 ppm 
ESI-MS(+): m/z 302 [M+H]+ 
HRMS: m/z calcd. for C13H12N5O2S+: 302.07062 found: 302.07065 [M+H]+ 
 
11: 2-(methylthio)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrimidine 
 
83 mg of 3 (0.5 mmol) and 51 mg phenylacetylene (0.5 mmol) was dissolved in 5ml 
tertBuOH:H2O (1:1), 10 mg sodium ascorbate (0.1 mmol) and 2.5mg CuSO4x5H2O 
(0.02 mmol) was added under inert atmosphere. The mixture was stirred at ambient 
temperature for 24 hours. The reaction mixture was extracted 3 times with EtOAc and 
the solvent was removed in vacuo. The residue was purified by flash chromatography 
(ethylacetate:hexane, 3:7) to yield 11 as a brownish solid (108 mg, 81%). 
1H-NMR (300 MHz, CDCl3) δ = 8.78 (s, 1H), 8.71 (d, J = 5.40 Hz, 1H), 7.91 - 8.04 (m, 
2H), 7.85 (d, J = 5.40 Hz, 1H), 7.44 - 7.58 (m, 2H), 7.35 - 7.44 (m, 1H), 2.66 (s, 3H) 
ppm 
13C-NMR (75 MHz, CDCl3) δ = 173.7, 159.6, 154.9, 148.5, 129.6, 129.0, 128.9, 
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ESI-MS(+): m/z 270.0 [M+H]+ 
HRMS: m/z calcd. for C13H12N5S+: 270.08079 found: 270.08099 [M+H]+ 
 
12: N-methyl-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrimidin-2-amine 
 
75 mg of 1 (0.5 mmol) and 51 mg phenylacetylene (0.5 mmol) was dissolved in 5 ml 
tertBuOH:H2O (1:1), 100 mg sodium ascorbate (0.5 mmol) and 25 mg CuSO4x5H2O 
(0.1 mmol) was added. The mixture was stirred at ambient temperature for 24 hrs. 
The reaction mixture was extracted 3 times with EtOAc and the solvent was removed 
in vacuo. The residue was purified by flash chromatography (ethylacetate:hexane, 
1:1) to yield 12 as a brownish solid (64 mg, 51 %). 
1H-NMR (300 MHz, CDCl3) δ = 8.73 (s, 1H), 8.47 (d, J = 5.12 Hz, 1H), 7.88 - 8.02 (m, 
2H), 7.35 - 7.57 (m, 4H), 5.36 (br. s., 1H), 3.11 (d, J = 5.12 Hz, 3H) ppm 
13C-NMR (75 MHz, CDCl3) δ = 162.8, 160.8, 155.8, 148.0, 129.9, 128.9, 128.6, 
126.0, 116.4, 98.7, 28.5 ppm 
ESI-MS(+): m/z 253.3 [M+H]+ 
HRMS: m/z calcd. for C13H13N6+: 253.11962 found: 253.11971 [M+H]+ 
 
14: N,N-dimethyl-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrimidin-2-amine 
 
54 mg of 6 (0.3 mmol) and 34 mg phenylacetylene (0.3 mmol) was dissolved in 3 ml 
tBuOH:H2O (1:1), 7.5 mg sodium ascorbate (0.0375 mmol) and 2 mg CuSO4x5H2O 
(0.0075 mmol) was added under inert atmosphere. The mixture was stirred at 
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ambient temperature for 24 hrs. The reaction mixture was extracted 3 times with 
EtOAc and the solvent was removed in vacuo. The residue was purified by flash 
chromatography (ethylacetate:hexane 3:7,) to yield 14 as a colorless solid (64 mg, 68 
%). 
1H NMR (500 MHz, CDCl3) d 8.72 (s, 1H), 8.50 (d, J = 5.36 Hz, 1H), 7.91 - 8.01 (m, 
2H), 7.45 - 7.52 (m, 2H), 7.40 (tt, J = 1.30, 7.60 Hz, 1H), 7.34 (d, J = 5.04 Hz, 1H), 
3.28 (s, 6H) 
13C NMR (126 MHz, CDCl3) δ = 161.9, 160.4, 155.4, 147.9, 130.0, 128.9, 128.6, 
126.0, 116.3, 97.0, 37.1 
ESI-MS(+): m/z 267.0 [M+H]+ 
HRMS: m/z calcd. for C14H15N6+: 267.13527 found: 267.13506 [M+H]+ 
 
15: 5-azidopyrimidine 
 
15 was synthesized as reported before with minor modifications.1 Briefly, to a solution 
of 50 mg of pyrimidine-5-boronic acid (0.4 mmol) in MeOH (5 ml) was added 60 mg 
sodium azide (1.0 mmol) and CuSO4 (0.04 mmol). The suspension was stirred 
vigorously at room temperature until TLC showed complete conversion of starting 
material. 50 ml water was added and the aqueous layer was extracted three times 
with EtOAc. The combined organic layers were dried over sodium sulfate and filtered 
over a double layer pad of Celite® and silica. Solvent was removed under reduced 
pressure to obtain the title compound as an off white solid (30 mg, 63 %). Analytical 
data is in good accordance with the published spectral data of Grimes et al.1  
FT-IR (cm-1): 3205, 3022, 2925, 2393, 2258, 2191, 2108, 1727, 1574, 1557, 1437, 
1415, 1354, 1296, 1191, 1167, 1097, 1036, 905, 884, 715, 693 
1H-NMR (500 MHz, MeOD) δ = 8.61 (s, 2H), 8.93 (s, 1H) ppm 
13C-NMR (126 MHz, MeOD) δ = 138.5, 149.2, 155.3 ppm 
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ESI-MS(+): m/z 122.0 [M+H]+ 
 
b) X-Ray Crystallography 
Crystallization of 3: 
100 mg of 3 was dissolved in hot chloroform. Crystals formed after 2 days at ambient 
temperature. 
CCDC-Number: 1045217 
 
Crystallization of 4: 
20 mg of 4 was dissolved in hot chloroform. Crystals formed after 4 days at ambient 
temperature. 
CCDC-Number: 1045218 
 
Crystallization of 5: 
20 mg of 5 was dissolved in hot MeOH. Crystals formed after 3 days at ambient 
temperature. 
CCDC-Number: 1045219 
 
X-ray structure determination of 3-5 
Crystals suitable for single-crystal x-ray analysis were obtained as described above. 
The data were collected at 133 K on a BrukerAXS X8Apex CCD diffractometer 
operating with graphite-monochromatized Mo Kα radiation. Frames of 0.5° oscillation 
were exposed; deriving data in the θ range of 2 to 30° with a completeness of ~99%. 
Structure solution and full least-squares refinement with anisotropic thermal 
parameters of all non-hydrogen atoms and rigid group refinement of the hydrogen 
were performed using SHELX2 (The final refinement result in: [1] R1= 0.026; [2] R1= 
0.036; [3] R1= 0.043. Crystallographic data for the structures have been deposited 
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with the Cambridge Crystallographic Data Centre, CCDC, 12 Union Road, 
Cambridge CB21EZ, UK. Copies of the data can be obtained free of charge on 
quoting the depository numbers CCDC (www.ccdc.cam.ac.uk/data_request/cif). 
 
c) Determination of pKa 
The pKa‘s of 5 and 9 were measured using the SiriusT3 automatic titration system 
(Sirius Analytical Ltd, Forest Row, UK) and the software supplied with the machine 
for the refinement of the experimental data. Standard solutions of hydrochloric acid 
0.5 M and potassium hydroxide 0.5 M in Millipore water were used as acid and base 
titrant, respectively. The ionic strength of the water used for dissolving the samples 
was adjusted adding potassium chloride obtaining a 0.15 M solution. A solution of 50 
% acetonitrile - 50 % Millipore water was prepared and potassium chloride was 
added in it for obtaining a final mixture 50 % acetonitrile with 0.15 M KCl. In each 
experiment, 5 was titrated three times in water media from high to low pH, while 9 
was titrated three times in acetonitrile – water solution (first titration in 42 %, second 
titration in 38 % and third titration in 32 % of acetonitrile) from basic to acidic pH. 
Three independent experiments were performed per each compound at room 
temperature. 
d) Molecular Modelling and Density Functional Calculations 
Modelling of steric clash of the aminodimethyl group and N2 of tetrazol of compound 
6: 
   
Based on the crystalstructure of 4 (CCDC-Number: 1045218) an additional 
methylgroup was introduced to the methylamine, resulting in the tetrazole tautomer of 
compound 6 (left figure). Steric clashes, indicated in orange, occur between methyl C 
and N2 of tetrazole, resulting in an energy demand of 4.6 kcal to accommodate this 
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structure. Energy minimization in vacuo with AMBER 10:EHT solvation model R-field 
(MOE) of this structure (right figure, pink structure) yielded a conformation where the 
methyl group and the tetrazole evade this clash which is accompanied by a 
deformation of the tetrazolo[1,5-c]pyrimidine ring (right figure, grey structure=before 
energy minimization, pink structure=after energy minimization)  
 
Modelling of compound 5 and 9 into the adenosyl bindingsite of PqsD: 
To predict the binding mode of compound 5 and 9 the cocrystal structure of PqsD 
with anthranoyl-CoA (PDB code: 3H77) was used. The anthranoyl-CoA chain was 
deleted and only the adenosine moiety was kept for further experiments. The 
adenosine was modified using Molecular Operating Environment, Chemical 
Computing Group to compound 5 and 9 and the resulting structures, and the 
residues in 3.5Å proximity were energy minimized inside the binding site of 
adenosine. For energy minimization MMFF94x (Merck Forcefield) of MOE software 
package was used with the preset standard parameters. 
 
Energy optimization of compounds 1-9 and solvation contributions:  
Structures were energetically optmized at B3LYP/aug-cc-pVDZ level of theory using 
default parameters. Single point energies were obtained applying the COSMO 
solvent model3 as implemented in NWChem (Version 6.1)4. The dielectric constants 
and solvent radii used were for water (78.0, 1.37), for DMSO (47.24, 2.455), and for 
CHCl3 (4.8069, 2.715), respectively. 
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e) Calculated physicochemical properties of compounds 1-9 
Physicochemical properties were calculated using ACD/Percepta version 2012 (Build 
2203, 29 jan. 2013), ACD/Labs. Calculation of LogP values was done using 
consensus LogP model and for pKa calculation the pKa classic module was used. 
Cmpd cLogD7,4 cLogP cpKa T A T A T A Exp 
1 -1.16 0.37 -1.16 0.37 
  
2 -1.34 0.05 -1.34 0.05 
  3 -0.06 1.96 -0.06 1.96 
  
4 -0.79 1.49 -0.79 1.49 
  
5 -2.63 -0.74 -1.21 -0.72 5.9 8.7 6.8 
6 -0.59 1.72 -0.59 1.72 
  
7 -0.22 1.21 -0.22 1.21 
  8 -1.05 0.88 -1.05 0.88 
  
9 -0.64 -1.35 -0.15 -0.35 7.1 6.4 4.6 
T=Tetrazol, A=Azide, Exp= experimentally determined.  
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f) Calculation of Ligand Efficiency (LE) and Ligand Lipophilicity Efficiency 
(LLEAstex) 
LE of compounds 5 and 9 was calculated based on their IC50:5  
LE = 1.4 ∗ ()*+,-./  (NHA= Number of heavy atoms) 
LLEAstex was calculated using IC50’s with minor changes to the formula, based on the 
findings of Shultz5,6:  
LLE/0123 = 0.11 + 1.4 ∗ pIC50 − cLogPNHA  
 
g) In vitro PqsD Inhibition Assay 
PqsD In vitro Inhibition Assay: The assay was performed monitoring enzyme activity 
by measuring HHQ formed by condensation of anthraniloyl-CoA and β-ketodecanoic 
acid. The reaction mixture contained MOPS buffer (0.05 M, pH 7.0) with 0.005 % 
(w/v) Triton X-100, 0.1 µM of the purified enzyme, and inhibitor. The test compounds 
were dissolved in DMSO and diluted with buffer. The final DMSO concentration was 
0.5%. After 10 min preincubation at 37 °C, the reaction was started by the addition 
anthraniloyl-CoA to a final concentration of 5 µM and β-ketodecanoic acid to a final 
concentration of 70 µM. Reactions were stopped byaddition of MeOH containing 1 
µM amitriptyline as internal standardfor LC/MS-MS analysis. HHQ was quantified 
using a HPLC-MS/MSmass spectrometer (Thermo Fisher, Dreieich, Germany) in ESI 
mode.Ionization of HHQ and the internal standard amitriptyline was optimized in each 
case. The solvent system consisted of 10 mM ammonium acetate (A) and acetonitrile 
(B), both containing 0.1 % trifluoroacetic acid. The initial concentration of B in A was 
45%, increasing the percentage of B to 100 % in 2.8 min and keeping it at 98% for 
0.7 min with a flow of 500 µl/min. The column used was a NUCLEODUR-C18, 100-
3/125-3 (Macherey & Nagel, Duehren,Germany). Control reactions without the 
inhibitor, but including identical amounts of DMSO, were performed in parallel, and 
the amount of HHQ produced was set to 100 %. All reactions were performed in 
triplicate except for adenine and hypoxanthine which were performed as single point 
measurements at 50 µM. Hypoxanthine inhibited 9% HHQ formation whereas 
adenine inhibited 0% HHQ formation. 
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h) SPAAC reactionkinetics  of 3, 4 and 5 under neutral, basic and acidic pH 
10 µl of Dibenzocyclooctyne-amine (100 mM DMSO Stock) and 20 µl of the 
corresponding azide-compound (50 mM in tertBuOH:Water [1:1]) was added to 1000 
µl of tertBuOH:Water (1:1) and shaken at room temperature for 1 hr  for neutral 
conditions. For acidic conditions 0.2 % TFA or 0.1 M HCl was and for basic 
conditions 0.1 M NaOH was used in 1000 µl tertBuOH:Water (1:1) final. 10 µl of the 
reaction mixture was injected into the LC-MS System.  
6 Supporting information 
147 
LC-MS Run of 3 under neutral conditions 
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LC-MS Run of 3 under acid conditions (0.2% TFA) 
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LC-MS Run of 3 under acid conditions (0.1 M HCl) 
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LC-MS Run of 3 under basic conditions (0.1 M NaOH) 
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LC-MS Run of 4 under neutral conditions: 
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LC-MS Run of 4 under acid conditions (0.2% TFA): 
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LC-MS Run of 4 under acid conditions (0.1 M HCl): 
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LC-MS Run of 4 under basic conditions (0.1 M NaOH): 
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LC-MS Run of 5 under neutral conditions 
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LC-MS Run of 5 under acid conditions (0.2%TFA) 
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LC-MS Run of 5 under acid conditions (0.1 M HCl) 
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LC-MS Run of 5 under basic conditions (0.1 M NaOH) 
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i) SPAAC reactionkinetic of 4 at pH 1.5, 2.5 and 4.1 and 15 at pH 1.4 and pH 7.0 
Compound 4: 
pH 1.5 
Time [min] AUC of 4 [mAU] 4 [%] AUC of product [mAU] Product [%] 
30 5734933 91.7 518946 8.3 
60 5602499 83.6 1101498 16.4 
90 5268856 77.8 1499674 22.2 
120 5003182 72.2 1924425 27.8 
150 4871904 67.8 2311144 32.2 
180 1370705 63.7 779760 36.3 
 
 
pH 2.5 
Time [min] AUC of 4 [mAU] 4 [%] AUC of product [mAU] Product [%] 
30 5695140 97.6 138559 2.4 
60 5178777 96.1 210430 3.9 
90 5230687 95.5 244025 4.5 
120 5262583 94.1 329738 5.9 
150 5207051 92.8 403243 7.2 
180 5176146 91.9 455522 8.1 
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pH 4.1 
Time [min] AUC of 4 [mAU] 4 [%] AUC of product [mAU] Product [%] 
30 4860187 99.3 31833 0.7 
60 4855123 98.5 74656 1.5 
90 5065370 98.1 99397 1.9 
120 5005964 97.8 114435 2.2 
150 5102021 97.5 132920 2.5 
180 5058522 97.5 129192 2.5 
Compound 15: 
 
pH 1.4 
Time [min] AUC of DBCOA
a
 
[mAU] 
DBCOAa 
[%] 
AUC of product 
[mAU] Product [%] 
30 3749764 62.2 2281874 37.8 
60 3128959 49.9 3138413 50.1 
90 2705288 39.2 4199670 60.8 
120 2153357 31.7 4642839 68.3 
150 2053435 27.9 5296846 72.1 
180 1702508 23.4 5561344 76.6 
aDBCOA = Dibenzocyclooctyne-amine 
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pH 7.0 
Time [min] AUC of DBCOA
a
 
[mAU] 
DBCOAa 
[%] 
AUC of product 
[mAU] Product [%] 
30 2912988 61.2 1850148 38.8 
60 2577175 47.8 2812106 52.2 
90 1980938 38.1 3220216 61.9 
120 1698357 28.9 4181186 71.1 
150 1483145 25.2 4412387 74.8 
180 1387631 23.5 4528455 76.5 
aDBCOA = Dibenzocyclooctyne-amine 
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II. Spectral Data 
a)  1H-NMR Spectra 
1H-NMR of 1 
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1H-NMR of 2 
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1H-NMR of 3 
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1H-NMR of 4 
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1H-NMR of 5 
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1H-NMR of 6 
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1H-NMR of 7 
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1H-NMR of 8 
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1H-NMR of 9 
 
 
 
The small peaks close to the dublets at 7.77 and 7.43 are possibly due to thionyl-thiol 
tautomerization 
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b) DMSO-d6 titration of 4 in CDCl3 monitored by 1H-NMR 
0% DMSO – 1H-NMR of 4 in CDCl3 
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1% DMSO – 1H-NMR of 4 in CDCl3 
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2% DMSO – 1H-NMR of 4 in CDCl3 
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2.9% DMSO – 1H-NMR of 4 in CDCl3 
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3.8% DMSO – 1H-NMR of 4 in CDCl3 
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4.8% DMSO – 1H-NMR of 4 in CDCl3 
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5.7% DMSO – 1H-NMR of 4 in CDCl3 
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6.4% DMSO – 1H-NMR of 4 in CDCl3 
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7.4DMSO – 1H-NMR of 4 in CDCl3 
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8.3% DMSO – 1H-NMR of 4 in CDCl3 
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9.1% DMSO – 1H-NMR of 4 in CDCl3 
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9.9% DMSO – 1H-NMR of 4 in CDCl3 
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10.7% DMSO – 1H-NMR of 4 in CDCl3 
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11.5% DMSO – 1H-NMR of 4 in CDCl3 
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12.9% DMSO – 1H-NMR of 4 in CDCl3 
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15.6% DMSO – 1H-NMR of 4 in CDCl3 
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18.1´% DMSO – 1H-NMR of 4 in CDCl3 
 
 
  
6 Supporting information 
188 
20.5% DMSO – 1H-NMR of 4 in CDCl3 
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24.8 DMSO – 1H-NMR of 4 in CDCl3 
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28.7%DMSO – 1H-NMR of 4 in CDCl3 
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1H-NMR shift of the NH-signal and percentage of azide-integrals to tetrazole-
integrals of 4 under DMSO titration in CDCl3   
 
 
 
 
 
DMSO [%] NH-shift [ppm] Azide [%] Tetrazole [%] 
0.0 6.38 15.0 85.0 
1.0 6.83 11.0 89.0 
2.0 7.13 9.0 91.0 
2.9 7.33 8.0 92.0 
3.8 7.48 7.0 93.0 
4.8 7.61 6.0 94.0 
5.7 7.70 5.7 94.3 
6.5 7.78 5.7 94.4 
7.4 7.83 5.0 95.1 
8.3 7.89 4.8 95.3 
9.1 7.94 4.8 95.2 
9.9 7.97 4.1 95.9 
10.7 8.00 3.7 96.3 
11.5 8.02 3.7 96.3 
12.9 8.06 3.0 97.0 
15.6 8.11 4.0 96.1 
18.1 8.15 2.8 97.2 
20.5 8.17 2.9 97.1 
24.8 8.18 2.7 97.3 
28.7 8.18 2.6 97.4 
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c) Acidic, basic and neutral 1H-NMR of 4 and 5 
1H-NMR of 4 in D2O (acidic + TFA) 
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1H-NMR of 4 in D2O (neutral) 
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1H-NMR of 4 in D2O (basic + 0.1M NaOH) 
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1H-NMR of 4 in D2O (basic + 1M NaOH) 
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1H-NMR of 5 in D2O (acidic + TFA) 
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1H-NMR of 5 in D2O (neutral) 
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1H-NMR of 5 in D2O (basic + 0.1M NaOH) 
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1H-NMR of 5 in D2O (basic + 1M NaOH) 
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d)   13C-NMR Spectra 
13C-NMR of 1 
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13C-NMR of 2 
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13C-NMR of 3 
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13C-NMR of 4 
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13C-NMR of 5 
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13C-NMR of 6 
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13C-NMR of 7 
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13C-NMR of 8 
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13C-NMR of 9 
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13C-NMR of 10 
 
 
13C-Signal of the methyl group at 39.53 was also detected by 1H-HMQC  
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13C-NMR of 11 
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13C-NMR of 12 
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13C-NMR of 14 
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13C-NMR of 15 
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e)  15N-NMR Spectra 
15N-NMR of 1 
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15N-NMR of 3 
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15N-NMR of 4 
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f)  Temperature gradient 1H-NMR of 3 
3 in DMSO at 300K 
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3 in DMSO at 333K 
 
 
  
6 Supporting information 
219 
3 in DMSO at 353K 
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g)  IR-Spectra 
IR Spectrum of 1 
 
 
 
FT-IR (cm-1):  3086, 3015, 2932, 2446, 2279, 2228, 2143, 1761, 1661, 1624, 1571, 
1539, 1435, 1356, 1306, 1246, 1200, 1133, 1086, 987, 966, 912, 850, 781, 761, 730, 
673, 617
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IR Spectrum of 2 
 
 
 
FT-IR (cm-1): 3480, 3072, 2919, 2443, 2287, 2216, 2134, 2058, 1756, 1560, 1539, 
1428, 1345, 1299, 1221, 1189, 1144, 1068, 985, 960, 909, 842, 773, 732, 670, 622, 
616, 585, 578, 572, 564, 553  
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IR Spectrum of 3 
 
 
 
FT-IR (cm-1): 3087, 3028, 2929, 2858, 2138, 1727, 1595, 1553, 1528, 1514, 1455, 
1417, 1368, 1349, 1332, 1306, 1263, 1210, 1124, 1084, 1057, 1044, 1025, 1012, 
980, 922, 840, 826, 762, 740, 710, 676, 655, 631  
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IR Spectrum of 4 
 
 
 
FT-IR (cm-1): 3234, 3053, 2956, 1963, 1728, 1639, 1601, 1579, 1488, 1410, 1360, 
1328, 1304, 1256, 1182, 1140, 1117, 1081, 1057, 1021, 998, 868, 791, 722, 694, 
667, 651  
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IR Spectrum of 4 hydrochloric salt (lyophilized) 
 
 
 
FT-IR (cm-1): 3157, 3050, 2528, 2245, 2198, 2149, 1645, 1623, 1529, 1431, 1354, 
1317, 1268, 1226, 1205, 1120, 1072, 985, 903, 847, 824, 799, 763, 695, 680 
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IR-Spectrum of 5 
 
 
 
FT-IR (cm-1): 3068, 2925, 2854, 2733, 2145, 1822, 1744, 1618, 1550, 1528, 1441, 
1403, 1364, 1312, 1282, 1242, 1138, 1080, 988, 888, 802, 719, 687, 631 
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IR-Spectrum of 6 
 
 
 
FT-IR (cm-1): 2930, 2436, 2313, 2187, 2123, 1581, 1536, 1429, 1406, 1372, 1345, 
1314, 1279, 1229, 1209, 1158, 1133, 1077, 1022, 996, 970, 954, 791, 748, 681 
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IR-Spectrum of 7 
 
 
 
FT-IR (cm-1): 3080, 3013, 2960, 2311, 2238, 2139, 1971, 1822, 1622, 1551, 1518, 
1473, 1449, 1428, 1392, 1366, 1354, 1334, 1275, 1242, 1187, 1151, 1123, 1086, 
1070, 993, 959, 859, 837, 791, 773, 735, 707, 679, 659  
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IR-Spectrum of 8 
 
 
 
FT-IR (cm-1): 2960, 2924, 2854, 1735, 1687, 1617, 1562, 1460, 1401, 1371, 1297, 
1259, 1199, 1097, 1078, 1014, 994, 879, 786, 720, 682, 638  
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IR-Spectrum of 9 
 
 
FT-IR (cm-1): 2924, 2854 ,1740, 1614, 1547, 1461, 1382, 1276, 1207, 1082, 1038, 
984, 918, 854, 803, 745, 663, 633 
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IR-Spectrum of 15 
 
 
FT-IR (cm-1): 3205, 3022, 2925, 2393, 2258, 2191, 2108, 1727, 1574, 1557, 1437, 
1415, 1354, 1296, 1191, 1167, 1097, 1036, 905, 884, 715, 693 
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6.3 Supporting information for Publication III 
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Supporting Information 
Mild and Catalyst-free Microwave-assisted Synthesis of 4,6-
Disubstituted 2-Methylthiopyrimidines – Exploiting Tetrazole as an 
Efficient Leaving Group 
Andreas Thomanna, Jens Eberharda, Giuseppe Allegrettaa, Martin Emptinga and Rolf W. 
Hartmanna,b* 
aHelmholtz-Institute for Pharmaceutical Research Saarland, Saarland University, Campus C 2.3, D-66123 
Saarbrücken, Germany 
bPharmaceutical and Medicinal Chemistry, Saarland University, Campus C 2.3, D-66123 Saarbrücken, Germany  
Fax: +49-681-302-70308 
E-mail: rolf.hartmann@helmholtz-hzi.de 
 
Instrumentation for routine analysis 
NMR spectra were recorded on a Bruker Avance AV 300 or a Bruker DRX 500. The 
residual proton, 1H, or carbon 13C resonances of the >99 % deuterated solvents were 
used for internal reference of all spectra acquired. (CDCl3 1H 7.260 ppm, 13C 
77.16 ppm; DMSO-d6, 1H 2.500 ppm, 13C 39.52 ppm).  
Electrospray ionization (ESI) mass spectrometry were recorded with a Surveyor LC 
system MSQ electrospray mass spectrometer LC-MS couple (ThermoFisher, 
Dreieich, Germany) by use of an acetonitrile/water gradient in positive mode (+), if 
not indicated otherwise. 0.1% TFA was added if necessary. 
  
6 Supporting information 
234 
Analytical and Experimental Data 
1H-Tetrazole: 
 
Sodium azide (0.2 mol, 13 g), ammonium chloride (0.2 mol, 10.7 g) and ethyl 
orthoformate (0.6 mol, 89 g) were charged in a round bottom flask. Glacial acid (0.8 
mol, 46 ml) was added slowly at room temperature. After addition, the mixture was 
stirred at 80°C for 16 hrs. The reaction mixture was evaporated to dryness in 
dynamic vacuum (at 40°C) and the resulting colorless residue was resuspended in 
boiling acetone and filtered hot (G4 glass frit). The acetone was removed in vacuo 
and the colorless residue was recrystallized from ethyl acetate to yield 1H-tetrazole 
as colorless needles (7.1 g, 51%). 
ESI-MS(-): m/z 68.9 [M-H]-  
1H NMR (300 MHz, DMSO-d6): δ = 9.38 ppm (s, 1 H) 
13C NMR (75 MHz, DMSO-d6): δ = 143.2 ppm 
 
General Procedure for the synthesis of compounds 2-24: 
1 equivalent of starting material (either compound 1 (for cmpds 2-24) or 4,6-dichloro-
2-thiomethylpyrimidine (for cmpds 1, 17op)) was dissolved in the solvent indicated in 
Table 3 or 4. The reactant (for equivalents see Table 3 or 4) and 1 equivalent of base 
was added at once and the mixture was stirred in a capped vial in a CEM Discover 
SP microwave oven connected to a CEM Explorer SP 12S autosampler for the 
indicated time and temperature (see Table 3 and 4). Isolation and purification of the 
desired compounds was achieved either by addition of water and subsequent 
filtration (2, 3, 5-8, 13-20, 22) or by column chromatography (4, 9-12, 21, 23, 24).  
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Compound 2:  
 
ESI-MS(+): m/z 210.0 [M-N2+H]+  
1H NMR (300 MHz, DMSO-d6): δ = 10.12 (s, 1 H), 6.88 (s, 1 H), 3.20 (br. s, 6 H), 2.54 
ppm (s, 3 H) 
13C NMR (75 MHz, DMSO-d6): δ = 171.1, 162.4, 151.9, 141.8, 86.9, 86.6, 13.0 ppm 
 
Compound 3:  
 
ESI-MS(+): m/z 196.0 [M-N2+H]+ 
1H NMR (300 MHz, DMSO-d6): δ = 10.10 (s, 1 H), 8.07 (d, J=4.1 Hz, 1 H), 6.73 (s, 1 
H), 2.91 (d, J=4.6 Hz, 3 H), 2.54 ppm (s, 3 H) 
13C NMR (75 MHz, DMSO-d6): δ = 172.5, 163.8, 151.0, 142.1, 90.0, 27.5, 14.1 ppm 
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Compound 4:  
 
ESI-MS(+): m/z 182.0 [M-N2+H]+ 
1H NMR (300 MHz, DMSO-d6) δ = 10.10 (s, 1H), 7.59 (br. s., 2H), 6.73 (s, 1H), 2.52 
(s, 3H) 
13C NMR (75 MHz, DMSO-d6): δ = 171.8, 164.9, 151.7, 141.6, 141.4, 13.4 ppm 
 
Compound 5: 
 
ESI-MS(+): m/z 299.9 [M+H]+, 271.9 [M-N2+H]+  
1H NMR (300 MHz, DMSO-d6): δ = 10.09 (s, 1 H), 8.62 (t, J=5.3 Hz, 1 H), 7.16-7.50 
(m, 5 H), 6.86 (s, 1 H), 4.64 (d, J=5.5 Hz, 2 H), 2.41 - 2.51 ppm (m, 3 H)  
13C NMR (300 MHz, DMSO-d6): δ = 172.4, 163.3, 152.0, 143.4, 139.2, 129.6, 128.3, 
127.1, 90.6, 44.4, 14.0 ppm 
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Compound 6:  
 
ESI-MS(+): m/z 236.0 [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.45 (s, 1 H), 6.65 (s, 1 H), 3.71 (t, J=6.6 
Hz, 2 H), 3.46 (t, J=6.6 Hz, 2 H), 2.55 (s, 3 H), 1.85-2.24 ppm (m, 4 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 116.1, 111.8, 108.0, 102.9, 80.8, 64.2, 
55.9, 55.5, 51.3 ppm 
 
Compound 7:  
 
ESI-MS(+): m/z 251.8 [M-N2+H]+ 
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.39 (s, 1 H), 6.81 (s, 1 H), 3.42-4.07 (m, 
8 H), 2.48 ppm (s, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 172.8, 162.6, 152.9, 140.3, 86.3, 66.3, 
44.5, 14.2 ppm 
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Compound 8:  
N
N S
N
N
NN
N
 
ESI-MS(+): m/z 278.2 [M+H]+, 251.2 [M-N2+H]+ 
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.45 (s, 1 H), 6.88 (s, 1 H), 3.73 (br. s, 4 
H), 2.54 (s, 3 H), 1.62-1.79 ppm (m, 6 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 172.5, 162.0, 152.8, 140.4, 140.2, 45.7, 
25.6,  24.4, 14.2 ppm 
 
Compound 9: 
 
ESI-MS(+): m/z 232.9 [M-N2+H]+ 
1H NMR (300 MHz, DMSO-d6): δ = 10.35 (s, 1 H), 8.87 (s, 1 H), 8.22 (s, 2 H), 7.22 (s, 
1 H), 2.71 ppm (s, 3 H) 
13C NMR (75 MHz, DMSO-d6): δ = 173.3, 156.8, 154.1, 142.3, 136.2, 131.2, 116.8, 
93.8, 14.0 ppm  
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Compound 10: 
N
N S
OH
N
NN
N
NH
N S
O
N
NN
N
 
ESI-MS: a signal for the molecular ion was not found 
1H NMR (300 MHz, DMSO-d6): δ = 10.28 (s, 1 H), 7.04 (s, 1 H), 2.62 ppm (s, 3 H) 
13C NMR (75 MHz, DMSO-d6): δ = 173.0, 162.4, 153.3, 142.5, 90.8, 14.2 ppm 
FT-IR (cm-1): 3107, 2936, 2732, 2288, 2235, 2185, 1626, 1588, 1523, 1474, 1439, 
1391, 1347, 1332, 1294, 1238, 1186, 1139, 1100, 1081, 1013, 980, 966, 936, 822, 
793, 763, 723, 773 
pKa = 3.17 ± 0.05 
 
 Compound 11: 
 
ESI-MS(+): m/z 197.0 [M-N2+H]+ 
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.48 (s, 1 H), 7.08 (s, 1 H), 4.09 (s, 3 H), 
2.64 ppm (s, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 173.9, 171.0, 153.4, 140.3, 92.6, 91.2, 
14.2 ppm 
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Compound 12: 
 
ESI-MS(+): m/z 239.1 [M+H]+, 211.1 [M-N2+H]+ 
1H NMR (500 MHz, CHLOROFORM-d): δ = 9.48 (s, 1 H), 7.04 (s, 1 H), 4.53 (q, J=7.1 
Hz, 2 H), 2.57 (s, 3 H), 1.44 ppm (t, J=7.1 Hz, 3 H) 
13C NMR (126 MHz, CHLOROFORM-d): δ = 173.7, 170.6, 153.4, 140.2, 92.0, 64.0, 
14.2, 14.2 ppm 
 
Compound 13: 
 
ESI-MS(+): m/z 258.9 [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d) δ = 9.43 (s, 1 H), 7.40 (d, J=7.7 Hz, 2H), 
6.97-7.31 (m, 4H), 2.42 (s, 3H) 
13C NMR (75 MHz, CHLOROFORM-d) δ = 174.4, 170.9, 154.3, 151.9, 140.3, 129.8, 
126.4, 121.4, 91.5, 14.2 
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Compound 14: 
 
ESI-MS(+): m/z 227.1 [M+H] +, 255.1 [M-N2+H] +  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.42 (s, 1 H), 7.43 (s, 1 H), 3.20 (q, J=7.4 
Hz, 2 H), 2.55 (s, 3 H), 1.36 ppm (t, J=7.4 Hz, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 174.5, 173.2, 151.0, 140.3, 102.2, 102.1, 
24.5, 14.2 ppm 
 
Compound 15: 
 
ESI-MS(+): m/z 283.2 [M+H]+, 255.1 [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.41 (s, 1 H), 7.38 (s, 1 H), 2.55 (s, 3 H), 
1.60 ppm (s, 9 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 175.6, 173.0, 150.8, 140.2, 103.0, 49.8, 
30.3, 14.5 ppm 
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Compound 16: 
 
ESI-MS(+): m/z 317.2 [M+H]+, 289.1  [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.40 (s, 1 H), 7.44 (s, 1 H), 6.99-7.39 (m, 
5 H), 4.44 (s, 2 H), 2.53 ppm (s, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d) δ = 173.7, 173.4, 151.1, 140.4, 140.2, 136.0, 
128.9, 128.8, 127.7, 102.1, 102.0, 34.2, 14.3 
 
Compound 17/17op: 
 
ESI-MS(+): m/z 303.1 [M+H]+, 275.1 [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.38 (s, 1 H), 7.32-7.73 (m, 5 H), 7.07 (s, 
1 H), 2.38 ppm (s, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 176.9, 173.3, 152.1, 140.4, 140.2, 135.9, 
130.9, 130.2, 126.6, 14.2 ppm 
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Compound 18: 
 
ESI-MS(+): m/z 337.3 [M+H]+, 309.1 [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.36 (s, 1 H), 7.29-7.60 (m, 4 H), 7.12 (s, 
1 H), 2.33 ppm (s, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 175.7, 173.5, 152.0, 140.4, 140.1, 137.4, 
137.1, 130.3, 125.0, 14.2 ppm 
 
Compound 19: 
 
ESI-MS(+): m/z 305.0  [M-N2+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 9.46 (s, 1 H), 7.54 (d, J=8.1 Hz, 2 H), 
6.87-7.18 (m, 3 H), 3.82-4.00 (m, 3 H), 2.51 ppm (s, 3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 178.1, 173.1, 161.7, 152.1, 140.3, 137.4, 
116.9, 115.8, 100.3, 55.5, 14.2 ppm 
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Compound 20: 
 
ESI-MS(+): m/z 289.0 [M+H]+  
1H NMR (300 MHz, DMSO-d6): δ = 10.22 (s, 1 H), 7.66 (d, J=7.5 Hz, 1 H), 7.48-7.59 
(m, 2 H), 7.34 - 7.45 (m, 1 H), 7.05 (s, 1 H), 2.44 (s, 3 H), 2.37 ppm (s, 3 H) 
13C NMR (75 MHz, DMSO-d6): δ = 174.5, 172.2, 152.1, 142.8, 142.0, 136.8, 131.4, 
131.3, 127.6, 125.6, 100.7, 20.3, 13.6 ppm 
 
Compound 21: 
 
ESI-MS(+): m/z 187.0 [M+H]+  
1H NMR (300 MHz, CHLOROFORM-d): δ = 5.73 (s, 1 H), 3.92 (s, 6 H), 2.56 ppm (s, 
3 H) 
13C NMR (75 MHz, CHLOROFORM-d): δ = 171.1, 170.9, 85.3, 54.0, 14.0 ppm 
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Compound 22: 
 
ESI-MS(+): m/z 343.0 [M+H]+  
1H NMR (300 MHz, DMSO-d6) δ = 7.33-7.46 (m, 10H), 5.72 (s, 1H), 2.32 (s, 3H) 
13C NMR (75 MHz, DMSO-d6): δ = 172.0, 170.8, 136.3, 135.8, 130.9, 130.5, 126.8, 
107.2, 13.9 ppm 
 
Compound 23: 
 
ESI-MS(+): m/z 340.0 [M+H]+ 
1H NMR (300 MHz, CHLOROFORM-d): δ = 7.46 (d, J=7.2 Hz, 2 H), 7.28-7.39 (m, 3 
H), 7.15-7.26 (m, 3 H), 7.09 (d, J=7.3 Hz, 2 H), 5.33 (s, 1 H), 5.00 (s, 1 H), 4.28 (br. 
s., 2 H), 2.34 ppm (s, 3 H) 
13C NMR (126 MHz, CHLOROFORM-d ): δ = 170.8, 161.4, 135.8, 129.6, 129.5, 
128.7, 128.6, 127.4, 127.3, 45.2, 13.9 ppm 
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Compound 24:  
 
ESI-MS(+): m/z 258.8 [M+H]+  
1H NMR (300 MHz, DMSO-d6): δ = 8.71 (t, J=1.0 Hz, 2 H), 8.07 (t, J=1.4 Hz, 2 H), 
7.90 (s, 1 H), 7.22 (dd, J=1.6, 0.8 Hz, 2 H), 2.64 ppm (s, 3 H) 
13C NMR (75 MHz, DMSO-d6,): δ = 172.8, 156.3, 135.8, 131.0, 130.8, 116.6, 90.3, 
13.6 ppm 
 
Crystallization of compound 1: 
10 mg of 1 was dissolved in a minimum amount of hot methanol (~800µl). The clear 
solution was allowed to cool down to room temperature and left standing open to 
atmosphere for slow evaporation. Colorless, needle shaped crystals formed after 2 
days. 
CCDC Number 1052351 contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from the Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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SI Table 1. Conditions tried to obtain N,N-dimethyl-2-(methylthio)-6-(1H-tetrazol-1-
yl)pyrimidin-4-amine starting from 6-chloro-N,N-dimethyl-2-(methylthio)pyrimidin-4-
amine 
Method Conditions 
Heating DMF, TEA, 60-140°C, 1-2 eq tetrazole, 24 hrs[a] 
Microwave DMF, TEA, 60-140°C, 1-2 eq tetrazole, 1 hr[a] 
Heating Neat, 2 eq tetrazole, 130°C, 24 hrs[a] 
[a] TLC showed no conversion of starting material 
 
Determination of the pKa of compound 10: 
The pKa of 10 was measured using the SiriusT3 automatic titration system (Sirius 
Analytical Ltd, Forest Row, UK) and the software supplied with the machine for the 
refinement of the experimental data. Standard solutions of hydrochloric acid 0.5 M 
and potassium hydroxide 0.5 M in Millipore water were used as acid and base titrant, 
respectively. The ionic strength of the water used for dissolving the samples was 
adjusted adding potassium chloride obtaining a 0.15 M solution. A solution of 50 % 
acetonitrile – 50 % Millipore water was prepared and potassium chloride was added 
in it for obtaining a final mixture 50 % acetonitrile with 0.15 M KCl. In each 
experiment 10 was titrated three times in acetonitrile – water solution (first titration in 
42 %, second titration in 35 % and third titration in 27 % of acetonitrile) from basic to 
acidic pH. Three independent experiments were performed per each compound at 
room temperature. The pKa was obtained by linear extrapolation of the psKa of each 
experiment resulting in a pKa = 3.17 ± 0.05 and in a acceptable coefficient of 
determination (R2 = 0.8927).  
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6.4 Supporting information for Publication IV 
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I. General experimental information - Chemistry 
 
a. Chemical Synthesis of compounds 3-6  
 
N
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N
NN3 S
N
NN S
NN
N
N
NN S
NN
N O O
N
NN S
NN
N
NN3 S
OO
N
NN S
OON
N
N
NN S
OON
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5 4
3
HO
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d)
1. e)
2. d)
d) c)
HO
4-chloro-2-thiomethylpyrimidine
 
Scheme S1. a) see reference 1b; b) See reference 1a; c) TMS-Acetylene, CuSO4, sodium ascorbate, 
tertBuOH:H2O, r.t.; d) Oxone, EtOAc:H2O, r.t.; e) heptane-1-thiol, DMF, K2CO3, 0°C.  
 
Compounds 3a, 3b and 6a were synthesized as reported before.1,2 
 
 
b. Crystallization of 6a for X-ray crystallography 
 
Figure S1. X-ray crystalstructure of compound 6a (green = nitrogen, grey = carbon, yellow = sulfur, 
white = hydrogen). 
6a was dissolved in hot chloroform and left standing open to atmosphere to allow 
evaporation. Colorless needles formed after 3 weeks. CCDC 1432241 contains the 
supplementary crystallographic data for this paper. These data can be obtained free 
of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/getstructures. 
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c. 13C-NMR spectra 
13C NMR of compound 3 
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HSQC NMR of compound 3 
 
 
6 Supporting information 
254 
13C NMR of compound 4 
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13C NMR of compound 5 
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13C NMR compound 6 
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d. LC purity of compounds 3-6 
Compound 3 
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Compound 4 
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Compound 5 
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Compound 6 
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II. General experimental information – Biology 
 
a. Chemicals, bacterial strains, and media 
Yeast extract was obtained from Fluka (Neu-Ulm, Germany), peptone and casein 
from Merck (Darmstadt, Germany), Bacto™ Tryptone from BD Biosciences 
(Heidelberg, Germany), and Gibco® PBS from Life Technologies (Darmstadt, 
Germany). Salts and organic solvents of analytical grade were obtained from VWR 
(Darmstadt, Germany). 
P. aeruginosa PA14 strain, and isogenic pqsR knockout mutant were stored in 
glycerol stocks at -80 °C. 
Minimal medium PPGAS3 and Luria Bertani (LB) were used. 
 
 
b. Pyocyanin assay 
 
Figure S2. IC50 curve of the improved inhibitory effect of 6 on pyocyanin production, an indicative of 
PqsR antagonism. Error bars represent standard error of three independent experiments (n = 3). 
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c. Prolonged Pyocyanin Assay. 
Effect of long-term PqsD inhibition on pyocyanin formation was assessed as 
previously described (pyocyanin assay) with slight modifications. Initially, treated 
(compound 1) and untreated cultures were incubated for 24 h under aerobic 
conditions. pyocyanin levels and bacterial density were determined from extracted 
culture aliquots. Obtained OD600 values were used to re-calculate the necessary 
dilution factors of each replicate for a final density of 0.02, transferred into a new 
plate with fresh PPGAS medium and DMSO or compound 1 for additional 24 h, 
accordingly. Pyocyanin formation and cell growth were again assessed as previously 
described, making up for a total of 48 h of incubation with treated samples under 
constant, long-term PqsD inhibition. 
 
 
Figure S3. Long-term effect of PqsD inhibitor 1 on pyocyanin production in PA14 wild type. Treament 
with 500 µM of 1 led to a reduction of pyocyanin levels to 83.5 ± 3.2 % after 48 h of incubation. The 
differences in values (compared to control) determined for 17 h and 24 h were not significant. All 
values are relative to a DMSO control without addition of inhibitors. Error bars represent the standard 
deviation of three independent experiments (n = 3). * = p < 0.05.  
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d. Growth curves of P. aeruginosa PA14  
Cultures of PA14 were diluted in PPGAS medium, adjusted to an initial OD600 of 0.02, 
and 1.5 mL added in triplicates into 24-well plates (Greiner Bio-One, Kremsmünster, 
Austria). Cultivation conditions as described above (SI, section II-a). Stock solutions 
of compound 6 in DMSO were diluted 1:100 to a final DMSO concentration of 1% 
(v/v), DMSO alone was used as control. Bacterial growth was measured over 48 h as 
a function of OD600 using FLUOstar Omega (BMG LabTech, Ortenberg, Germany). 
 
Figure S3. Growth curves of PA14 in PPGAS minimal medium in the absence (control) and presence 
of varying concentrations (100 µM to 500 µM) of compound 6. 
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e. Antibiofilm effects of compound 2 
 
 
Figure S5. Effects of compound 2 (15 µM; solubility maximum) on volume of P. 
aeruginosa strain PA14 biofilm. Experiment was performed as described in the 
experimental section of the main text. Error bars represent standard error of at least 
two independent experiments. 
 
 
f. PqsD in vitro assay 
The assay was performed as reported before.4 
 
 
g. PqsR in vitro assay 
The assay was performed in E. Coli DH5α as reported before.5
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I. Purification, yield and compound characterization  
2-(methylthio)-4-(1H-tetrazol-1-yl)pyrimidine (1b): 
 
As previously described.[1]  
 
2-(methylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (2a): 
 
As previously described.[2]  
 
4-iodo-2-(methylthio)pyrimidine (3a): 
N
N SI
 
Purification and yield see experimental section in the manuscript. 1H NMR (CDCl3, 
300 MHz): δ = 7.98 (d, J = 5.1 Hz, 17 H), 7.38 (d, J = 5.1 Hz, 17 H), 2.53 ppm (s, 3 
H); 13C NMR (CDCl3, 75 MHz): δ = 173.2, 155.7, 129.3, 127.2, 14.3 ppm. 
 
2-(methylthio)pyrimidine-4-carbonitrile (3b): 
 
Purification and yield see experimental section in the manuscript. 1H NMR (CDCl3, 
300 MHz): δ = 8.71 (d, J = 4.8 Hz, 1 H), 7.26 (d, J = 4.8 Hz, 1 H), 2.58 ppm (s, 3 H); 
13C NMR (CDCl3, 75 MHz): δ = 175.2, 158.6, 141.3, 118.7, 115.2, 14.2 ppm. 
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2-(methylthio)-4-(1H-tetrazol-5-yl)pyrimidine (3c): 
 
Purification and yield see experimental section in the manuscript. 1H NMR (CDCl3, 
300 MHz): δ = 8.77 (d, J = 5.0 Hz, 1 H), 7.91 (d, J = 5.0 Hz, 1 H), 6.09 (br. s, 1 H), 
2.62 ppm (s, 3 H); 13C NMR (CDCl3, 75 MHz): δ = 173.8, 159.0, 151.4, 113.8, 14.2 
ppm. 
 
2-(methylthio)-4-(1H-1,2,4-triazol-1-yl)pyrimidine (4a): 
 
As previously described.[1] 
 
2-(methylthio)-4-(1H-pyrazol-1-yl)pyrimidine (5a): 
 
As previously described.[1] 
 
 
4-(1H-imidazol-1-yl)-2-(methylthio)pyrimidine (6a): 
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As previously described.[1] 
 
4-bromo-2-(methylthio)pyrimidine (7a): 
 
To a solution of 4-chloro-2-(methylthio)pyrimidine in ACN was added TMSBr and the 
mixture was stirred for 24 h at 40 °C under argon (pink color). Afterwards, the 
reaction was quenched by the addition of a sat. solution of NaHCO3 (45 mL). The 
aqueous phase was extracted twice with EtOAc (40 mL) and the combined organic 
layers were washed with water and brine (each 30 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (cyclohexane:ethyl acetate, 9:1) to yield an off white solid (96%). 1H 
NMR (CDCl3 , 300 MHz): δ = 8.25 (d, J = 5.2 Hz, 1 H), 7.15 (d, J = 5.2 Hz, 1 H), 2.56 
ppm (s, 4 H). 13C NMR (CDCl3, 75 MHz): δ = 173.9, 157.2, 152.5, 120.3, 14.3 ppm. 
 
4-bromo-2-(methylsulfonyl)pyrimidine (7b): 
 
To a solution of 7a in EtOH was added a mixture of H2O2 and ammonium molybdate 
tetrahydrate at 0 °C and stirring continued overnight in an ice bath. Afterwards, the 
crude mixture was concentrated under reduced pressure and the residue taken up in 
water/EtOAc 1:1 (50 mL). The organic phase was separated and the aqueous one 
extracted twice with EtOAc. The combined organic phases were dried over MgSO4 
and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (cyclohexane:ethyl acetate = 1:1) to give a white solid (94%). 1H 
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NMR (CDCl3, 300 MHz): δ = 8.69 (d, J = 5.2 Hz, 1 H), 7.76 (d, J = 5.2 Hz, 1 H), 3.38 
ppm (s, 4 H); 13C NMR (CDCl3, 75 MHz): δ = 166.1, 158.5, 154.7, 128.6, 39.1 ppm. 
 
1-(2-(methylthio)pyrimidin-4-yl)-1H-benzo[d]imidazole (8a): 
 
As previously described.[1] 
 
1-(2-(methylthio)pyrimidin-4-yl)-1H-benzo[d][1,2,3]triazole (9a): 
 
As previously described.[1] 
 
4-azido-2-(methylthio)pyrimidine (10a): 
 
As described previously.[3] 
 
4-azido-2-(methylsulfonyl)pyrimidine (10b): 
 
As described previously.[3] 
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4-ethynyl-2-(methylthio)pyrimidine (22a): 
 
 
22a was prepared as previously described. Analytical data is in good accordance 
with the literature.[4] 1H NMR (CDCl3, 300MHz): δ = 8.47 (d, J = 5.0 Hz, 1 H), 7.02 (d, 
J=  5.0 Hz, 1 H), 2.57 (s, 3 H), 0.28 ppm (s, 9 H). 
 
4-ethynyl-2-(methylthio)pyrimidine (22b): 
 
Purification and yield see experimental section in the manuscript. Analytical data is in 
good accordance with the literature.[4] 1H NMR (CDCl3, 500 MHz): δ = 8.51 (d, J = 4.7 
Hz, 1 H), 7.06 (d, J = 5.0 Hz, 1 H), 3.34 (s, 1 H), 2.57 ppm (s, 3 H); 13C NMR (CDCl3, 
126 MHz): δ = 173.4, 157.2, 149.8, 118.7, 81.4, 80.7, 14.1 ppm. 
 
4-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(methylthio)pyrimidine (22c): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (60%). 1H NMR 
(CDCl3, 300 MHz): δ = 8.58 (d, J = 5.1 Hz, 1 H), 8.15 (s, 1 H), 7.77 (d, J = 5.2 Hz, 1 
H), 7.36 - 7.47 (m, 3 H), 7.28 - 7.36 (m, 2 H), 5.60 (s, 2 H), 2.57 ppm (s, 3 H); 13C 
NMR (CDCl3, 75 MHz): δ = 172.6, 157.9, 157.2, 146.6, 134.1, 129.3, 129.0, 128.2, 
123.7, 111.7, 54.5, 14.1 ppm. 
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N-methyl-2-(methylthio)-6-(1H-tetrazol-1-yl)pyrimidin-4-amine (23b): 
 
As previously described.[5]  
 
2-(methylthio)-6-(1H-tetrazol-1-yl)pyrimidin-4-amine (24a): 
 
As previously described.[5]  
 
N-(2-(methylthio)-6-(1H-tetrazol-1-yl)pyrimidin-4-yl)acetamide (24b): 
N
N SN
NN
N
HN O
 
Flash chromatography (ethyl acetate:hexane, 7:3); white solid (47%). 1H NMR 
(DMSO-d6 ,300 MHz): δ = 11.33 (s, 1 H), 10.28 (s, 1 H), 8.35 (s, 1 H), 2.63 (s, 3 H), 
2.19 ppm (s, 3 H); 13C NMR (DMSO-d6 ,75 MHz): δ = 172.8, 171.7, 160.5, 154.0, 
142.1, 93.8, 24.8, 14.3 ppm. 
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N-benzyl-2-(methylthio)-6-(1H-tetrazol-1-yl)pyrimidin-4-amine (25a) 
 
As previously described.[5]  
 
2-(methylthio)-4-phenoxy-6-(1H-tetrazol-1-yl)pyrimidine  (26a): 
 
As previously described.[5]  
 
2-(isopropylthio)-4-(1H-1,2,3-triazoll-1-yl)pyrimidine (27a): 
 
The crude product was directly taken to the next step without further purification. 
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2-(tert-butylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (28a): 
 
Flash chromatography (ethyl acetate:hexane, 3:7); white solid (62%). 1H NMR 
(CDCl3, 500 MHz): δ = 8.69 (d, J = 5.4 Hz, 1 H), 8.56 (d, J = 1.3 Hz, 1 H), 7.86 (d, J = 
1.3 Hz, 1 H), 1.68 ppm (s, 9 H); 13C NMR (CDCl3, 126 MHz): δ = 174.0, 159.6, 154.6, 
134.6, 121.1, 104.8, 47.9, 29.9 ppm. 
 
2-(ethylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (29a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (36%). 1H NMR 
(CDCl3, 300 MHz): δ = 8.69 (d, J = 5.4 Hz, 1 H), 8.59 (d, J = 1.3 Hz, 1 H), 7.85 (d, J = 
1.3 Hz, 1 H), 7.81 (d, J = 5.4 Hz, 1 H), 3.21 (q, J = 7.4 Hz, 2 H), 1.44 ppm (t, J = 7.4 
Hz, 3 H); 13C NMR (CDCl3, 75 MHz): δ = 173.4, 159.8, 154.9, 134.5, 121.1, 104.9, 
25.5, 14.2 ppm. 
 
2-(propylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (30a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (57%). 1H NMR 
(CDCl3, 300 MHz): δ = 8.69 (dd, J = 5.4, 0.8 Hz, 1 H), 8.53 - 8.63 (m, 1 H), 7.84 - 
7.89 (m, 1 H), 7.81 (dd, J = 5.4, 0.9 Hz, 1 H), 3.19 (td, J = 7.3, 0.8 Hz, 2 H), 1.82 (sxt, 
J = 7.3 Hz, 2 H), 1.00 - 1.17 ppm (m, 3 H); 13C NMR (CDCl3, 75 MHz): δ = 173.5, 
159.8, 154.9, 134.5, 121.1, 104.9, 33.1, 22.4, 13.5 ppm. 
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2-(butylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (31a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (72%). 1H NMR CDCl3, 
300 MHz): δ = 8.69 (d, J = 5.4 Hz, 1 H), 8.58 (d, J = 1.2 Hz, 1 H), 7.86 (d, J = 1.2 Hz, 
1 H), 7.81 (d, J = 5.4 Hz, 1 H), 3.21 (t, J = 7.4 Hz, 2 H), 1.69 - 1.85 (m, 2 H), 1.52 (dq, 
J = 14.9, 7.4 Hz, 2 H), 0.88 - 1.08 ppm (m, 3 H); 13C NMR (CDCl3, 75 MHz): δ = 
173.5, 159.8, 154.9, 134.5, 121.1, 104.8, 31.0, 30.9, 22.0, 13.6 ppm. 
 
2-(pentylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (32a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (62%). 1H NMR 
(CDCl3, 300 MHz): δ = 8.68 (d, J = 5.4 Hz, 1 H), 8.58 (d, J = 1.2 Hz, 1 H), 7.86 (d, J = 
1.2 Hz, 1 H), 7.81 (d, J = 5.4 Hz, 1 H), 3.14 - 3.25 (m, 2 H), 1.79 (quin, J = 7.4 Hz, 2 
H), 1.29 - 1.55 (m, 4 H), 0.85 - 0.99 ppm (m, 3 H); 13C NMR (CDCl3, 75 MHz): δ = 
173.6, 159.8, 154.9, 134.5, 121.1, 104.8, 31.1, 31.1, 28.6, 22.2, 13.9 ppm. 
 
2-(hexylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (33a): 
N
N SN
NN
 
Flash chromatography (ethyl acetate:hexane, 1:9); white solid (48%). 1H NMR 
(CDCl3, 300 MHz): δ = 8.69 (d, J = 5.4 Hz, 1 H), 8.59 (d, J = 1.3 Hz, 1 H), 7.86 (d, J = 
1.3 Hz, 1 H), 7.81 (d, J = 5.4 Hz, 1 H), 3.13 - 3.27 (m, 2 H), 1.79 (quin, J = 7.4 Hz, 2 
H), 1.43 - 1.55 (m, 2 H), 1.34 (dq, J = 7.3, 3.6 Hz, 4 H), 0.84 - 0.93 ppm (m, 3 H); 13C 
6 Supporting information 
277 
NMR (CDCl3, 75 MHz): δ = 173.6, 159.8, 154.9, 134.5, 121.1, 104.9, 31.4, 31.2, 
28.9, 28.6, 22.5, 14.0 ppm. 
 
2-(heptylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (34a): 
 
As previously described.[2]  
 
methyl 3-((4-(1H-1,2,3-triazol-1-yl)pyrimidin-2-yl)thio)propanoate  (35a): 
 
Flash chromatography (ethyl acetate:hexane, 3:7); white solid (59%). 1H NMR 
(CDCl3, 500 MHz): δ = 8.70 (d, J = 5.4 Hz , 1 H), 8.63 (d, J = 1.6 Hz, 1 H), 7.86 (d, J 
= 5.4, 1 H), 7.85 (d, J= 5.4, 1 H), 3.73 (s, 3 H), 3.46 (t, J = 6.9 Hz, 2 H), 2.86 ppm (t, J 
= 7.3 Hz, 2 H); 13C NMR (CDCl3, 126 MHz): 172.5, 172.2, 160.0, 155.0, 134.6, 121.2, 
105.2, 51.9, 34.0, 26.2 ppm.   
 
2-(phenylthio)-4-(1H-1,2,3-triazol-1-yl)pyrimidine (36a): 
 
The crude product was directly used for the next step without further purification. 
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2-(phenylthio)-4-(1H-tetrazol-1-yl)pyrimidine (37a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (57%). 1H NMR 
(CDCl3, 300 MHz): δ = 9.06 (s, 1 H), 8.76 (d, J = 5.2 Hz, 1 H), 7.59 - 7.71 (m, 3 H), 
7.45 - 7.58 ppm (m, 3 H); 13C NMR (CDCl3, 75 MHz): δ = 174.4, 161.0, 152.9, 140.1, 
135.6, 130.1, 129.5, 128.1, 105.5 ppm. 
 
2-((4-chlorophenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (38a): 
 
Flash chromatography (ethyl acetate:hexane, 3:7), white solid (63%). 1H NMR 
(CDCl3, 300 MHz): δ = 9.18 (s, 1 H), 8.76 (d, J = 5.3 Hz, 1 H), 7.72 (d, J = 5.3 Hz, 1 
H), 7.58 (dt, J = 8.6, 2.4 Hz, 2 H), 7.48 ppm (dt, J = 8.7, 2.3 Hz, 2 H); 13C NMR 
(CDCl3, 126 MHz): δ = 173.8, 161.1, 153.0, 140.0, 136.8, 136.6, 129.7, 126.5, 105.9 
ppm. 
 
2-((4-methoxyphenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (39a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (64%).1H NMR 
(CDCl3, 500 MHz): δ = 9.14 (s, 1 H), 8.76 (d, J = 5.4 Hz, 1 H), 7.67 (d, J = 5.4 Hz, 1 
H), 7.48 - 7.61 (m, 2 H), 6.93 - 7.08 (m, 2 H), 3.89 ppm (s, 3 H); 13C NMR (CDCl3, 
126 MHz): δ = 175.1, 161.2, 161.0, 152.9, 140.1, 137.3, 118.6, 115.0, 105.3, 55.4 
ppm. 
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2-((4-fluorophenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (40a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (64%). 1H NMR 
(CDCl3, 500 MHz): δ 9.15 (s, 1 H), 8.76 (d, J = 5.4 Hz, 1 H), 7.71 (d, J=5.4 Hz, 1 H), 
7.57 - 7.66 (m, 2 H), 7.13 - 7.24 ppm (m, 2 H); 13C NMR (CDCl3, 126 MHz): δ = 
174.4, 164.2, 161.3, 153.2, 140.3, 138.1, 123.6, 117.0, 106.0 ppm. 
 
2-((3-fluorophenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (41a): 
 
Flash chromatography (ethyl acetate:hexane, 15:85); white solid (77%). 1H NMR 
(CDCl3, 500 MHz) δ 9.15 (s, 1H), 8.78 (d, J = 5.4 Hz, 1H), 7.72 ppm (d, J = 5.4 Hz, 
1H), 7.35 - 7.53 (m, 3H), 7.20 - 7.27 (m, 1H); 13C NMR (CDCl3, 126 MHz) δ 173.6, 
162.7, 161.1, 153.0, 140.0, 131.2, 130.7, 129.9, 122.4, 117.3, 105.9 ppm. 
 
2-((3-chlorophenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (42a): 
 
Flash chromatography (ethyl acetate:hexane, 3:7), white solid (63%). 1H NMR 
(CDCl3, 300 MHz): δ = 9.07 (s, 1 H), 8.70 (d, J = 5.3 Hz, 1 H), 7.65 (d, J = 5.3 Hz, 1 
H), 7.60 (t, J = 1.8 Hz, 1 H), 7.45 (tt, J=7.5, 1.5 Hz, 2 H), 7.36 ppm (t, J = 7.6 Hz, 1 
H); 13C NMR (CDCl3, 126 MHz): δ = 173.5, 161.2, 153.0, 140.0, 135.3, 134.9, 133.6, 
130.4, 130.3, 129.8, 105.9 ppm. 
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2-((3-methoxyphenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (43a): 
 
Flash chromatography (ethyl acetate:hexane, 2:8); white solid (74%). 1H NMR 
(CDCl3, 500 MHz): δ = 9.13 (s, 1 H), 8.77 (d, J = 5.0 Hz, 1 H), 7.69 (d, J = 5.4 Hz, 1 
H), 7.37 - 7.46 (m, 1 H), 7.23 (dt, J = 7.6, 1.3 Hz, 1 H), 7.18 - 7.21 (m, 1 H), 7.07 
(ddd, J = 8.3, 2.6, 0.8 Hz, 1 H), 3.85 ppm (s, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 
174.4, 161.1, 160.2, 152.9, 140.1, 130.2, 129.0, 127.7, 120.9, 115.8, 105.5, 55.5 
ppm 
 
2-((3,4-dichlorophenyl)thio)-4-(1H-tetrazol-1-yl)pyrimidine (44a): 
 
Flash chromatography (ethyl acetate:hexane, 3:7), white solid (79%). 1H NMR 
(CDCl3, 300 MHz): δ = 9.24 (s, 1 H), 8.77 (d, J = 5.3 Hz, 1 H), 7.77 (d, J=2.0 Hz, 1 
H), 7.75 (d, J = 5.4 Hz, 1 H), 7.54 - 7.62 (m, 1 H), 7.44 - 7.52 ppm (m, 1 H); 13C NMR 
(CDCl3, 75 MHz): d = 173.0, 161.2, 153.1, 140.0, 136.9, 134.8, 134.5, 133.4, 131.2, 
127.9, 106.2 ppm. 
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II. Biological assays 
PqsD in vitro enzyme inhibition assay 
The assay was performed as previously described.[6] Briefly, the assay was 
performed monitoring enzyme activity by measuring HHQ formed by condensation of 
anthraniloyl-CoA and β-ketodecanoic acid. The reaction mixture contained MOPS 
buffer (0.05 M, pH 7.0) with 0.005% (w/v) Triton X-100, 0.1 µM of the purified enzyme 
and inhibitor. The test compounds were dissolved in DMSO and diluted with buffer. 
The final DMSO concentration was 0.5%. After 10 min preincubation at 37 °C, the 
reaction was started by the addition anthraniloyl-CoA to a final concentration of 5 µM 
and β-ketodecanoic acid to a final concentration of 70 µM. Reactions were stopped 
by addition of MeOH containing 1 µM amitriptyline as internal standard for LC/MS–
MS analysis. HHQ was quantified using a HPLC-MS/MS mass spectrometer 
(ThermoFisher, Dreieich, Germany) in ESI mode. Ionization of HHQ and the internal 
standard amitriptyline was optimized in each case. The solvent system consisted of 
10 mM ammonium acetate (A) and acetonitrile (B), both containing 0.1% 
trifluoroacetic acid. The initial concentration of B in A was 45%, increasing the 
percentage of B to 100% in 2.8 min and keeping it at 98% for 0.7 min with a flow of 
500 µL/min. The column used was a NUCLEODUR-C18, 100–3/125–3 (Macherey 
Nagel, Dühren, Germany). Control reactions without the inhibitor, but including 
identical amounts of DMSO, were performed in parallel and the amount of HHQ 
produced was set to 100%. All experiments were performed in at least duplicates 
except compound 26 which was determined once. 
 
PqsR reporter gene assay in E. coli 
The assay was performed as previously described.[7] The ability of the compounds to 
either stimulate or antagonize the PqsR-dependent transcription was analysed using 
a β-galactosidase reporter gene assay in E. coli expressing PqsR. A culture of E. coli 
DH5α cells containing the plasmid pEAL08-2, which encodes PqsR under the control 
of the tac promoter and the β-galactosidase reporter gene lacZ controlled by the 
pqsA promoter, were co incubated with test compound. Antagonistic effects of 
compounds were assayed in the presence of 50 nM PQS. After incubation, β-
galactosidase activity was measured spectrophotometrically at OD420nm using 
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POLARstar Omega (BMG Labtech, Ortenberg, Germany) and expressed as percent 
stimulation of controls. All experiments were at least performed in duplicates.  
 
P. aeruginosa PA14 biofilm assay and detection of extracellular DNA  
The assays were performed as previously described.[2] For the determination of 
biofilm mass, P. aeruginosa PA14 strain was cultivated in 96 well plates using M63 
medium. CV staining was used to detect compound effects on the overall biofilm 
biomass. Impact on eDNA was assessed by incubation of biofilm with propidium 
iodine solution (0,05 mg ml-1) for 3 h and detection of specific florescence at 620 nm 
after a thorough washing step with 18MΩ H2O. 
Levels of pyocyanin have been determined as published previously.[2] 
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III.  Solubility of compounds 1 – 44 
SI Table 2. Solubility of compounds 1 – 44 as 2% DMSO in water mixtures determined by 
visual inspection. 
Compound Solubility [µM]  Compound Solubility [µM] 
1 ≥ 1000  23 ≥ 200 
2 ≥ 200  24 ≥ 200 
3 ≥ 200  25 ≥ 200 
4 ≥ 200  26 ≥ 200 
5 ≥ 200  27 ≥ 200 
6 ≥ 200  28 ≥ 200 
7 ≥ 200  29 ≥ 200 
8 ≥ 200  30 ≥ 200 
9 ≥ 200  31 ≥ 200 
10 ≥ 200  32 ≥ 200 
11 ≥ 200  33 ≥ 200 
12 ≥ 200  34 100 
13 ≥ 200  35 ≥ 200 
14 ≥ 200  36 ≥ 200 
15 ≥ 200  37 ≥ 200 
16 ≥ 200  38 ≥ 200 
17 ≥ 200  39 ≥ 200 
18 10  40 ≥ 200 
19 10  41 ≥ 200 
20 50  42 ≥ 200 
21 50  43 ≥ 200 
22 ≥ 200  44 100 
 
  
6 Supporting information 
284 
IV.  Correlation of π and cLogP with pIC50 of compounds 37 – 44  
SI Table 2. Summary of pIC50, cLogP and π values for compounds 37 – 44 with 
corresponding groups attached to the sulfophenyl residue. 
Compound Group pIC50 cLogP π 
37 H 4.638 0.39 0.00 
38 4-F 4.602 0.37 0.14 
39 4-Cl 4.732 1.15 0.71 
40 4-OMe 5.004 0.41 -0.02 
41 3-F 5.537 0.49 0.14 
42 3-Cl 5.769 1.10 0.71 
43 3-OMe 5.769 0.56 -0.02 
44 3,4-di-Cl 4.638 1.67 1.42 
 
 
SI Figure 1. Correlation of pIC50 of compounds 37 – 44 and π 
 
 
SI Figure 2. Correlation of pIC50 of compounds 37 – 44 and cLogP 
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V.  Molecular modeling and Hansch analysis 
Molecular Modeling (Flexible alignment) 
For the flexible alignment of HHQ/β-decanoic acid and compound 2 Molecular 
Operating Environment (Chemical Computing Group) was used with the following 
general parameters: Forcefield = MMF94x; Alignment Mode = Flexible; Iteration Limit 
= 200; Failure Limit = 20; Energy Cutoff = 15. Settings used for HHQ alignment: 
Volume = 1; Aromaticity = 1; LogP (o/w) = 1; H-Bond Acceptor = 3; Hydrophobe = 1; 
Hydrophobe –Don/Acc = -1; H-Bond Acc projection = 1; Aromatic Center =1. CO2-
type Centroid = 1. Settings used for β-decanoic acid: H-Bond Donor = 3; LogP (o/w) 
= 1; H-Bond Acc Projecttion = 1; CO2-type Centroid =1. The resulting alignment was 
then sorted by score and the best rated was refined using all Atom Based Similarity 
and Projected Pharmacophore Similarity Terms. 
 
Physicochemical Properties  
Physicochemical properties calculation was performed as reported before.[3] 
 
Hansch Analysis 
pIC50 values were plotted against either the Hammett parameter of substituent or the 
alkyl chain length. Graphs were fitted using Graph Pad Prism 5 (GraphPad Software 
Inc.). To derive the Hansch equations for the Hammett parameter versus pIC50 the 
“linear regression model” and for alkyl chain length versus pIC50 the “One site – Fit 
logIC50” model was used.  
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6.6 Supporting information for Chapter VI 
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Supporting Information 
 
Biophysical Screening of a Focused Library for the 
Discovery of CYP121 Inhibitors as Novel 
Antimycobacterials  
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1. Chemical synthesis cYY and Mycocyclosin: 
 
1.1 Synthesis of cyclo-di-L-tyrosine (cYY) 
 
cyclo-di-L-thyrosine (cYY): 
 
cYY was synthesized as previously described.1 Spectral data is in accordance with 
the previously published results:1 
1H NMR (300 MHz, DMSO-d6) δ 9.19 (s, 1H), 7.75 (d, J = 2.6 Hz, 1H), 7.05 – 6.78 
(m, 2H), 6.78 – 6.55 (m, 2H), 3.85 (s, 1H), 2.54 (dd, J = 4.6 Hz, 1H), 2.11 (dd, J = 
13.7, 6.5 Hz, 1H); 13C NMR (75 MHz, DMSO) δ 166.7, 156.5, 131.2, 127.0, 115.5, 
56.2, 39.3; ESI-MS(+) = m/z 327.1 [M+H]+. 
 
1.2 Synthesis of mycocyclosine 
 
Mycocyclosine: 
 
Mycocyclosine was synthesized as previously described.1,2 Spectral data is in 
accordance with the previously published results:1 
1H NMR (300 MHz, DMSO-d6) δ 7.98 (s, 1H), 6.84 (dd, J = 2.51, 7.9 Hz, 1H), 6.62 (d, 
J = 8.1 Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 4.32 (d, J = 4.8 Hz, 1H), 3.46 (d, J = 15.7 
Hz, 1H), 2.64 (dd, J = 5.73, 15.6 Hz, 1H). 
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2. SDS-PAGE of His-tagged CYP121 
 
 
Figure S1. SDS-PAGE of Ni-NTA purified heterologous expressed CYP121. The 
band corresponds to a molecular mass of > 46000 Da which is in good accordance 
with the calculated protein mass of 43256 Da. 
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3. Activity of CYP121/ CO Spectra 
 
 
Figure S2. UV-VIS carbonmonoxide difference spectra (COD) of CYP121 after 
treatment with sodium sulfide and carbonmonoxide. The characteristic band at ~420 
nm shows CO coordination to the reduced iron-heme. 
 
Figure S3. UV-VIS carbonmonoxide difference spectra (COD) of CYP121 after 
incubation with reductase Arh1_A18G and ferrodoxin Etp1fd (516-618)followed by 
carbonmonoxide treatment. The characteristic band at ~420 nm shows CO 
coordination to the reduced iron-heme
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4. LC-MS analysis of in vitro CYP121 enzyme reaction and effect 
of I:47  
 
 
Figure S4. LC-MS/MS quantification of CYP121 enzyme reaction: internal standard 
estrone tR = 4.05 min (A); mycocyclosin tR = 1.30 min (B); cYY tR = 1.95 min (C).  
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Figure S5. LC-MS/MS based quantification of CYP121 in vitro enzyme reaction 
product mycocyclosin with addition of I:47 (100 µM, lower chromatogram) and 
without the presence of the inhibitor (upper chromatogram).
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5. Surface Plasmon Resonance Sensorgramm of Econazole 
 
Figure S6. Representative example for SPR binding curve of econazole to CYP121 
injected from 100 µM sample. 
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6. Screening overview 
 
Table S1. Overview of the results of SPR screening, Heme binding assay, 
BCG and Mtb growth inhibition and MIC determination 
Cmpd SPR [R/Rpos] 
Heme 
coord.a 
Heme-
KD [µM] 
BCGT 
Inhibition 
@ 100 µM 
[%] 
MICBCGT 
[µM] 
MICMtb 
[µM] 
I:1 0.4 N  10   
I:2 0      
I:3 0.1      
I:4 0.2      
I:5 0.1      
I:6 0.1      
I:7 0.5      
I:8 0.5      
I:9 0      
I:10 0      
I:11 0.6 N     
I:12 0.4      
I:13 0      
I:14 0.2      
I:15 0.3 Y (T-II) 34 87 41  
I:16 1.2 Y (T-II) 1 78 5 6 
I:17 1.9 Y (T-II) 3 65 38  
I:18 0.1      
I:19 0      
I:20 0.4      
I:21 0.1      
I:22 0.1      
I:23 0.1      
I:24 0.3      
I:25 0.5      
I:26 0.1      
I:27 1.0 Y (T-II) weak    
I:28 0.3      
I:29 0.4      
I:30 1.4 Y (T-II) 11 94 11 48 
I:31 1.5 N     
I:32 1.1 Y (T-II) 14 85 30 41 
I:33 0.1 N  0   
I:34 0.7 Y (T-II) 29 25   
I:35 0.5      
I:36 0.1      
I:37 0.2      
I:38 0.2      
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I:39 0.1      
I:40 0.3      
I:41 0.1      
I:42 0.1      
I:43 0.2      
I:44 0.2      
I:45 0.5      
I:46 0.1      
I:47 0.6 Y (T-II) 5 87 1 1 
I:48 0.8 Y (T-II) 5 88 7 12 
II:1 0.3      
II:2 0.3      
II:3 0.5      
II:4 0.2      
II:5 0.2      
II:6 0.1      
II:7 0.0      
II:8 0.3      
II:9 0.2      
II:10 0.1      
II:11 0.3      
II:12 0.2      
II:13 0.1      
II:14 0.5 N     
II:15 0.1      
II:16 0.2      
II:17 0.2      
II:18 0.2      
II:19 0.2      
II:20 1.3 Y (T-II) 9 48   
II:21 0.7 Y (T-II) 31 
 
  
II:22 0.2      
II:23 0.6 N     
II:24 0.1      
II:25 0.2      
II:26 0.8 Y (T-II) 16 
 
  
II:27 0.9 Y (T-II) 20    
II:28 0.9 Y (T-II) 19    
II:29 0.7 Y (T-II) 62    
II:30 0.8 Y (T-II) weak    
II:31 0.6 Y (T-II) weak 
 
  
II:32 0.7 Y (T-II) weak    
II:33 0.3      
II:34 0.7 Y (T-II) 12 0   
II:35 1.0 Y (T-II) weak    
II:36 0.9 Y (T-II) 16    
II:37 1.4 Y (T-II) 50    
II:38 1.2 Y (T-II) weak    
II:39 1.4 N     
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II:40 0.7 Y (T-II) 27 
 
  
II:41 0.9 Y (T-II) 13 7   
II:42 0.2      
III:1 0.3      
III:2 0.4      
III:3 1.7 Y (T-II) weak 20   
III:4 1.7 N  20   
III:5 0.5      
III:6 0.3      
III:7 1.8 N  18   
III:8 1.4 Y (T-II) weak 5   
III:9 0.6 Y (T-II) weak    
III:10 0.4      
III:11 0.3      
III:12 0.2      
III:13 0.1      
III:14 0.3      
III:15 0.4      
III:16 0.2      
III:17 0.2      
III:18 0.4      
III:19 0.4      
III:20 0.2      
III:21 0.3      
IV:1 0.2      
IV:2 0.1      
IV:3 0.1      
IV:4 0.3      
IV:5 0.1 N     
IV:6 0.5      
IV:7 0.6 N     
IV:8 0.5      
IV:9 0.4      
IV:10 0.5   60   
IV:11 0.9 Y (T-II) weak    
IV:12 0.9 N     
IV:13 0.8 Y (T-II) 62    
V:1 0.0      
V:2 0.3      
V:3 0.2      
V:4 0.1      
V:5 0.2      
V:6 0.1      
V:7 0.3      
V:8 0.8 N     
V:9 0.8 N     
VI:1 0.6 N  50   
VI:2 1.2 N     
VI:3 1.5 N     
VI:4 1.3 N     
VI:5 0.4      
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VI:6 1.3 N     
Ecob 1.0 Y (T-II) 3 71 14 113 
cYYc  Y (T-I) 12    
an= no, y= yes, T-I = type I binding profile, T-II = type II binding profile, b Eco = 
econazole, cYY = cyclo-di-L-tyrosine 
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7. KD determination by UV-VIS Heme coordination assay 
 
 
Figure S7. Determination of KD’s by titration of I:48 (A), I:47 (B), I:16 (C) and 
econazole (D) and monitoring the difference between the absorption at 430 nm 
minus absorption at 410 nm In the presence of CYP121. Graphs were plotted with 
SigmaPlot using Marquardt - Levenberg algorithm. 
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8. Protein Blast of Mtb H37RV CYP121 (Rv2276) and M. bovis BCG Pasteur 
CYP121 (BCG_2293) 
 
 
Figure S8. Results of the Protein Blast of Mtb CYP121 (upper sequence) and BCGT 
CYP121 (lower sequence) showing 100% amino acid identity between both proteins. 
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9. MICBCGT determination against Mycobacterium bovis  
 
Figure S9. Growth inhibition of BCG versus control (%) of econazole (A), I:15 (B), 
I:16 (C), I:30 (D) of concentrations ranging from 100-1.56 µM of the respective 
compounds. Endpoint optical density was measured at 600 nm. MICBCGT were 
determined by GraphPad Prismn using OneSite Log IC50 model provided by the 
software. 
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Figure S10. Growth inhibition of BCG versus control (%) of I:32 (A), I:47 (B), I:48 (C) 
of concentrations ranging from 100-1.56 µM of the respective compounds. Endpoint 
optical density was measured at 600 nm. MICBCGT were determined by GraphPad 
Prismn using OneSite Log IC50 model provided by the software. 
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10. Calculation of antimicrobial efficiency 
 
@ABCD@EFAC	ADAED = −  !" 
Table S2. Antimicrobial efficiency 4 of I:16, I:30, I:32, I:47, I:48, econazole, 
isoniazide and rifampicine calculated for effects on Mycobacterium tuberculosis. 
Cmp
d. 
MIC 
[mg/L] MW NHAa 
Antibacterial 
Efficiency 
I:16 1.90 310 24 0.26 
I:30 11.20 234 18 0.25 
I:32 9.60 234 18 0.26 
I:47 0.30 278 21 0.39 
I:48 3.50 292 22 0.26 
Eco 4.20 382 23 0.24 
INHb 0.05 137 10 0.99 
Rifc 0.11 823 57 0.16 
aNHA = number of heavy atoms, INH = isoniazide 3, Rif = rifampicine 3. 
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11.  Toxicity assessment against human cancer cell lines HEK293 
and HepG2 
 
SI Table 3. Toxicity data against human cancer cell lines HEK293 and HepG2 of 
I:47, I:16 and econazole (Eco). 
Compounds LD50 
HEK293 
[µM] 
SD LD50 
HEK293 
[mg/L] 
LD50 
HepG2 
[µM] 
SD LD50 
HepG2 
[mg/L] 
I:47 66.9  5.3 18.6 47.5 8.1 17.1 
I:16 19.6 3.8 6.1 12.1 2.8 3.9 
Eco 15.6 3.8 6.0 11.8 4.3 3.1 
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12. MIC against Escherichia coli and Staphylococcus aureus in 
comparison to growth inhibition against Mycobacterium bovis 
BCG 
 
 
Figure S11. Comparison of growth inhibition of econazole (A), I:16 (B), I:47 (C) and 
I:48 (D) against M. bovis (▲, c = 1.56 - 100 µM), E. Coli (▪, c = 3.125 - 100 µM), S. 
aureus (●, c = 3.125 - 100µM) of concentrations ranging from 100-0.725 µM of the 
respective compounds. Endpoint optical density was measured at 600 nm. Graphs 
were plotted with GraphPad Prismn using OneSite Log IC50 model provided by the 
software. 
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13. Physicochemical data: 
 
I:16 
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I:47 
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Econazole 
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I:48 
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14.  Bacterial strains and growth conditions.  
Bacterial strains used in this study were Mycobacterium bovis DSM-43990 (BCGT), 
Mycobacterium tuberculosis H37Rv (Mtb), Escherichia coli TolC acr A/B deficient, 
Staphyllococcus aureus (Newman strain) and E. coli K12 BL21. Mammalian cell lines 
for cytotoxicity evaluation were HEK293 (human embrionic kidney) and Hep2G 
(human liver carcinoma cells) cells. Mycobacteria were cultured in 7H9GC-Tween5 or 
Middlebrook 7H9 broth complemented with ADC Enrichment (Middlebrook). E. coli 
TolC and S. aureus tests were performed in lysogenic broth (LB) and LB plus ADC 
Enrichment. 
 
15. Chemical synthesis and analytical characterization.  
Chemicals were purchased from commercial suppliers and used without further 
purification. Column flash chromatography was performed on silica gel (40−63 µm), 
and reaction progress was monitored by TLC on TLC Silica Gel 60 F254 plates 
(Merck, Darmstadt, Germany). All moisture-sensitive reactions were performed under 
nitrogen atmosphere using anhydrous solvents. 1H and 13C NMR spectra were 
recorded on Bruker Fourier spectrometers (300 MHz) at ambient temperature with 
the chemical shifts recorded as δ values in ppm units by reference to the 
hydrogenated residues of deuterated solvent as internal standard. Coupling 
constants (J) are given in Hertz (Hz), and signal patterns are indicated as follows: s, 
singlet; d, doublet; dd, doublet of doublets; t, triplet; m, multiplet, br, broad signal. The 
purity of the final compounds was >95% measured by HPLC with UV detection at 
254 nm. The SpectraSystem LC system consisted of a pump, an autosampler, and a 
UV/Vis detector (ThermoFisher, Dreieich, Germany). Mass spectrometry was 
performed on an LC-coupled Surveyor MSQ electrospray mass spectrometer 
(ThermoFisher, Dreieich, Germany). The system was operated by the Xcalibur 
software. An RP C18 NUCLEODUR ec 100-5 125×3 mm 5 µm column (Macherey-
Nagel GmbH, Düren, Germany) was used as the stationary phase. All solvents were 
HPLC grade. In a gradient run, the percentage of acetonitrile (containing 0.1 % 
trifluoroacetic acid) was increased from an initial concentration of 0 % at 0 min to 
100 % at 15 min and kept at 100 % for 5 min. The injection volume was 10 µL, and 
flow rate was set to 800 µL/min. MS analysis was carried out at a spray voltage of 
3800 V, a source CID of 10 V and a capillary temperature of 350 °C. Spectra were 
acquired in positive mode from 100 to 1000 m/z. 
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cYY and mycocyclosin were synthesized as described.6–8 Experimental details on 
modification of cYY and mycocyclosin synthesis and analytical data can be found in 
the Supplementary Data (Supp. Data, section 1). 
The synthesis of library compounds has been described previously: class I9–14, class 
II15,16, class III17, class IV18 , class V19, and class VI20. 
 
16. Protein expression, purification and biotinylation.  
E. coli K12 BL21 (DE3) cells were transformed with plasmid harboring cyp121 gene 
(pHAT2/cyp121).21  
The previously described22 enzyme expression and purification method was slightly 
modified: His6-tagged CYP121 (H6-CYP121) was expressed in E. coli K12 BL21 and 
purified using a single affinity chromatography step. Briefly, E. coli K12 BL21 cells 
containing the pHAT2/cyp121 were grown in terrific broth medium containing 
100 µg/mL ampicillin at 37 °C until an OD600 of approximately 0.8 units was reached, 
followed by induction with 0.5 mM IPTG and 0.5 mM δ-aminolevulinic acid for 36 h at 
25 °C and 200 rpm. The cells were harvested by centrifugation (5000 rpm, 10 min, 
4 °C), and the cell pellet was resuspended in 100 mL of binding buffer containing 1% 
Triton-X-100 (50 mM tris-HCl, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH = 
7.2) and lysed by sonication for a total process time of 2.5 min. Cellular debris was 
removed by centrifugation (18,500 rpm, 40 min, 4 °C), and the supernatant was 
filtered through a syringe filter (0.2 µm). The clear lysate was immediately applied to 
a Ni-NTA affinity column, washed with binding buffer, and eluted with a one-step 
gradient of 500 mM imidazole. The protein containing fractions were buffer-
exchanged into storage buffer (140 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM 
KH2PO4 and 10% glycerol (v/v), pH = 7.2), using a PD10 column (GE Healthcare, 
Little Chalfont, UK) and judged to be pure by SDS-PAGE analysis. Then protein was 
stored in aliquots at −80 °C in a final concentration of 50 µM. 22 
Before SPR streptavidin immobilization CYP121 was biotinylated. For biotinylation, 
Sulfo-NHS-LC-LC-Biotin (Thermo Science, Waltham, US) was dissolved in storage 
buffer (140 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM KH2PO4 and 10% 
glycerol (v/v)) with CYP121 in 1:1 molar ratio. The solution was incubated on ice for 
2 h and mixed carefully every 30 min. The biotinylated CYP121 was purified by size 
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exclusion chromatography using the storage buffer and subsequently stored at -
80 °C at a final concentration of 10 µM.23  
 
17. In silico binding mode.  
In silico studies were performed with the X-ray co-crystal structure of a type II 
inhibitor and CYP121 (PDB-ID: 4G44) using MOE software package (Chemical 
Computing Group).24 Prior to modelling, a pharmacophore model was created, 
placing a feature for an interacting metal on the heme iron (ML2, R = 1) and a second 
feature for a metal ligand (ML, R = 1) on the iron-coordinating nitrogen of the co-
crystalized ligand. Both features were set to be essential and constrained 
(Atoms/Projections). Before energy minimization with LigX the solvent and the ligand 
was deleted from the structure. For LigX, an AMBER10:EHT forcefield with the 
default parameters were used but the solvation model was changed to R-Field as 
recommended by the manufacturer. For docking experiments the following 
parameters were used: Protocols = induced fit, Receptor = Receptor+Solvent, Site = 
Selected Atoms (these consisted of the heme and the surrounding amino acids in 4.5 
Å proximity), Pharmacophore = File (as described above), Ligand = MDB File 
(Database file with I:47, energy minimized with MMFF94x), Placement = 
Pharmacophore, Rescoring 1 = London dG, Refinement = Forcefield, Rescoring 2 = 
GBVI/WSA dG. 30 poses were retained within the placement and refinement step. 
The resulting poses were sorted by their E_refine score and the first (best) pose was 
selected for further evaluation. 
18.  Physicochemical properties.  
Physicochemical properties were calculated using ACD/Percepta version 2012 (Build 
2203, 29 jan. 2013), ACD/Labs. 
 
19. Cyp121 in vitro enzyme inhibition assay.  
The enzyme inhibition assay was performed in 200 mL PBS buffer pH 7.2. 
Compounds were used in a concentration of 100 µM and incubated with 1 µM 
CYP121 for 30 minutes at 30 °C. The final DMSO concentration did not exceed 2%. 
After incubation the electron transfer system Arh1_A18G (5 µM), Etp1fd (15 µM) and 
NADPH+H+ (200 µM) was added. The reaction was started with the addition of cYY 
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(50 µM) and stopped after 30 min by addition of 200 µl methanol with internal 
standard estrone (1 µM final concentration, addition included). 
The characterization of CYP121 activity was conducted by a UHPLC-MS/MS analysis 
carried out on a TSQ Quantum Access Max mass spectrometer equipped with an 
HESI-II source and a triple quadrupole mass detector (Thermo Scientific, Dreieich, 
Germany). Compounds were separated on an Accucore RP-MS 150×2.1 mm 2.6 µm 
column (Thermo Fisher, Waltham, US) by a methanol/water gradient (from 1.4 min - 
3.5 min 50% methanol to 3.5 min - 5.0 min 90% methanol) with a flow of 550 µL/min. 
Compounds were ionized in negative mode by electrospray ionization. Ionization was 
assisted by a post-column addition of 2 mM ammonia in methanol with an automated 
syringe at 1.25 µL/min. Monitored ions were (mother ion [m/z], product ion [m/z], 
scan time [s], scan width [m/z], collision energy [V], tube lens offset [V], polarity): 
mycocyclosin: 323.101, 111.100, 0.3, 0.7, 28, negative; CYY: 325.129, 113.043, 0.3, 
0.7. 29, negative; internal standard (estrone): 269.153, 145.035, 0.3, 0.7, 42, 
negative. Samples were injected in a volume of 25 µL. Xcalibur software was used 
for data acquisition. For quantification, the ratios of the area under the curve of the 
educt and the product were used. 
 
20. Determination MICMtb using MABA.  
The assay for determination of minimal inhibition concentration against Mtb was 
performed as previously described.5  
 
21. MICEco E. coli TolC and MICSa S.aureus Newman 
MICEco /MICSa values were performed for econazole, I:16, I:47, I:48 in E. coli TolC 
and S. aureus Newman. A start OD600 of 0.03 was used in a total volume of 200 mL 
in lysogeny broth (LB) + ACD enrichment containing the compounds predissolved in 
DMSO. Final compound concentrations were prepared from serial dilutions ranging 
from 1.56 to 100 µM in duplicates. The maximal DMSO concentration in the 
experiment was 1%. The recorded OD600 values were determined after addition of 
the compounds and again after incubation for 18 h at 37 °C and 50 rpm in a 96-well 
plate (Sarstedt, Nümbrecht, Germany) using a FLUOStar Omega (BMG Labtech, 
Ortenberg, Germany). Given MICEco /MICSa values are means of two independent 
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experiments (two different clones) and are defined as concentrations at which no 
bacterial growth was detectable. 
 
22. Spectroscopic characterization of enzyme activity.  
Recombinant CYP121 from Mycobacterium tuberculosis as well as ferredoxin Etp1fd 
(516-618) and ferredoxin reductase Arh1_A18G from the fission yeast 
Schizosaccharomyces pombe were expressed and purified as described 
previously.25,26  
Functionality of CYP121 and electron transfer were assayed by the occurrence of the 
characteristic absorbance maximum at G ≅450 nm, related to the reduced, CO-bound 
heme complex. The assay was conducted following the method of Omura and Sato27 
with slight modifications. CYP121 (2 µM) was reduced through the addition of a few 
grains of sodium dithionite or incubation with NADPH (100 µM), ferredoxin 
Etp1fd(516-618) (40 µM), and Arh1_A18G ferredoxin reductase (2 µM) and divided in 
two cuvettes to record a baseline. One of the samples was saturated with carbon 
monoxide for 60 s and difference spectra were recorded until the absorbance at 
G ≅450 nm was constant. 
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1. SPR Response Curve of Econazole (positive control) 
 
 
SI Figure 1. SPR response curve of 100 µM econazole (eco, black, positive binder) 
and baseline (grey) recorded against biotin labeled CYP125 immobilized on a 
streptavidine coated sensorchip. 
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2. Comparison of CYP125 from M. tuberculosis and M. bovis 
BCG 
 
 
SI Figure 2. Result of the Protein BLAST of CYP125 from M. tuberculosis (gene-ID: 
Rv3545c) and M. bovis BCG (gene-ID: BCG_3609c) showing 100% amino acid 
identity of both proteins. 
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3. Representative KD Dose Response Curves and Difference 
Spectra 
 
 
SI Figure 3. Representative KD dose response curves (left) and difference spectra 
(right) of a type I (C24, lower spectra) and a type II (C128, upper spectra) CYP125 
heme ligands.  
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4. Summary of Binding Constants, Profile and Ligand Efficency 
Indices of SPR Hits 
 
SI Table 1. Relative responses of SPR hits (R/Rpos) and their respective heme 
binding profiles, binding affinities (KD) and Ligand efficiency scores (LE) against 
CYP125. 
Compound 
SPR 
[R/R
pos
] 
Heme assay 
Binding Type
c
 
Heme assay 
K
D
 [µM] 
Ligand efficiency 
[kcal/HA] 
Econazole (Eco = 
Rpos) 
1.0 I 0.94 0.36 
CHN
a
 - I 4.6 - 
LP10
b
 - rI 6.1 0.24 
C003 1.3 II 19 0.35 
C005 1.0 II 28 0.29 
C016 1.1 I 16 0.32 
C023 1.0 I 1.5 0.37 
C024 1.1 I 0.26 0.42 
C025 0.9 no - - 
C036 2.8 I 1.3 0.46 
C037 3 I 1.1 0.49 
C042 0.0 no - - 
C043 1.2 II 13.1 0.26 
C052 2.8 no - - 
C053 0.5 - - - 
C055 1.2 II 38.7 0.29 
C059 0.8 - - - 
C060 1.1 I 0.28 0.42 
C068 1.0 II 38.7 0.34 
C080 1.6 II 39.6 0.22 
C083 2.9 no - - 
C087 1.2 no - - 
C090 1.7 no - - 
C119 2.0 no - - 
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C126 1.2 II 2.1 0.27 
C127 3.1 II 0.85 0.47 
C128 1.1 II 0.08 0.50 
C129 2.6 II 1.34 0.41 
C130 2.4 II 0.174 0.53 
a 
CHN = Cholest-4-en-3-one; 
b
 LP10 = α-[(4-methylcyclohexyl)carbonyl amino]-N-4-pyridinyl-1H-indole-3-
propanamide; 
c
 I = Type I binding profile, II = Type II binding profile, rI = reverse Type II binding profile no = no 
binding profile observed at the highest  tested concentration (100 µM).  
 
 
5. Absorbance maximum in Heme assay 
 
SI Table 2. Binding affinities (KD) and 
absorbance maxima of selected compounds 
against CYP125. 
Compound 
Heme assay 
KD [µM] 
Heme assay 
Absorbance 
maximum [nm] 
LP10 6.1 419 
C127 0.85 421 
C128 0.08 420 
C129 1.34 422 
C130 0.17 421 
 
 
6. Synthesis, analytical and biological data of the screening 
compounds and their derivatives 
 
C1,[1] C2,[1] , C3,[2] C4,[1] C5,[3] C6,[1] C7 - C10,[5] C11 - C18,[4] C19 - C27,[5] C28 - 
C29,[1] C30 - C33,[6] C34 - C74,[7] C75 - C121,[8] C122 - C125,[9] C127 - C130.[10] 
[1] C. Zimmer, M. Hafner, M. Zender, D. Ammann, R. W. Hartmann, C. A. Vock, Bioorganic & 
medicinal chemistry letters 2011, 21, 186–190. 
[2] S. S. Gunatilleke, C. M. Calvet, J. B. Johnston, C.-K. Chen, G. Erenburg, J. Gut, J. C. Engel, Ang, 
Kenny K H, J. Mulvaney, S. Chen et al., PLoS neglected tropical diseases 2012, 6, e1736. 
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[3] M. Balcells, J. Avilla, J. Profitos, R. Canela, Journal of Agricultural and Food Chemistry 2000, 48, 
83–87. 
[4] J. Emmerich, Q. Hu, N. Hanke, R. W. Hartmann, Journal of medicinal chemistry 2013, 56, 6022–
6032. 
[5] Q. Hu, J. Kunde, N. Hanke, R. W. Hartmann, European journal of medicinal chemistry 2015, 96, 
139–150. 
[6] a) R. Heim, S. Lucas, C. M. Grombein, C. Ries, K. E. Schewe, M. Negri, U. Müller-Vieira, B. Birk, 
R. W. Hartmann, Journal of medicinal chemistry 2008, 51, 5064–5074; b) S. Lucas, M. Negri, R. 
Heim, C. Zimmer, R. W. Hartmann, Journal of medicinal chemistry 2011, 54, 2307–2319; c) Q. 
Hu, L. Yin, R. W. Hartmann, Journal of medicinal chemistry 2012, 55, 7080–7089. 
[7] a) U. E. Hille, Q. Hu, C. Vock, M. Negri, M. Bartels, U. Müller-Vieira, T. Lauterbach, R. W. 
Hartmann, European journal of medicinal chemistry 2009, 44, 2765–2775; b) U. E. Hille, C. 
Zimmer, C. A. Vock, R. W. Hartmann, ACS medicinal chemistry letters 2011, 2, 2–6; c) U. E. Hille, 
C. Zimmer, J. Haupenthal, R. W. Hartmann, ACS medicinal chemistry letters 2011, 2, 559–564. 
[8] a) L. Yin, Q. Hu, R. W. Hartmann, Journal of medicinal chemistry 2013, 56, 460–470; b) L. Yin, Q. 
Hu, J. Emmerich, M. M.-C. Lo, E. Metzger, A. Ali, R. W. Hartmann, Journal of medicinal chemistry 
2014, 57, 5179–5189; c) L. Yin, S. Lucas, F. Maurer, U. Kazmaier, Q. Hu, R. W. Hartmann, 
Journal of medicinal chemistry 2012, 55, 6629–6633. 
[9] W. Zhu, Q. Hu, N. Hanke, van Koppen, Chris J, R. W. Hartmann, Journal of medicinal chemistry 
2014, 57, 7811–7817. 
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Abstract of Poster I: 
Steering the Azido-Tetrazole Equilibrium of 4-Azidopyrimidines via Substituent 
Variation – Implications for Drug Design 
A. Thomann, Saarbrücken/DE, J. Zapp, Saarbrücken/DE, M. Hutter, 
Saarbrücken/DE, M. Empting, Saarbrücken/DE, R. W. Hartmann, Saarbrücken/DE 
Andreas Thomann, Helmholtz Institute for Pharmaceutical Research Saarland, 
Campus C2.3, 66123 Saarbrücken, Germany 
 
This study focuses on an interesting constitutional isomerism called azido-tetrazole 
equilibrium which is observed in azido-substituted N-heterocycles [1]. We present a 
systematic investigation on the effect of different substituents on the ratio of the two 
isomers within a 2-substituted 4-azidopyrimidine model scaffold. To this end, NMR- 
and IR-spectroscopic as well as X-Ray crystallographic analysis of synthesized 
derivatives were performed demonstrating the possibility to steer this valence 
tautomerism towards the isomer of choice by means of substituent variation.  
Furthermore, we investigated the impact of this tetrazole-based disguise of the azido 
group in reactivity regarding copper(I)-catalyzed as well as strain-promoted azide-
alkyne cycloadditions (CuAAC and SPAAC, respectively). Substituents stabilized 
tetrazoles showed a highly decreased or even abolished reactivity in our CuAAC 
setup whereas the azides and compounds in the equilibrium were directly converted. 
By use of an pH sensitive derivative, we provide, to our knowledge, the first 
experimental basis for a possible exploitation of this dynamic isomerism as a pH-
dependent azide-protecting motif for selective SPAAC conjugations in aqueous 
media.  
Fragment-based drug design (FBDD) has emerged to be a powerful technique for the 
discovery of highly effective drug leads. Our tetrazolo[1,5-c]pyrimidines display ideal 
physicochemical properties for the use as potential fragment inhibitors. Furthermore, 
they share a high degree of similarity with adenosine, a motif occurring frequently in 
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natural molecules e.g. nucleic acids or Co-enzyme A. To demonstrate the 
applicability of these tetrazolo[1,5-c]pyrimidines for FBDD we investigated whether 
they could inhibit PqsD. This anthranoyl-CoA-dependent enzyme mediates a key 
step in the signal molecule synthesis of the pqs quorum sensing system which 
regulates virulence of P. aeruginosa and biofilm formation [2, 3]. Two fragments from 
our library inhibited PqsD in micromolar concentrations resulting in high Ligand – and 
Ligand Lipophilicity Efficiencies (LE and LLE, respectively). Hence, they can be 
considered as ideal starting points for further fragment growing or merging 
approaches.  
 
[1] W. E. Hull et al., Angew. Chem. Int. Ed. Engl., 1980, 19, 924.  [2] M. P. Storz et 
al., JACS, 2012, 134, 16143. [3] Sahner et al, J. Med. Chem., 2013, 56, 8656.  
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Abstract of Poster II: 
Biological evaluation of an in vivo-potent dual target PQS-Quorum 
Sensing inhibitor that hinders biofilm formation 
Andreas Thomann1, Antonio G. Martins1, Christian Brengel1, Elisabeth Weidel1, 
Alberto Plaza1, Carsten Börger2, Martin Empting1, Rolf W. Hartmann1,3* 
1Helmholtz Institute for Pharmaceutical Research Saarland, Campus C 2.3, 66123 Saarbrücken, 
Germany;  
2PharmBioTec GmbH, Sciencepark 1, Universtät des Saarlandes, 66123 Saarbrücken, Germany;  
3Department for Pharmaceutical and Medicinal Chemistry, Campus C 2.3, Saarland University, 66123 
Saarbrücken, Germany; email: Rolf.Hartmann@helmholtz-hzi.de. 
 
Keywords: Pseudomonas aeruginosa, PQS, Dual Target QS Inhibitors, PqsD, PqsR, 
Drug Discovery  
Abstract 
Emergence of Pseudomonas aeruginosa (PA) as a leading cause of nosocomial 
infections and morbidity in immunocompromised patients has consolidated it in the 
race for novel anti-microbial compounds. PA infections are notoriously difficult to 
eradicate due to intrinsic resistance to a variety of available antibiotics. Its 
distinguished ability to form biofilms amplifies resistance and promotes immune 
response evasion.  
The PA quorum-sensing (QS) system is a sophisticated network of genome-wide 
regulation. A major player is the pseudomonas quinolone signal system (PQS-QS) 
that regulates the production of several non-vital virulence and biofilm-related 
determinants. Therefore, QS circuitry is an attractive target for anti-virulence 
therapeutics with lowered resistance development potential[1,2,3]. We have developed 
a dual-inhibitor compound (cmpd. A) of low molecular weight and high solubility that 
targets PQS transcriptional regulator (PqsR) and PqsD, a key enzyme in the 
biosynthesis of PQS-QS signal molecules (HHQ and PQS). 
In this context, cmpd. A markedly reduced virulence factor production without 
affecting bacterial growth. Additionally, ciprofloxacin co-administration in vitro 
increased susceptibility of PA14 to antibiotic administration under biofilm conditions. 
Disruption of pathogenicity mechanisms was assessed in vivo, with significant 
increased survival of challenged larvae in an established Galleria mellonella infection 
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model. Finally, we observed considerable reduction of biofilm volume and 
extracellular DNA. 
Favourable physicochemical properties and effects on virulence/biofilm establish a 
promising starting point for further optimization. In particular, interference with biofilm 
holds great promise in lowering pathogenicity and increasing susceptibility to 
pharmacological treatment and immune responses in chronic and persistent 
infections. 
References  
 
1. M. P. Storz et al., J. Am. Chem. Soc., 134:16143-16146, 2012, doi: 10.1021/ja3072397;  
2. C. Lu et al., Angew. Chem., 126:1127-1130, 2014, doi: 10.1002/ange.201307547;  
3. E. Weidel et al, Future Med Chem, 6:2057-72, 2014, doi: 10.4155/fmc.14.142 
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Abstract for Poster III: 
Biophysical Screening of a Focused Library for the Discovery of 
Novel Antimycobacterials targeting CYP121 
 
Brengel, Christian+1, Thomann, Andreas+1, Schifrin, Alexander2, Bernhardt, Rita2, 
Kamal, Ahmed1, Cho, Sang Hyun3, Franzblau, Scott G.3 and Hartmann, Rolf W.*1 
1 Helmholtz Institute for Pharmaceutical Research Saarland, , Department for Drug 
Development and Optimization, Campus C2.3,66123 Saarbrücken, Germany, E-mail: 
Rolf.Hartmann@helmholtz-hzi.de 
2 Biochemie, Universität des Saarlandes, Campus B2.2, 66123 Saarbrücken, 
Germany 
3 Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at 
Chicago, 833 S. Wood St., Chicago, Illinois 60612-7231, USA 
* Corresponding author; + Authors equally contributed to this work 
 
Abstract 
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is still the most deadly 
bacterial infection worldwide. In 2011 the WHO registered about 1.4 million cases of 
death related to Mtb infections.[1] Despite a broad arsenal of available anti-
mycobacterial agents, treatment becomes ineffective caused by the increased 
abundance of multiresistant mutants.[2] These circumstances underline the urgency 
for new therapeutic strategies with novel modes of action. The mycobacterial P450 
enzyme CYP121, being essential for Mtb growth in vitro[3], is such a promising new 
drug target for prospective anti-microbial agents. Previous studies revealed azole 
antifungals (e.g. econazol)[4] to be nanomolar binders to CYP121 with effectivity 
against Mtb in vitro and in vivo.[5]  
To identify new hits against CYP121, we employed a CYP-Inhibitor focused library in 
a Surface Plasmon Resonance spectroscopic (SPR) screening. The 44 identified hits 
were validated in a P450 coordination assay resulting in 14 heme type II binders with 
low micromolar KD’s. Those compounds displayed single digit µg/ml MIC50’s in vitro 
against Mycobaterium bovis BCG. The frontrunner compound I:47 was selected for 
further evaluation against the human pathogen Mtb and showed significant growth 
inhibition with a MIC90 of 0.28 µg/ml. Additionally, I:47 was evaluated in a HEK293 
Cell assay for toxicity and displayed a LD50 that was 40 times higher than its MIC. 
Finally, we could demonstrate that I:47 does not only bind to CYP121 but does also 
inhibit the enzyme reaction in vitro.  
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Promising anti-mycobacterial activity, low toxicity and a novel mode of action together 
with the low molecular weight make I47 an excellent basis for further drug 
development.  
 
References 
1 WHO, Global Tuberculosis Report, 2012. 
2 ZF Udwadia et al., Clin. Infect. Dis., 2012, 54, 579-81. 
3 KJ McLean et al., J. Biol. Chem., 2008, 283, 33406-16. 
4 KJ. McLean et al., J. Inorg. Bioch., 2002, 91, 527-41. 
5 S. T. Byrne et al, J. Med. Microbiol.,   2007, 56, 1047-51. 
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